Identification

Name
Cyclosporine
Accession Number
DB00091  (BTD00003, BIOD00003)
Type
Small Molecule
Groups
Approved, Investigational, Vet approved
Description

A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. Cyclosporine is produced as a metabolite by the fungus species Cordyceps militaris. (From Martindale, The Extra Pharmacopoeia, 30th ed).

Structure
Thumb
Synonyms
  • Ciclosporin
  • Ciclosporina
  • Ciclosporine
  • Ciclosporinum
  • CsA
  • CyA
  • Cyclosporin
  • Cyclosporin A
External IDs
27-400 / Antibiotic S 7481F1 / Antibiotic S-7481F1 / NSC-290193 / OL-27-400 / SANG-35 / SDZ-OXL-400
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CyclosporineCapsule25 mgOralSandoz Canada IncorporatedNot applicableNot applicableCanada
NeoralCapsule, liquid filled25 mg/1OralCardinal Health1995-07-142018-02-23Us
NeoralCapsule, liquid filled100 mg/1OralNovartis1995-07-14Not applicableUs
NeoralCapsule, liquid filled25 mg/1OralNovartis1995-07-14Not applicableUs
NeoralSolution100 mg/mLOralNovartis1995-07-14Not applicableUs
Neoral 100mgCapsule100 mgOralNovartis1995-12-31Not applicableCanada
Neoral 10mgCapsule10 mgOralNovartis1998-10-02Not applicableCanada
Neoral 25mgCapsule25 mgOralNovartis1995-12-31Not applicableCanada
Neoral 50mgCapsule50 mgOralNovartis1995-12-31Not applicableCanada
Neoral Oral Solution 100mg/mlSolution100 mgOralNovartis1995-12-31Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-cyclosporine Oral SolutionSolution100 mgOralApotex Corporation2002-07-30Not applicableCanada
CyclosporineCapsule, gelatin coated100 mg/1OralApotex Corporation2002-05-29Not applicableUs
CyclosporineInjection, solution50 mg/mLIntravenousPerrigo International2003-10-07Not applicableUs
CyclosporineCapsule, liquid filled100 mg/1OralMayne Pharma2016-07-18Not applicableUs
CyclosporineCapsule, gelatin coated25 mg/1OralAmerincan Health Packaging2014-12-15Not applicableUs
CyclosporineCapsule, liquid filled100 mg/1OralCardinal Health2010-09-012018-03-30Us00172 7312 46 nlmimage10 972bcbde
CycloSPORINECapsule, liquid filled100 mg/1OralActavis Pharma Company2008-12-01Not applicableUs
CyclosporineCapsule, liquid filled100 mg/1OralPhysicians Total Care, Inc.2011-02-10Not applicableUs
CyclosporineSolution100 mg/mLOralTeva2005-03-29Not applicableUs
CyclosporineCapsule, gelatin coated25 mg/1OralApotex Corporation2002-05-29Not applicableUs
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Aqua-stasisCyclosporine (.0005 g/100mL)LiquidOphthalmicDr Marc's Manufacturing And Sales2016-02-232018-05-11Us
Cyclo-dermCyclosporine (.25 g/100mL)LiquidTopicalDr Marc's Manufacturing And Sales2016-02-232018-05-11Us
Cyclosporine/Chondroitin PFCyclosporine (1 mg/mL)EmulsionOphthalmicImprimis Njof, Llc2018-07-01Not applicableUs
Cyclosporine/Chondroitin Sulfate PFCyclosporine (1 mg/mL)EmulsionOphthalmicImprimis Rx Nj2018-02-01Not applicableUs
Hydro-stasisCyclosporine (.0005 g/100mL)LiquidOphthalmicDr Marc's Manufacturing And Sales2016-02-232018-05-11Us
Nail Cyclosporin-ACyclosporine (.25 g/100mL)LiquidTopicalDr Marc's Manufacturing And Sales2016-02-232018-05-11Us
International/Other Brands
Sangcya
Categories
UNII
83HN0GTJ6D
CAS number
59865-13-3
Weight
Average: 1202.635
Monoisotopic: 1201.841368058
Chemical Formula
C62H111N11O12
InChI Key
PMATZTZNYRCHOR-CGLBZJNRSA-N
InChI
InChI=1S/C62H111N11O12/c1-25-27-28-40(15)52(75)51-56(79)65-43(26-2)58(81)67(18)33-48(74)68(19)44(29-34(3)4)55(78)66-49(38(11)12)61(84)69(20)45(30-35(5)6)54(77)63-41(16)53(76)64-42(17)57(80)70(21)46(31-36(7)8)59(82)71(22)47(32-37(9)10)60(83)72(23)50(39(13)14)62(85)73(51)24/h25,27,34-47,49-52,75H,26,28-33H2,1-24H3,(H,63,77)(H,64,76)(H,65,79)(H,66,78)/b27-25+/t40-,41+,42-,43+,44+,45+,46+,47+,49+,50+,51+,52-/m1/s1
IUPAC Name
(3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(1R,2R,4E)-1-hydroxy-2-methylhex-4-en-1-yl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-bis(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecone
SMILES
CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C

Pharmacology

Indication

For treatment of transplant (kidney, liver, and heart) rejection, rheumatoid arthritis, severe psoriasis.

Associated Conditions
Pharmacodynamics

Used in immunosuppression for prophylactic treatment of organ transplants, cyclosporine exerts specific and reversible inhibition of immunocompetent lymphocytes in the G0-or G1-phase of the cell cycle. T-lymphocytes are preferentially inhibited. The T1-helper cell is the main target, although the T1-suppressor cell may also be suppressed. Sandimmune (cyclosporine) also inhibits lymphokine production and release including interleukin-2.

Mechanism of action

Cyclosporine binds to cyclophilin. The complex then inhibits calcineurin which is normally responsible for activating transcription of interleukin 2. Cyclosporine also inhibits lymphokine production and interleukin release. In ophthalmic applications, the precise mechanism of action is not known. Cyclosporine emulsion is thought to act as a partial immunomodulator in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca.

TargetActionsOrganism
ACalcium signal-modulating cyclophilin ligand
binder
Human
ACalcineurin subunit B type 2
inhibitor
Human
UPeptidyl-prolyl cis-trans isomerase ANot AvailableHuman
UPeptidyl-prolyl cis-trans isomerase F, mitochondrial
binder
Human
Absorption

The absorption of cyclosporine from the gastrointestinal tract is incomplete and variable. The extent of absorption is dependent on the individual patient, the patient population, and the formulation. The absolute bioavailability of cyclosproine administered as Sandimmune® is dependent on the patient population, estimated to be less than 10% in liver transplant patients and as great as 89% in some renal transplant patients. Compared to an intravenous infusion, the absolute bioavailability of the oral solution is approximately 30% based upon the results in 2 patients. The cyclosporine capsules and oral solution are bioequivalent. The time of peak blood concentrations (Tmax) following oral administration of cyclosporine [modified] ranged from 1.5 - 2.0 hours.

Volume of distribution

The steady state volume of distribution during intravenous dosing has been reported as 3 to 5 L/kg in solid organ transplant recipients. Cyclosporine is excreted in human milk.

Protein binding

In the plasma, approximately 90% is bound to proteins, primarily lipoproteins. In blood, the distribution is concentration dependent. Approximately 33% to 47% is in plasma, 4% to 9% in lymphocytes, 5% to 12% in granulocytes, and 41% to 58% in erythrocytes.

Metabolism

Hepatic, extensively metabolized by the cytochrome P450 3A enzyme system in the liver. It is also metabolized in the gastrointestinal tract and kidney to a lesser degree. The metabolites are significantly less potent than the parent compound. The major metabolites (M1, M9, and M4N) result from oxidation at the 1-beta, 9-gamma, and 4-N-demethylated positions, respectively.

Route of elimination

Elimination is primarily biliary with only 6% of the dose (parent drug and metabolites) excreted in the urine. Only 0.1% of the dose is excreted in the urine as unchanged drug.

Half life

Biphasic and variable, approximately 7 hours (range 7 to 19 hours) in children and approximately 19 hours (range 10 to 27 hours) in adults.

Clearance

Following intravenous administration, the blood clearance of cyclosporine (assay: HPLC) is approximately 5 to 7 mL/min/kg in adult recipients of renal or liver allografts. Blood cyclosporine clearance appears to be slightly slower in cardiac transplant patients. The following are clearance parameters (CL/F) for select patient populations: * 593 ± 204 mL/min [De novo renal transplant patients, 597±174 mg/day] * 492 ± 140 mL/min [Stable renal transplant patients, 344±122 mg/day] * 577 ± 309 mL/min [De novo liver transplant, 458±190 mg/day] * 613 ± 196 mL/min [De novo rheumatoid arthritis, 182±55.6 mg/day] * 723 ± 186 mL/min [De novo psoriasis, 189±69.8 mg/day]
* 285 ± 94 mL/min [Stable Liver Transplant, Age 2 - 8, Dosed T.I.D 101±25 mg/day] * 378 ± 80 mL/min [Stable Liver Transplant, Age 8 - 15, Dosed B.I.D 188±55 mg/day]
* 171 mL/min [Stable liver transplant, Age 3, Dosed B.I.D 120 mg/day] * 328 ± 121 mL/min [Stable liver transplant, Age 8 - 15, Dosed B.I.D 158±55 mg/day]
* 418 ± 143 mL/min [Stable renal transplant, Age 7 - 15, Dosed B.I.D 328±83 mg/day]

Toxicity

The oral LD50 is 2329 mg/kg in mice, 1480 mg/kg in rats, and > 1000 mg/kg in rabbits. The I.V. LD50 is 148 mg/kg in mice, 104 mg/kg in rats, and 46 mg/kg in rabbits.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(R)-warfarinThe metabolism of (R)-warfarin can be decreased when combined with Cyclosporine.Experimental
(S)-WarfarinThe metabolism of (S)-Warfarin can be decreased when combined with Cyclosporine.Experimental, Investigational
16-BromoepiandrosteroneThe metabolism of 16-Bromoepiandrosterone can be decreased when combined with Cyclosporine.Investigational
2-MethoxyethanolThe risk or severity of adverse effects can be increased when Cyclosporine is combined with 2-Methoxyethanol.Experimental
3,4-MethylenedioxyamphetamineThe risk or severity of adverse effects can be increased when 3,4-Methylenedioxyamphetamine is combined with Cyclosporine.Experimental, Illicit
3,5-diiodothyropropionic acidThe metabolism of 3,5-diiodothyropropionic acid can be decreased when combined with Cyclosporine.Investigational
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Cyclosporine.Experimental, Illicit
4-hydroxycoumarinThe metabolism of 4-hydroxycoumarin can be decreased when combined with Cyclosporine.Experimental
4-MethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Methoxyamphetamine is combined with Cyclosporine.Experimental, Illicit
5-(2-methylpiperazine-1-sulfonyl)isoquinolineThe metabolism of Cyclosporine can be increased when combined with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline.Experimental
5-androstenedioneThe metabolism of 5-androstenedione can be decreased when combined with Cyclosporine.Experimental, Illicit
6-Deoxyerythronolide BThe metabolism of Cyclosporine can be decreased when combined with 6-Deoxyerythronolide B.Experimental
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Cyclosporine.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Cyclosporine.Experimental
9-(N-methyl-L-isoleucine)-cyclosporin AThe risk or severity of adverse effects can be increased when Cyclosporine is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.Investigational
AbataceptThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Abatacept.Approved
AbemaciclibThe serum concentration of Abemaciclib can be increased when it is combined with Cyclosporine.Approved, Investigational
AbetimusThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Abetimus.Investigational
AbirateroneThe metabolism of Abiraterone can be decreased when combined with Cyclosporine.Approved
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Cyclosporine.Approved, Investigational
AceclofenacThe risk or severity of renal failure and hypertension can be increased when Aceclofenac is combined with Cyclosporine.Approved, Investigational
AcemetacinThe risk or severity of renal failure and hypertension can be increased when Acemetacin is combined with Cyclosporine.Approved, Experimental, Investigational
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Cyclosporine.Approved, Investigational
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Cyclosporine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Cyclosporine.Approved
AcetaminophenThe serum concentration of Cyclosporine can be increased when it is combined with Acetaminophen.Approved
AcetazolamideThe serum concentration of Cyclosporine can be increased when it is combined with Acetazolamide.Approved, Vet Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Acetophenazine is combined with Cyclosporine.Approved
Acetyl sulfisoxazoleThe metabolism of Cyclosporine can be increased when combined with Acetyl sulfisoxazole.Approved, Vet Approved
Acetylglycinamide chloral hydrateThe risk or severity of adverse effects can be increased when Acetylglycinamide chloral hydrate is combined with Cyclosporine.Experimental
Acetylsalicylic acidThe risk or severity of renal failure and hypertension can be increased when Acetylsalicylic acid is combined with Cyclosporine.Approved, Vet Approved
ActeosideThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Acteoside.Investigational
AdalimumabThe serum concentration of Cyclosporine can be decreased when it is combined with Adalimumab.Approved
AdinazolamThe risk or severity of adverse effects can be increased when Adinazolam is combined with Cyclosporine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Cyclosporine.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Cyclosporine.Approved
AfelimomabThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Afelimomab.Investigational
AgmatineThe metabolism of Agmatine can be decreased when combined with Cyclosporine.Experimental, Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Cyclosporine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Alaproclate.Experimental
AlbendazoleThe serum concentration of Cyclosporine can be increased when it is combined with Albendazole.Approved, Vet Approved
AlclofenacThe risk or severity of renal failure and hypertension can be increased when Alclofenac is combined with Cyclosporine.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Alclometasone.Approved
AlcuroniumThe therapeutic efficacy of Alcuronium can be increased when used in combination with Cyclosporine.Experimental
AldesleukinThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Aldesleukin.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Aldosterone.Experimental, Investigational
AlectinibThe serum concentration of Cyclosporine can be increased when it is combined with Alectinib.Approved, Investigational
AlefaceptThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Alefacept.Approved, Investigational, Withdrawn
AlemtuzumabThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Alemtuzumab.Approved, Investigational
Alendronic acidThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Cyclosporine is combined with Alendronic acid.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Cyclosporine.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Cyclosporine.Approved, Illicit
AlfuzosinThe metabolism of Alfuzosin can be decreased when combined with Cyclosporine.Approved, Investigational
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Cyclosporine.Approved, Vet Approved
AliskirenThe serum concentration of Aliskiren can be increased when it is combined with Cyclosporine.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Cyclosporine.Approved, Investigational
AllobarbitalThe risk or severity of adverse effects can be increased when Allobarbital is combined with Cyclosporine.Experimental
AllopregnanoloneThe risk or severity of adverse effects can be increased when Allopregnanolone is combined with Cyclosporine.Investigational
AllylestrenolThe metabolism of Allylestrenol can be decreased when combined with Cyclosporine.Approved
AlminoprofenThe risk or severity of renal failure and hypertension can be increased when Alminoprofen is combined with Cyclosporine.Experimental
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Cyclosporine.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Cyclosporine.Approved
AlosetronThe metabolism of Alosetron can be decreased when combined with Cyclosporine.Approved, Withdrawn
alpha-Tocopherol acetateThe metabolism of alpha-Tocopherol acetate can be decreased when combined with Cyclosporine.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Cyclosporine.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Cyclosporine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Cyclosporine.Approved, Illicit, Investigational
AlprenololThe risk or severity of hyperkalemia can be increased when Alprenolol is combined with Cyclosporine.Approved, Withdrawn
AltretamineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Altretamine.Approved
Aluminium clofibrateThe risk or severity of renal failure can be increased when Cyclosporine is combined with Aluminium clofibrate.Experimental
AlvocidibThe serum concentration of Alvocidib can be increased when it is combined with Cyclosporine.Experimental, Investigational
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Cyclosporine.Approved, Investigational
AmbroxolThe metabolism of Ambroxol can be decreased when combined with Cyclosporine.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Amcinonide.Approved
AmikacinThe risk or severity of adverse effects can be increased when Amikacin is combined with Cyclosporine.Approved, Investigational, Vet Approved
AmilorideThe risk or severity of hyperkalemia can be increased when Amiloride is combined with Cyclosporine.Approved
AmineptineThe risk or severity of adverse effects can be increased when Amineptine is combined with Cyclosporine.Illicit, Withdrawn
AminophenazoneThe risk or severity of renal failure and hypertension can be increased when Aminophenazone is combined with Cyclosporine.Approved, Withdrawn
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Cyclosporine.Approved
AmiodaroneThe serum concentration of Cyclosporine can be increased when it is combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Cyclosporine.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Cyclosporine.Approved
AmitriptylinoxideThe risk or severity of adverse effects can be increased when Amitriptylinoxide is combined with Cyclosporine.Approved, Investigational
AmlodipineThe metabolism of Amlodipine can be decreased when combined with Cyclosporine.Approved
AmobarbitalThe metabolism of Cyclosporine can be increased when combined with Amobarbital.Approved, Illicit
AmodiaquineThe serum concentration of Cyclosporine can be increased when it is combined with Amodiaquine.Approved, Investigational
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Cyclosporine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Cyclosporine.Experimental
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Cyclosporine.Approved, Illicit, Investigational
Amphotericin BAmphotericin B may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational
AmprenavirThe serum concentration of Amprenavir can be increased when it is combined with Cyclosporine.Approved, Investigational
AmsacrineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Amsacrine.Approved, Investigational
AnakinraThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Anakinra.Approved
AndrostenedioneThe metabolism of Androstenedione can be decreased when combined with Cyclosporine.Experimental, Illicit
AniracetamThe risk or severity of adverse effects can be increased when Aniracetam is combined with Cyclosporine.Experimental
AnisodamineThe risk or severity of hyperkalemia can be increased when Anisodamine is combined with Cyclosporine.Investigational
AnnamycinThe serum concentration of Cyclosporine can be increased when it is combined with Annamycin.Investigational
Anthrax immune globulin humanThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Cyclosporine.Approved
Anthrax vaccineThe risk or severity of infection can be increased when Anthrax vaccine is combined with Cyclosporine.Approved
Anthrax vaccineThe therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Cyclosporine.Approved
Antilymphocyte immunoglobulin (horse)The risk or severity of adverse effects can be increased when Cyclosporine is combined with Antilymphocyte immunoglobulin (horse).Approved, Investigational
AntipyrineThe risk or severity of renal failure and hypertension can be increased when Antipyrine is combined with Cyclosporine.Approved, Investigational
Antithymocyte immunoglobulin (rabbit)The risk or severity of adverse effects can be increased when Cyclosporine is combined with Antithymocyte immunoglobulin (rabbit).Approved
AntrafenineThe risk or severity of renal failure and hypertension can be increased when Antrafenine is combined with Cyclosporine.Approved
ApalutamideThe serum concentration of Cyclosporine can be decreased when it is combined with Apalutamide.Approved, Investigational
ApramycinThe risk or severity of adverse effects can be increased when Apramycin is combined with Cyclosporine.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Apremilast.Approved, Investigational
AprepitantThe serum concentration of Cyclosporine can be increased when it is combined with Aprepitant.Approved, Investigational
AprobarbitalThe risk or severity of adverse effects can be increased when Aprobarbital is combined with Cyclosporine.Approved, Illicit
ApronalideThe risk or severity of adverse effects can be increased when Apronalide is combined with Cyclosporine.Experimental
AranidipineThe metabolism of Aranidipine can be decreased when combined with Cyclosporine.Approved, Investigational
Arbaclofen PlacarbilThe risk or severity of adverse effects can be increased when Arbaclofen Placarbil is combined with Cyclosporine.Investigational
ArbekacinThe risk or severity of adverse effects can be increased when Arbekacin is combined with Cyclosporine.Approved, Investigational
ArdeparinThe risk or severity of hyperkalemia can be increased when Ardeparin is combined with Cyclosporine.Approved, Investigational, Withdrawn
ArgatrobanThe metabolism of Argatroban can be decreased when combined with Cyclosporine.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Cyclosporine.Approved, Investigational
Aripiprazole lauroxilThe risk or severity of adverse effects can be increased when Aripiprazole lauroxil is combined with Cyclosporine.Approved, Investigational
ArmodafinilThe serum concentration of Cyclosporine can be decreased when it is combined with Armodafinil.Approved, Investigational
ArotinololThe risk or severity of hyperkalemia can be increased when Arotinolol is combined with Cyclosporine.Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Arsenic trioxide.Approved, Investigational
ArtemetherThe metabolism of Artemether can be decreased when combined with Cyclosporine.Approved
Ascorbic acidThe serum concentration of Cyclosporine can be decreased when it is combined with Ascorbic acid.Approved, Nutraceutical
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Cyclosporine.Approved
AstemizoleThe serum concentration of Cyclosporine can be increased when it is combined with Astemizole.Approved, Withdrawn
AsunaprevirThe serum concentration of Asunaprevir can be increased when it is combined with Cyclosporine.Approved, Investigational, Withdrawn
AtazanavirThe metabolism of Cyclosporine can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe risk or severity of hyperkalemia can be increased when Atenolol is combined with Cyclosporine.Approved
AtomoxetineThe risk or severity of adverse effects can be increased when Atomoxetine is combined with Cyclosporine.Approved
AtorvastatinThe excretion of Atorvastatin can be decreased when combined with Cyclosporine.Approved
AtovaquoneThe metabolism of Atovaquone can be decreased when combined with Cyclosporine.Approved
AtracuriumThe therapeutic efficacy of Atracurium can be increased when used in combination with Cyclosporine.Approved, Experimental, Investigational
Atracurium besylateThe therapeutic efficacy of Atracurium besylate can be increased when used in combination with Cyclosporine.Approved
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Cyclosporine.Approved
AvatrombopagThe serum concentration of Avatrombopag can be increased when it is combined with Cyclosporine.Approved, Investigational
AVE9633The metabolism of Cyclosporine can be decreased when combined with AVE9633.Investigational
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Cyclosporine.Approved, Investigational
AzacitidineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Azacitidine.Approved, Investigational
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Cyclosporine.Investigational, Vet Approved
AzapropazoneThe risk or severity of renal failure and hypertension can be increased when Azapropazone is combined with Cyclosporine.Withdrawn
AzathioprineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Azathioprine.Approved
AZD-3043The risk or severity of adverse effects can be increased when AZD-3043 is combined with Cyclosporine.Investigational
AzelastineCyclosporine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelnidipineThe metabolism of Azelnidipine can be decreased when combined with Cyclosporine.Approved, Investigational
Azilsartan medoxomilThe risk or severity of hyperkalemia can be increased when Azilsartan medoxomil is combined with Cyclosporine.Approved, Investigational
AzithromycinThe metabolism of Cyclosporine can be decreased when combined with Azithromycin.Approved
AzosemideThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Azosemide.Investigational
Bacillus calmette-guerin substrain connaught live antigenThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Cyclosporine.Approved, Investigational
Bacillus calmette-guerin substrain connaught live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Cyclosporine.Approved, Investigational
Bacillus calmette-guerin substrain danish 1331 live antigenThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Cyclosporine.Investigational
Bacillus calmette-guerin substrain danish 1331 live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain danish 1331 live antigen can be decreased when used in combination with Cyclosporine.Investigational
Bacillus calmette-guerin substrain tice live antigenThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Cyclosporine.Approved
Bacillus calmette-guerin substrain tice live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Cyclosporine.Approved
BacitracinThe risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Bacitracin.Approved, Vet Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Cyclosporine.Approved
Bafilomycin A1The serum concentration of Cyclosporine can be increased when it is combined with Bafilomycin A1.Experimental
Bafilomycin B1The serum concentration of Cyclosporine can be increased when it is combined with Bafilomycin B1.Experimental
BalaglitazoneThe metabolism of Balaglitazone can be decreased when combined with Cyclosporine.Investigational
BalsalazideThe risk or severity of renal failure and hypertension can be increased when Balsalazide is combined with Cyclosporine.Approved, Investigational
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Cyclosporine.Investigational
BarbexacloneThe metabolism of Cyclosporine can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Cyclosporine can be increased when combined with Barbital.Illicit
BaricitinibThe serum concentration of Baricitinib can be increased when it is combined with Cyclosporine.Approved, Investigational
BarnidipineThe serum concentration of Barnidipine can be increased when it is combined with Cyclosporine.Approved
BasiliximabThe risk or severity of adverse effects can be increased when Basiliximab is combined with Cyclosporine.Approved, Investigational
BCG vaccineThe risk or severity of infection can be increased when BCG vaccine is combined with Cyclosporine.Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Cyclosporine.Investigational
BeclamideThe risk or severity of adverse effects can be increased when Beclamide is combined with Cyclosporine.Experimental
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Beclomethasone dipropionate.Approved, Investigational
BedaquilineThe metabolism of Bedaquiline can be decreased when combined with Cyclosporine.Approved
BefunololThe risk or severity of hyperkalemia can be increased when Befunolol is combined with Cyclosporine.Experimental
BegelomabThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Begelomab.Experimental, Investigational
BekanamycinThe risk or severity of adverse effects can be increased when Bekanamycin is combined with Cyclosporine.Experimental
BelataceptThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Belatacept.Approved, Investigational
BelimumabThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Belimumab.Approved
BelinostatThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Belinostat.Approved, Investigational
BemiparinThe risk or severity of hyperkalemia can be increased when Bemiparin is combined with Cyclosporine.Approved, Investigational
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Cyclosporine.Withdrawn
BenazeprilThe risk or severity of hyperkalemia can be increased when Benazepril is combined with Cyclosporine.Approved, Investigational
BenazeprilatThe risk or severity of hyperkalemia can be increased when Benazeprilat is combined with Cyclosporine.Experimental
BencyclaneThe metabolism of Bencyclane can be decreased when combined with Cyclosporine.Experimental
BendamustineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Bendamustine.Approved, Investigational
BendazacThe risk or severity of renal failure and hypertension can be increased when Bendazac is combined with Cyclosporine.Experimental
BendroflumethiazideThe metabolism of Cyclosporine can be increased when combined with Bendroflumethiazide.Approved
BenidipineThe metabolism of Benidipine can be decreased when combined with Cyclosporine.Approved, Investigational
BenmoxinThe risk or severity of adverse effects can be increased when Benmoxin is combined with Cyclosporine.Withdrawn
BenorilateThe risk or severity of renal failure and hypertension can be increased when Benorilate is combined with Cyclosporine.Experimental
BenoxaprofenThe risk or severity of renal failure and hypertension can be increased when Benoxaprofen is combined with Cyclosporine.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Benperidol is combined with Cyclosporine.Approved, Investigational
BenzoctamineThe risk or severity of adverse effects can be increased when Benzoctamine is combined with Cyclosporine.Approved
BenzphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Cyclosporine.Approved, Illicit
BenzquinamideThe serum concentration of Cyclosporine can be increased when it is combined with Benzquinamide.Withdrawn
BenzthiazideThe metabolism of Cyclosporine can be increased when combined with Benzthiazide.Approved
BenzydamineThe risk or severity of renal failure and hypertension can be increased when Benzydamine is combined with Cyclosporine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Cyclosporine.Approved
BepridilThe serum concentration of Cyclosporine can be increased when it is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Betamethasone.Approved, Vet Approved
BetaxololThe risk or severity of hyperkalemia can be increased when Betaxolol is combined with Cyclosporine.Approved, Investigational
BevacizumabThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Bevacizumab.Approved, Investigational
BevantololThe risk or severity of hyperkalemia can be increased when Bevantolol is combined with Cyclosporine.Approved
BexaroteneThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Bexarotene.Approved, Investigational
BezafibrateThe risk or severity of renal failure can be increased when Cyclosporine is combined with Bezafibrate.Approved, Investigational
BicalutamideThe metabolism of Cyclosporine can be decreased when combined with Bicalutamide.Approved
BictegravirThe metabolism of Bictegravir can be decreased when combined with Cyclosporine.Approved, Investigational
BifemelaneThe risk or severity of adverse effects can be increased when Bifemelane is combined with Cyclosporine.Experimental
BifeprunoxThe risk or severity of adverse effects can be increased when Bifeprunox is combined with Cyclosporine.Investigational
BioallethrinThe metabolism of Bioallethrin can be decreased when combined with Cyclosporine.Approved, Experimental
Biricodar dicitrateThe serum concentration of Cyclosporine can be increased when it is combined with Biricodar dicitrate.Investigational
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Cyclosporine.Approved
BL-1020The risk or severity of adverse effects can be increased when BL-1020 is combined with Cyclosporine.Investigational
BleomycinThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Bleomycin.Approved, Investigational
BlinatumomabThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Blinatumomab.Approved, Investigational
BlonanserinThe risk or severity of adverse effects can be increased when Blonanserin is combined with Cyclosporine.Approved, Investigational
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Cyclosporine.Approved, Withdrawn
BopindololThe risk or severity of hyperkalemia can be increased when Bopindolol is combined with Cyclosporine.Approved
BortezomibThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Bosentan can be increased when it is combined with Cyclosporine.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Cyclosporine.Approved
Botulinum Toxin Type AThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Botulinum Toxin Type B.Approved, Investigational
Brefeldin AThe metabolism of Cyclosporine can be decreased when combined with Brefeldin A.Experimental
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Cyclosporine.Approved, Investigational
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Cyclosporine.Approved, Investigational
BriakinumabThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Briakinumab.Investigational
BrigatinibThe serum concentration of Brigatinib can be increased when it is combined with Cyclosporine.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Cyclosporine.Approved
BrinzolamideThe metabolism of Brinzolamide can be decreased when combined with Cyclosporine.Approved
BrivaracetamThe risk or severity of adverse effects can be increased when Brivaracetam is combined with Cyclosporine.Approved, Investigational
BrodalumabThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Brodalumab.Approved, Investigational
BrofaromineThe risk or severity of adverse effects can be increased when Brofaromine is combined with Cyclosporine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Cyclosporine.Approved, Illicit, Investigational
BromfenacThe risk or severity of renal failure and hypertension can be increased when Bromfenac is combined with Cyclosporine.Approved
BromisovalThe risk or severity of adverse effects can be increased when Bromisoval is combined with Cyclosporine.Experimental
BromocriptineThe serum concentration of Cyclosporine can be increased when it is combined with Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Bromperidol is combined with Cyclosporine.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Cyclosporine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Cyclosporine.Approved, Investigational, Withdrawn
Bryostatin 1The metabolism of Cyclosporine can be decreased when combined with Bryostatin 1.Investigational
BucindololThe risk or severity of hyperkalemia can be increased when Bucindolol is combined with Cyclosporine.Investigational
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Cyclosporine.Approved
BufexamacThe risk or severity of renal failure and hypertension can be increased when Bufexamac is combined with Cyclosporine.Approved, Experimental
BufotenineThe risk or severity of adverse effects can be increased when Bufotenine is combined with Cyclosporine.Experimental, Illicit
BufuralolThe risk or severity of hyperkalemia can be increased when Bufuralol is combined with Cyclosporine.Experimental, Investigational
BumadizoneThe risk or severity of renal failure and hypertension can be increased when Bumadizone is combined with Cyclosporine.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Bumetanide.Approved
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Cyclosporine.Approved, Investigational
BupranololThe risk or severity of hyperkalemia can be increased when Bupranolol is combined with Cyclosporine.Approved
BuprenorphineCyclosporine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Bupropion is combined with Cyclosporine.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Cyclosporine.Approved, Investigational
BusulfanThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Busulfan.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Cyclosporine.Approved, Illicit
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Cyclosporine.Approved, Illicit
ButaperazineThe risk or severity of adverse effects can be increased when Butaperazine is combined with Cyclosporine.Experimental
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Cyclosporine.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Cyclosporine.Approved, Illicit, Vet Approved
ButriptylineThe risk or severity of adverse effects can be increased when Butriptyline is combined with Cyclosporine.Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Cabazitaxel.Approved
CabergolineThe metabolism of Cabergoline can be decreased when combined with Cyclosporine.Approved
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Cyclosporine.Approved, Investigational
CaffeineThe serum concentration of Cyclosporine can be increased when it is combined with Caffeine.Approved
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Cyclosporine.Approved, Nutraceutical
CamazepamThe risk or severity of adverse effects can be increased when Camazepam is combined with Cyclosporine.Approved, Illicit
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Cyclosporine.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Cyclosporine.Approved
CanakinumabThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Canakinumab.Approved, Investigational
CandesartanThe risk or severity of hyperkalemia can be increased when Candesartan is combined with Cyclosporine.Experimental
Candesartan cilexetilThe risk or severity of hyperkalemia can be increased when Candesartan cilexetil is combined with Cyclosporine.Approved
CandicidinThe metabolism of Cyclosporine can be decreased when combined with Candicidin.Withdrawn
CannabidiolThe metabolism of Cannabidiol can be decreased when combined with Cyclosporine.Approved, Investigational
CannabidivarinThe risk or severity of adverse effects can be increased when Cannabidivarin is combined with Cyclosporine.Investigational
CapecitabineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Capecitabine.Approved, Investigational
CapreomycinThe risk or severity of adverse effects can be increased when Capreomycin is combined with Cyclosporine.Approved
CaptodiameThe risk or severity of adverse effects can be increased when Captodiame is combined with Cyclosporine.Approved, Investigational
CaptoprilThe serum concentration of Cyclosporine can be increased when it is combined with Captopril.Approved
CarbamazepineThe serum concentration of Cyclosporine can be decreased when it is combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of renal failure and hypertension can be increased when Carbaspirin calcium is combined with Cyclosporine.Experimental, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Cyclosporine.Approved
CarbomycinThe metabolism of Cyclosporine can be decreased when combined with Carbomycin.Vet Approved
CarboplatinThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Carboplatin.Approved
CarboxyamidotriazoleThe metabolism of Carboxyamidotriazole can be decreased when combined with Cyclosporine.Investigational
CarbromalThe risk or severity of adverse effects can be increased when Carbromal is combined with Cyclosporine.Experimental
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Cyclosporine.Illicit, Investigational, Vet Approved
CarfilzomibThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Carfilzomib.Approved, Investigational
CariprazineThe risk or severity of adverse effects can be increased when Cariprazine is combined with Cyclosporine.Approved, Investigational
CarisbamateThe risk or severity of adverse effects can be increased when Carisbamate is combined with Cyclosporine.Investigational
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Cyclosporine.Approved
CarmustineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Carmustine.Approved, Investigational
CaroverineThe metabolism of Caroverine can be decreased when combined with Cyclosporine.Experimental
CaroxazoneThe risk or severity of adverse effects can be increased when Caroxazone is combined with Cyclosporine.Withdrawn
CarprofenThe risk or severity of renal failure and hypertension can be increased when Carprofen is combined with Cyclosporine.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of hyperkalemia can be increased when Carteolol is combined with Cyclosporine.Approved
CarvedilolThe serum concentration of Cyclosporine can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Caspofungin.Approved
CastanospermineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Castanospermine.Experimental
CathinoneThe risk or severity of adverse effects can be increased when Cathinone is combined with Cyclosporine.Illicit
CefacetrileThe risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefacetrile.Approved
CefaclorThe risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefaclor.Approved
CefadroxilThe risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefadroxil.Approved, Vet Approved, Withdrawn
CefalotinThe risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefalotin.Approved, Investigational, Vet Approved
CefamandoleThe risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefamandole.Approved, Investigational
CefapirinThe risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefapirin.Approved, Vet Approved
CefatrizineThe risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefatrizine.Experimental
CefazedoneThe risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefazedone.Experimental
CefazolinThe risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefazolin.Approved
CefbuperazoneThe risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefbuperazone.Experimental
CefcapeneThe risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefcapene.Experimental
CefditorenThe risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefditoren.Approved, Investigational
CefepimeThe risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefepime.Approved, Investigational
CefetametThe risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefetamet.Experimental
CefmenoximeThe risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefmenoxime.Approved
CefmetazoleThe risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefmetazole.Approved, Investigational
CefminoxThe risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefminox.Approved
CefodizimeThe risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefodizime.Experimental
CefonicidThe risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefonicid.Approved, Investigational
CefoperazoneThe serum concentration of Cyclosporine can be increased when it is combined with Cefoperazone.Approved, Investigational
CeforanideThe risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Ceforanide.Approved
CefotaximeThe risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefotaxime.Approved
CefotetanThe risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefotetan.Approved
CefotiamThe risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefotiam.Approved, Investigational
CefoxitinThe risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefoxitin.Approved
CefozopranThe risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefozopran.Experimental
CefpiramideThe risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefpiramide.Approved
CefpiromeThe risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefpirome.Approved
CefpodoximeThe risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefpodoxime.Approved, Vet Approved
CefprozilThe risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefprozil.Approved
CefradineThe risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefradine.Approved
CefroxadineThe risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefroxadine.Withdrawn
CefsulodinThe risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefsulodin.Experimental
Ceftaroline fosamilThe risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Ceftaroline fosamil.Approved, Investigational
CeftazidimeThe risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Ceftazidime.Approved
CeftezoleThe risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Ceftezole.Experimental
CeftibutenThe risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Ceftibuten.Approved, Investigational
CeftizoximeThe risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Ceftizoxime.Approved, Investigational
CeftobiproleThe risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Ceftobiprole.Approved, Investigational
CeftriaxoneThe serum concentration of Cyclosporine can be increased when it is combined with Ceftriaxone.Approved
CefuroximeThe risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefuroxime.Approved
CelecoxibThe risk or severity of renal failure and hypertension can be increased when Celecoxib is combined with Cyclosporine.Approved, Investigational
CeliprololThe serum concentration of Celiprolol can be increased when it is combined with Cyclosporine.Approved, Investigational
CephalexinThe risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cephalexin.Approved, Investigational, Vet Approved
CephaloglycinThe risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cephaloglycin.Approved
CephaloridineThe risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cephaloridine.Approved, Withdrawn
Cephalothin GroupThe risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cephalothin Group.Experimental
CeritinibThe serum concentration of Cyclosporine can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Cyclosporine.Approved, Withdrawn
Cerliponase alfaThe serum concentration of Cerliponase alfa can be increased when it is combined with Cyclosporine.Approved, Investigational
Certolizumab pegolThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Certolizumab pegol.Approved
CertoparinThe risk or severity of hyperkalemia can be increased when Certoparin is combined with Cyclosporine.Approved, Investigational
CethromycinThe metabolism of Cyclosporine can be decreased when combined with Cethromycin.Investigational
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Cyclosporine.Approved
CevimelineThe metabolism of Cevimeline can be decreased when combined with Cyclosporine.Approved
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be decreased when combined with Cyclosporine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Cyclosporine.Approved, Illicit, Investigational, Vet Approved
ChlorambucilThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Chlorambucil.Approved
Chloramine-TThe metabolism of Cyclosporine can be increased when combined with Chloramine-T.Vet Approved
ChloramphenicolThe serum concentration of Cyclosporine can be increased when it is combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Cyclosporine.Approved, Illicit, Investigational
ChlormadinoneThe metabolism of Chlormadinone can be decreased when combined with Cyclosporine.Experimental
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Cyclosporine.Approved, Investigational, Withdrawn
ChloroformThe serum concentration of Cyclosporine can be increased when it is combined with Chloroform.Vet Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Cyclosporine.Approved, Investigational, Vet Approved
ChlorothiazideThe metabolism of Cyclosporine can be increased when combined with Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Cyclosporine.Approved
ChlorphenesinThe risk or severity of adverse effects can be increased when Chlorphenesin is combined with Cyclosporine.Approved, Vet Approved, Withdrawn
ChlorproethazineThe risk or severity of adverse effects can be increased when Chlorproethazine is combined with Cyclosporine.Experimental
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Cyclosporine.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Cyclosporine.Approved, Investigational, Withdrawn
ChlorsulfaquinoxalineThe metabolism of Cyclosporine can be increased when combined with Chlorsulfaquinoxaline.Investigational
ChlortetracyclineThe risk or severity of adverse effects can be increased when Chlortetracycline is combined with Cyclosporine.Approved, Investigational, Vet Approved
ChlorthalidoneThe metabolism of Cyclosporine can be increased when combined with Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Cyclosporine.Approved
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Cyclosporine.Approved, Nutraceutical
Cholic AcidCyclosporine may decrease the excretion rate of Cholic Acid which could result in a higher serum level.Approved
Choline magnesium trisalicylateThe risk or severity of renal failure and hypertension can be increased when Choline magnesium trisalicylate is combined with Cyclosporine.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Ciclesonide.Approved, Investigational
CiglitazoneThe metabolism of Ciglitazone can be decreased when combined with Cyclosporine.Experimental
CilazaprilThe risk or severity of hyperkalemia can be increased when Cilazapril is combined with Cyclosporine.Approved
CilnidipineThe metabolism of Cilnidipine can be decreased when combined with Cyclosporine.Approved, Investigational
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Cyclosporine.Approved, Investigational
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Cyclosporine.Approved, Investigational
CimicoxibThe risk or severity of renal failure and hypertension can be increased when Cimicoxib is combined with Cyclosporine.Investigational
CinacalcetThe metabolism of Cinacalcet can be decreased when combined with Cyclosporine.Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Cyclosporine.Approved, Investigational
CinolazepamThe risk or severity of adverse effects can be increased when Cinolazepam is combined with Cyclosporine.Approved
CiprofibrateThe risk or severity of renal failure can be increased when Cyclosporine is combined with Ciprofibrate.Approved, Investigational
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Cyclosporine.Approved, Investigational
CisaprideThe metabolism of Cisapride can be decreased when combined with Cyclosporine.Approved, Investigational, Withdrawn
CisatracuriumThe therapeutic efficacy of Cisatracurium can be increased when used in combination with Cyclosporine.Approved
CisplatinThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Cisplatin.Approved
CitalopramThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Citalopram.Approved
CladribineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Cladribine.Approved, Investigational
ClarithromycinThe metabolism of Cyclosporine can be decreased when combined with Clarithromycin.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Cyclosporine.Approved, Investigational
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Cyclosporine.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Cyclosporine.Approved
ClindamycinThe risk or severity of adverse effects can be increased when Clindamycin is combined with Cyclosporine.Approved, Vet Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Cyclosporine.Approved, Illicit
ClobetasolThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Cyclosporine is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClofarabineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Clofarabine.Approved, Investigational
ClofazimineThe serum concentration of Cyclosporine can be increased when it is combined with Clofazimine.Approved, Investigational
ClofenamideThe metabolism of Cyclosporine can be increased when combined with Clofenamide.Experimental
ClofibrateThe risk or severity of renal failure can be increased when Cyclosporine is combined with Clofibrate.Approved, Investigational
ClofibrideThe risk or severity of renal failure can be increased when Cyclosporine is combined with Clofibride.Experimental
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Cyclosporine.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Cyclosporine.Approved, Investigational, Vet Approved
ClomocyclineThe risk or severity of adverse effects can be increased when Clomocycline is combined with Cyclosporine.Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Cyclosporine.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Cyclosporine.Approved
ClonixinThe risk or severity of renal failure and hypertension can be increased when Clonixin is combined with Cyclosporine.Approved
ClopamideThe metabolism of Cyclosporine can be increased when combined with Clopamide.Experimental
ClopenthixolThe risk or severity of adverse effects can be increased when Clopenthixol is combined with Cyclosporine.Experimental
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Cyclosporine.Approved
CloprednolThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Cloprednol.Experimental
CloranololThe risk or severity of hyperkalemia can be increased when Cloranolol is combined with Cyclosporine.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Cyclosporine.Approved, Illicit
ClorexoloneThe metabolism of Cyclosporine can be increased when combined with Clorexolone.Experimental
ClorindioneThe metabolism of Clorindione can be decreased when combined with Cyclosporine.Experimental
ClorsulonThe metabolism of Cyclosporine can be increased when combined with Clorsulon.Vet Approved
Clostridium tetani toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Cyclosporine.Approved
ClothiapineThe risk or severity of adverse effects can be increased when Clothiapine is combined with Cyclosporine.Experimental
ClotiazepamThe risk or severity of adverse effects can be increased when Clotiazepam is combined with Cyclosporine.Approved, Illicit
ClotrimazoleThe metabolism of Cyclosporine can be decreased when combined with Clotrimazole.Approved, Vet Approved
CloxazolamThe risk or severity of adverse effects can be increased when Cloxazolam is combined with Cyclosporine.Approved, Investigational
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Cyclosporine.Approved
CobicistatThe metabolism of Cyclosporine can be decreased when combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Cyclosporine.Approved, Investigational
CocaineThe metabolism of Cocaine can be decreased when combined with Cyclosporine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Cyclosporine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Cyclosporine.Approved
ColesevelamThe serum concentration of Cyclosporine can be decreased when it is combined with Colesevelam.Approved
ColistimethateThe risk or severity of adverse effects can be increased when Colistimethate is combined with Cyclosporine.Approved, Vet Approved
ColistinThe risk or severity of adverse effects can be increased when Colistin is combined with Cyclosporine.Approved
Coltuximab ravtansineThe metabolism of Cyclosporine can be decreased when combined with Coltuximab ravtansine.Investigational
Concanamycin AThe serum concentration of Cyclosporine can be increased when it is combined with Concanamycin A.Experimental
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Cyclosporine.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be increased when it is combined with Cyclosporine.Approved
CopanlisibThe serum concentration of Copanlisib can be increased when it is combined with Cyclosporine.Approved, Investigational
CorticosteroneThe metabolism of Corticosterone can be decreased when combined with Cyclosporine.Experimental
CorticotropinThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Corticotropin.Approved, Investigational, Vet Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Cortisone acetate.Approved, Investigational
CortivazolThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Cortivazol.Investigational
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Cyclosporine.Approved
CrizotinibThe serum concentration of Cyclosporine can be increased when it is combined with Crizotinib.Approved
CurcuminThe metabolism of Cyclosporine can be decreased when combined with Curcumin.Approved, Investigational
CyamemazineThe risk or severity of adverse effects can be increased when Cyamemazine is combined with Cyclosporine.Approved
CyclandelateThe metabolism of Cyclandelate can be decreased when combined with Cyclosporine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Cyclosporine.Approved
CyclobarbitalThe risk or severity of adverse effects can be increased when Cyclobarbital is combined with Cyclosporine.Experimental
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Cyclosporine.Approved
CyclopentamineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Cyclopentamine.Withdrawn
CyclopenthiazideThe metabolism of Cyclosporine can be increased when combined with Cyclopenthiazide.Experimental
CyclophosphamideThe serum concentration of Cyclosporine can be decreased when it is combined with Cyclophosphamide.Approved, Investigational
CyclopropaneThe risk or severity of adverse effects can be increased when Cyclopropane is combined with Cyclosporine.Experimental
CyclothiazideThe metabolism of Cyclosporine can be increased when combined with Cyclothiazide.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Cyclosporine.Approved
Cyproterone acetateThe metabolism of Cyproterone acetate can be decreased when combined with Cyclosporine.Approved, Investigational
CytarabineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Cytarabine.Approved, Investigational
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Cyclosporine.Approved
DabrafenibThe serum concentration of Cyclosporine can be decreased when it is combined with Dabrafenib.Approved, Investigational
DacarbazineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Dacarbazine.Approved, Investigational
DaclatasvirThe serum concentration of Cyclosporine can be increased when it is combined with Daclatasvir.Approved, Investigational
DaclizumabThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Daclizumab.Investigational, Withdrawn
DactinomycinThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Dactinomycin.Approved, Investigational
DalteparinThe risk or severity of hyperkalemia can be increased when Dalteparin is combined with Cyclosporine.Approved
DanaparoidThe risk or severity of hyperkalemia can be increased when Danaparoid is combined with Cyclosporine.Approved, Withdrawn
DanazolDanazol may increase the hepatotoxic activities of Cyclosporine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Cyclosporine.Approved, Investigational
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Cyclosporine.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Cyclosporine.Approved
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Cyclosporine.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Cyclosporine.Approved, Investigational
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Cyclosporine.Approved, Investigational
DarodipineThe metabolism of Darodipine can be decreased when combined with Cyclosporine.Experimental
DarunavirThe metabolism of Cyclosporine can be increased when combined with Darunavir.Approved
DasabuvirThe serum concentration of Cyclosporine can be increased when it is combined with Dasabuvir.Approved
DasatinibThe serum concentration of Cyclosporine can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Daunorubicin.Approved
DeanolThe risk or severity of adverse effects can be increased when Deanol is combined with Cyclosporine.Experimental
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Cyclosporine.Approved, Investigational
DecamethoniumThe therapeutic efficacy of Decamethonium can be increased when used in combination with Cyclosporine.Approved
DecitabineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Decitabine.Approved, Investigational
DeferasiroxThe serum concentration of Cyclosporine can be decreased when it is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Deflazacort.Approved, Investigational
DelafloxacinThe serum concentration of Delafloxacin can be increased when it is combined with Cyclosporine.Approved, Investigational
DelamanidThe metabolism of Delamanid can be decreased when combined with Cyclosporine.Approved, Investigational
DelaprilThe risk or severity of hyperkalemia can be increased when Delapril is combined with Cyclosporine.Investigational
DelavirdineThe metabolism of Cyclosporine can be decreased when combined with Delavirdine.Approved
DelorazepamThe risk or severity of adverse effects can be increased when Delorazepam is combined with Cyclosporine.Approved, Illicit, Investigational
DemeclocyclineThe risk or severity of adverse effects can be increased when Demeclocycline is combined with Cyclosporine.Approved
DemegestoneThe metabolism of Demegestone can be decreased when combined with Cyclosporine.Approved
DenosumabThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Denosumab.Approved
DeoxyspergualinThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Deoxyspergualin.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Cyclosporine.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Cyclosporine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Cyclosporine.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Cyclosporine.Approved, Investigational
DesmethylsertralineThe serum concentration of Cyclosporine can be increased when it is combined with Desmethylsertraline.Experimental
DesogestrelThe metabolism of Desogestrel can be decreased when combined with Cyclosporine.Approved
DesonideThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe metabolism of Desoxycorticosterone acetate can be decreased when combined with Cyclosporine.Approved
Desoxycorticosterone PivalateThe metabolism of Desoxycorticosterone Pivalate can be decreased when combined with Cyclosporine.Experimental, Vet Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Cyclosporine.Vet Approved
DeutetrabenazineThe metabolism of Deutetrabenazine can be decreased when combined with Cyclosporine.Approved, Investigational
DexamethasoneThe serum concentration of Cyclosporine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Dexamethasone isonicotinate.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Cyclosporine.Approved
Dexchlorpheniramine maleateThe metabolism of Dexchlorpheniramine maleate can be decreased when combined with Cyclosporine.Approved
DexibuprofenThe risk or severity of renal failure and hypertension can be increased when Dexibuprofen is combined with Cyclosporine.Approved, Investigational
DexketoprofenThe risk or severity of renal failure and hypertension can be increased when Dexketoprofen is combined with Cyclosporine.Approved, Investigational
DexlansoprazoleThe metabolism of Dexlansoprazole can be decreased when combined with Cyclosporine.Approved, Investigational
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Cyclosporine.Approved, Vet Approved
DexniguldipineThe serum concentration of Cyclosporine can be increased when it is combined with Dexniguldipine.Experimental
DexrabeprazoleThe metabolism of Dexrabeprazole can be decreased when combined with Cyclosporine.Experimental
DexrazoxaneThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Dexrazoxane.Approved, Withdrawn
DextofisopamThe risk or severity of adverse effects can be increased when Dextofisopam is combined with Cyclosporine.Investigational
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Cyclosporine.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Cyclosporine.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Cyclosporine.Approved, Illicit, Investigational, Withdrawn
DexverapamilThe serum concentration of Cyclosporine can be increased when it is combined with Dexverapamil.Experimental
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Cyclosporine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Cyclosporine.Approved, Illicit, Investigational, Vet Approved
DiazoxideThe metabolism of Cyclosporine can be increased when combined with Diazoxide.Approved
DibekacinThe risk or severity of adverse effects can be increased when Dibekacin is combined with Cyclosporine.Experimental
DibenzepinThe risk or severity of adverse effects can be increased when Dibenzepin is combined with Cyclosporine.Experimental
DichloralphenazoneThe risk or severity of adverse effects can be increased when Dichloralphenazone is combined with Cyclosporine.Approved, Illicit
DiclofenacThe risk or severity of renal failure and hypertension can be increased when Diclofenac is combined with Cyclosporine.Approved, Vet Approved
DiclofenamideThe metabolism of Cyclosporine can be increased when combined with Diclofenamide.Approved, Investigational
DicoumarolThe metabolism of Dicoumarol can be decreased when combined with Cyclosporine.Approved
DienogestThe metabolism of Dienogest can be decreased when combined with Cyclosporine.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Diethyl ether is combined with Cyclosporine.Experimental
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Cyclosporine.Approved, Investigational
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Cyclosporine.Approved, Illicit
DifenpiramideThe risk or severity of renal failure and hypertension can be increased when Difenpiramide is combined with Cyclosporine.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Diflorasone.Approved
DiflunisalThe risk or severity of renal failure and hypertension can be increased when Diflunisal is combined with Cyclosporine.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Difluprednate.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Cyclosporine.Approved, Investigational
Dihydro-alpha-ergocryptineThe metabolism of Dihydro-alpha-ergocryptine can be decreased when combined with Cyclosporine.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Cyclosporine.Approved, Illicit
DihydroergocornineThe metabolism of Dihydroergocornine can be decreased when combined with Cyclosporine.Approved
DihydroergocristineThe metabolism of Dihydroergocristine can be decreased when combined with Cyclosporine.Approved, Experimental
DihydroergocryptineThe metabolism of Dihydroergocryptine can be decreased when combined with Cyclosporine.Experimental
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Cyclosporine.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Cyclosporine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Cyclosporine.Experimental, Illicit
DihydrostreptomycinThe risk or severity of adverse effects can be increased when Dihydrostreptomycin is combined with Cyclosporine.Investigational, Vet Approved
DiltiazemThe metabolism of Cyclosporine can be decreased when combined with Diltiazem.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Cyclosporine.Approved
DimetacrineThe risk or severity of adverse effects can be increased when Dimetacrine is combined with Cyclosporine.Approved, Withdrawn
Dimethyl fumarateThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Dimethyl fumarate.Approved, Investigational
DimethyltryptamineThe risk or severity of adverse effects can be increased when Dimethyltryptamine is combined with Cyclosporine.Experimental, Illicit
DinutuximabThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Dinutuximab.Approved, Investigational
DiphenadioneThe metabolism of Diphenadione can be decreased when combined with Cyclosporine.Experimental
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Cyclosporine.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Cyclosporine.Approved, Illicit
DipyridamoleThe serum concentration of Cyclosporine can be increased when it is combined with Dipyridamole.Approved
DirithromycinThe metabolism of Cyclosporine can be decreased when combined with Dirithromycin.Approved, Investigational
DisopyramideThe metabolism of Disopyramide can be decreased when combined with Cyclosporine.Approved
DisulfiramThe metabolism of Disulfiram can be decreased when combined with Cyclosporine.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Dixyrazine is combined with Cyclosporine.Experimental
DocetaxelThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Docetaxel.Approved, Investigational
DofequidarThe serum concentration of Cyclosporine can be increased when it is combined with Dofequidar.Experimental, Investigational
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Cyclosporine.Approved, Investigational
DolasetronThe metabolism of Dolasetron can be decreased when combined with Cyclosporine.Approved, Investigational
DolutegravirThe serum concentration of Dolutegravir can be increased when it is combined with Cyclosporine.Approved
Domoic AcidThe risk or severity of adverse effects can be increased when Domoic Acid is combined with Cyclosporine.Experimental
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
DonepezilThe risk or severity of adverse effects can be increased when Donepezil is combined with Cyclosporine.Approved
DoramectinThe metabolism of Cyclosporine can be decreased when combined with Doramectin.Vet Approved
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Cyclosporine.Approved
DosulepinThe risk or severity of adverse effects can be increased when Dosulepin is combined with Cyclosporine.Approved
DotarizineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Dotarizine.Investigational
DovitinibThe serum concentration of Cyclosporine can be increased when it is combined with Dovitinib.Investigational
DoxacuriumThe therapeutic efficacy of Doxacurium can be increased when used in combination with Cyclosporine.Approved
DoxazosinThe serum concentration of Cyclosporine can be increased when it is combined with Doxazosin.Approved
DoxefazepamThe risk or severity of adverse effects can be increased when Doxefazepam is combined with Cyclosporine.Experimental
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Cyclosporine.Approved, Investigational
DoxifluridineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Doxifluridine.Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Cyclosporine.Approved, Investigational
DoxycyclineThe metabolism of Cyclosporine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Cyclosporine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Cyclosporine.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Cyclosporine.Approved, Illicit
DronedaroneThe serum concentration of Dronedarone can be increased when it is combined with Cyclosporine.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Cyclosporine.Approved, Vet Approved
DrospirenoneThe metabolism of Drospirenone can be decreased when combined with Cyclosporine.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Cyclosporine.Experimental, Illicit
DroxicamThe risk or severity of renal failure and hypertension can be increased when Droxicam is combined with Cyclosporine.Withdrawn
DuloxetineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Duloxetine.Approved
DutasterideThe metabolism of Dutasteride can be decreased when combined with Cyclosporine.Approved, Investigational
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Cyclosporine.Approved
DydrogesteroneThe metabolism of Dydrogesterone can be decreased when combined with Cyclosporine.Approved, Investigational, Withdrawn
EconazoleThe serum concentration of Cyclosporine can be increased when it is combined with Econazole.Approved
EcopipamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Cyclosporine.Investigational
EculizumabThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Eculizumab.Approved, Investigational
EdivoxetineThe risk or severity of adverse effects can be increased when Edivoxetine is combined with Cyclosporine.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Cyclosporine.Approved
EfalizumabThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Efalizumab.Approved, Investigational
EfavirenzThe serum concentration of Cyclosporine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfonidipineThe metabolism of Efonidipine can be decreased when combined with Cyclosporine.Approved, Investigational
ElacridarThe serum concentration of Cyclosporine can be increased when it is combined with Elacridar.Investigational
ElagolixThe serum concentration of Elagolix can be increased when it is combined with Cyclosporine.Approved, Investigational
ElbasvirThe serum concentration of Elbasvir can be increased when it is combined with Cyclosporine.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Cyclosporine.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Cyclosporine.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Eltanolone is combined with Cyclosporine.Investigational
EluxadolineThe serum concentration of Eluxadoline can be increased when it is combined with Cyclosporine.Approved, Investigational
ElvitegravirThe metabolism of Elvitegravir can be decreased when combined with Cyclosporine.Approved
EmeproniumThe risk or severity of adverse effects can be increased when Emepronium is combined with Cyclosporine.Experimental
EmopamilThe serum concentration of Cyclosporine can be increased when it is combined with Emopamil.Experimental
EmylcamateThe risk or severity of adverse effects can be increased when Emylcamate is combined with Cyclosporine.Experimental
EnalaprilThe metabolism of Enalapril can be decreased when combined with Cyclosporine.Approved, Vet Approved
EnalaprilatThe risk or severity of hyperkalemia can be increased when Enalaprilat is combined with Cyclosporine.Approved
EnasidenibThe serum concentration of Enasidenib can be increased when it is combined with Cyclosporine.Approved, Investigational
EncorafenibThe metabolism of Encorafenib can be decreased when combined with Cyclosporine.Approved, Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Cyclosporine.Approved, Investigational, Vet Approved
EnoxaparinThe risk or severity of hyperkalemia can be increased when Enoxaparin is combined with Cyclosporine.Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Cyclosporine.Approved, Investigational
EnzalutamideThe serum concentration of Cyclosporine can be decreased when it is combined with Enzalutamide.Approved
EpanololThe risk or severity of hyperkalemia can be increased when Epanolol is combined with Cyclosporine.Experimental
EperisoneThe risk or severity of adverse effects can be increased when Eperisone is combined with Cyclosporine.Approved, Investigational
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Cyclosporine.Approved, Investigational
EpirizoleThe risk or severity of renal failure and hypertension can be increased when Epirizole is combined with Cyclosporine.Approved
EpirubicinThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Epirubicin.Approved
EplerenoneEplerenone may increase the hyperkalemic activities of Cyclosporine.Approved
EpofolateThe metabolism of Cyclosporine can be decreased when combined with Epofolate.Investigational
Epothilone DThe metabolism of Cyclosporine can be decreased when combined with Epothilone D.Experimental, Investigational
EprinomectinThe metabolism of Cyclosporine can be decreased when combined with Eprinomectin.Vet Approved
EprosartanThe risk or severity of hyperkalemia can be increased when Eprosartan is combined with Cyclosporine.Approved
EquileninThe metabolism of Equilenin can be decreased when combined with Cyclosporine.Experimental
EquilinThe metabolism of Equilin can be decreased when combined with Cyclosporine.Approved
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Cyclosporine.Approved, Nutraceutical
Ergoloid mesylateThe metabolism of Ergoloid mesylate can be decreased when combined with Cyclosporine.Approved
ErgonovineThe metabolism of Ergonovine can be decreased when combined with Cyclosporine.Approved
ErgotamineThe metabolism of Ergotamine can be decreased when combined with Cyclosporine.Approved
EribulinThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Eribulin.Approved, Investigational
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Cyclosporine.Approved, Investigational
ErtugliflozinThe serum concentration of Ertugliflozin can be increased when it is combined with Cyclosporine.Approved, Investigational
ErythromycinThe metabolism of Cyclosporine can be decreased when combined with Erythromycin.Approved, Investigational, Vet Approved
EsatenololThe risk or severity of hyperkalemia can be increased when Esatenolol is combined with Cyclosporine.Experimental
EscitalopramThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Escitalopram.Approved, Investigational
EslicarbazepineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Eslicarbazepine.Approved
Eslicarbazepine acetateThe risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Cyclosporine.Approved
EsmirtazapineThe risk or severity of adverse effects can be increased when Esmirtazapine is combined with Cyclosporine.Investigational
EsmololThe risk or severity of hyperkalemia can be increased when Esmolol is combined with Cyclosporine.Approved
EsomeprazoleThe serum concentration of Cyclosporine can be increased when it is combined with Esomeprazole.Approved, Investigational
EsreboxetineThe risk or severity of adverse effects can be increased when Esreboxetine is combined with Cyclosporine.Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Cyclosporine.Approved, Illicit
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
Estradiol acetateThe serum concentration of Estradiol acetate can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
Estradiol benzoateThe serum concentration of Estradiol benzoate can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
Estradiol cypionateThe serum concentration of Estradiol cypionate can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
Estradiol dienanthateThe serum concentration of Estradiol dienanthate can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
Estradiol valerateThe serum concentration of Estradiol valerate can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
EstramustineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Estramustine.Approved, Investigational
EstriolThe serum concentration of Estriol can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
Estrogens, esterifiedThe metabolism of Estrogens, esterified can be decreased when combined with Cyclosporine.Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Cyclosporine.Approved
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Cyclosporine.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Cyclosporine.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Cyclosporine.Approved, Investigational
EthadioneThe risk or severity of adverse effects can be increased when Ethadione is combined with Cyclosporine.Experimental
EthanolCyclosporine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Cyclosporine.Approved, Illicit, Withdrawn
EthenzamideThe risk or severity of renal failure and hypertension can be increased when Ethenzamide is combined with Cyclosporine.Experimental
Ethinyl EstradiolThe risk or severity of liver damage can be increased when Ethinyl Estradiol is combined with Cyclosporine.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Cyclosporine.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Cyclosporine.Approved
EthoxzolamideThe metabolism of Cyclosporine can be increased when combined with Ethoxzolamide.Withdrawn
Ethyl biscoumacetateThe metabolism of Ethyl biscoumacetate can be decreased when combined with Cyclosporine.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Cyclosporine.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ethyl chloride is combined with Cyclosporine.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Cyclosporine.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Cyclosporine.Approved, Illicit
EthynodiolThe metabolism of Ethynodiol can be decreased when combined with Cyclosporine.Experimental
Ethynodiol diacetateThe metabolism of Ethynodiol diacetate can be decreased when combined with Cyclosporine.Approved
Etidronic acidThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Cyclosporine is combined with Etidronic acid.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Cyclosporine.Investigational, Withdrawn
EtiracetamThe risk or severity of adverse effects can be increased when Etiracetam is combined with Cyclosporine.Investigational
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Cyclosporine.Approved
EtodolacThe risk or severity of renal failure and hypertension can be increased when Etodolac is combined with Cyclosporine.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of renal failure and hypertension can be increased when Etofenamate is combined with Cyclosporine.Approved, Investigational
EtofibrateThe risk or severity of renal failure can be increased when Cyclosporine is combined with Etofibrate.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Cyclosporine.Approved
EtonogestrelThe metabolism of Etonogestrel can be decreased when combined with Cyclosporine.Approved, Investigational
EtoperidoneThe risk or severity of adverse effects can be increased when Etoperidone is combined with Cyclosporine.Withdrawn
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Cyclosporine.Approved
EtoricoxibThe risk or severity of renal failure and hypertension can be increased when Etoricoxib is combined with Cyclosporine.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Cyclosporine.Illicit, Vet Approved
EtravirineThe serum concentration of Cyclosporine can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Cyclosporine.Approved
ExemestaneThe metabolism of Exemestane can be decreased when combined with Cyclosporine.Approved, Investigational
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Cyclosporine.Approved, Investigational
FabomotizoleThe risk or severity of adverse effects can be increased when Fabomotizole is combined with Cyclosporine.Experimental
FamciclovirThe metabolism of Famciclovir can be decreased when combined with Cyclosporine.Approved, Investigational
Fazadinium bromideThe risk or severity of adverse effects can be increased when Fazadinium bromide is combined with Cyclosporine.Experimental
FebarbamateThe risk or severity of adverse effects can be increased when Febarbamate is combined with Cyclosporine.Experimental
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Cyclosporine.Approved
FelbinacThe risk or severity of renal failure and hypertension can be increased when Felbinac is combined with Cyclosporine.Experimental
FelodipineThe metabolism of Felodipine can be decreased when combined with Cyclosporine.Approved, Investigational
FenbufenThe risk or severity of renal failure and hypertension can be increased when Fenbufen is combined with Cyclosporine.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Cyclosporine.Approved, Illicit, Withdrawn
FendilineThe metabolism of Fendiline can be decreased when combined with Cyclosporine.Withdrawn
FenofibrateThe risk or severity of renal failure can be increased when Cyclosporine is combined with Fenofibrate.Approved
Fenofibric acidThe risk or severity of renal failure can be increased when Cyclosporine is combined with Fenofibric acid.Approved
FenoprofenThe risk or severity of renal failure and hypertension can be increased when Fenoprofen is combined with Cyclosporine.Approved
FenquizoneThe metabolism of Cyclosporine can be increased when combined with Fenquizone.Experimental
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Cyclosporine.Approved, Illicit, Investigational, Vet Approved
FentiazacThe risk or severity of renal failure and hypertension can be increased when Fentiazac is combined with Cyclosporine.Experimental
FenyramidolThe risk or severity of adverse effects can be increased when Fenyramidol is combined with Cyclosporine.Experimental
FeprazoneThe risk or severity of renal failure and hypertension can be increased when Feprazone is combined with Cyclosporine.Experimental
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Cyclosporine.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Cyclosporine.Approved, Investigational
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Cyclosporine.Approved
FimasartanThe serum concentration of Fimasartan can be increased when it is combined with Cyclosporine.Approved, Investigational
FinasterideThe metabolism of Finasteride can be decreased when combined with Cyclosporine.Approved
FingolimodThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Fingolimod.Approved, Investigational
FirocoxibThe risk or severity of renal failure and hypertension can be increased when Firocoxib is combined with Cyclosporine.Experimental, Vet Approved
Fish oilThe metabolism of Fish oil can be decreased when combined with Cyclosporine.Approved, Nutraceutical
FlibanserinThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Flibanserin.Approved, Investigational
FloctafenineThe risk or severity of renal failure and hypertension can be increased when Floctafenine is combined with Cyclosporine.Approved, Withdrawn
FlomoxefThe risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Flomoxef.Investigational
FloxuridineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Floxuridine.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Fluanisone is combined with Cyclosporine.Experimental
Fluciclovine (18F)The serum concentration of Fluciclovine (18F) can be increased when it is combined with Cyclosporine.Approved
FlucloroloneThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Fluclorolone.Experimental
FlucytosineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Flucytosine.Approved, Investigational
FludarabineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Fludarabine.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Cyclosporine.Approved, Illicit
FludrocortisoneThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Fludrocortisone.Approved, Investigational
FluindioneThe metabolism of Fluindione can be decreased when combined with Cyclosporine.Approved, Investigational
FlumethasoneThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Flumethasone.Approved, Vet Approved
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Cyclosporine.Approved
FlunisolideThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Flunisolide.Approved, Investigational
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Cyclosporine.Approved, Illicit
FlunixinThe risk or severity of renal failure and hypertension can be increased when Flunixin is combined with Cyclosporine.Vet Approved
FlunoxaprofenThe risk or severity of renal failure and hypertension can be increased when Flunoxaprofen is combined with Cyclosporine.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Fluocinonide.Approved, Investigational
FluocortinThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Fluocortin.Experimental
FluocortoloneThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Fluorometholone.Approved, Investigational
FluorouracilThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Fluorouracil.Approved
FluoxetineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Fluoxetine.Approved, Vet Approved
FluoxymesteroneFluoxymesterone may increase the hepatotoxic activities of Cyclosporine.Approved, Illicit
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Cyclosporine.Approved, Investigational, Withdrawn
FluperoloneThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Fluperolone.Experimental
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Cyclosporine.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Fluprednisolone.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Flurandrenolide.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Cyclosporine.Approved, Illicit, Investigational
FlurbiprofenThe risk or severity of renal failure and hypertension can be increased when Flurbiprofen is combined with Cyclosporine.Approved, Investigational
FlurithromycinThe metabolism of Cyclosporine can be decreased when combined with Flurithromycin.Experimental
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Cyclosporine.Approved, Investigational
FlutamideThe metabolism of Flutamide can be decreased when combined with Cyclosporine.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Fluticasone propionate.Approved
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Cyclosporine.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Fluvoxamine.Approved, Investigational
Folic AcidThe serum concentration of Folic Acid can be increased when it is combined with Cyclosporine.Approved, Nutraceutical, Vet Approved
ForasartanThe risk or severity of hyperkalemia can be increased when Forasartan is combined with Cyclosporine.Experimental
FormocortalThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Formocortal.Experimental
FosamprenavirThe metabolism of Cyclosporine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Cyclosporine can be increased when it is combined with Fosaprepitant.Approved
FoscarnetFoscarnet may increase the nephrotoxic activities of Cyclosporine.Approved
FosinoprilThe risk or severity of hyperkalemia can be increased when Fosinopril is combined with Cyclosporine.Approved
FosinoprilatThe risk or severity of hyperkalemia can be increased when Fosinoprilat is combined with Cyclosporine.Experimental
FosnetupitantThe metabolism of Fosnetupitant can be decreased when combined with Cyclosporine.Approved
FosphenytoinThe serum concentration of Cyclosporine can be decreased when it is combined with Fosphenytoin.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Cyclosporine.Approved, Illicit, Investigational
FostamatinibThe metabolism of Fostamatinib can be decreased when combined with Cyclosporine.Approved, Investigational
FramycetinThe risk or severity of adverse effects can be increased when Framycetin is combined with Cyclosporine.Approved
FulvestrantThe metabolism of Fulvestrant can be decreased when combined with Cyclosporine.Approved, Investigational
FurazolidoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Cyclosporine.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Cyclosporine can be increased when it is combined with Fusidic Acid.Approved, Investigational
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Cyclosporine.Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Cyclosporine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Cyclosporine.Approved, Investigational
GaboxadolThe risk or severity of adverse effects can be increased when Gaboxadol is combined with Cyclosporine.Investigational
GalantamineThe metabolism of Galantamine can be decreased when combined with Cyclosporine.Approved
GallamineThe therapeutic efficacy of Gallamine can be increased when used in combination with Cyclosporine.Experimental
Gallamine TriethiodideThe therapeutic efficacy of Gallamine Triethiodide can be increased when used in combination with Cyclosporine.Approved
Gallium nitrateThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Gallium nitrate.Approved, Investigational
GallopamilThe serum concentration of Cyclosporine can be increased when it is combined with Gallopamil.Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Cyclosporine.Approved, Illicit, Investigational
Gantacurium ChlorideThe risk or severity of adverse effects can be increased when Gantacurium Chloride is combined with Cyclosporine.Investigational
GedocarnilThe risk or severity of adverse effects can be increased when Gedocarnil is combined with Cyclosporine.Experimental
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Cyclosporine.Approved, Investigational
GemcitabineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Gemcitabine.Approved
GemfibrozilThe risk or severity of renal failure can be increased when Cyclosporine is combined with Gemfibrozil.Approved
Gemtuzumab ozogamicinThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Gemtuzumab ozogamicin.Approved, Investigational
GeneticinThe risk or severity of adverse effects can be increased when Geneticin is combined with Cyclosporine.Experimental
GenisteinThe serum concentration of Cyclosporine can be increased when it is combined with Genistein.Investigational
GentamicinThe risk or severity of adverse effects can be increased when Gentamicin is combined with Cyclosporine.Approved, Vet Approved
GENTAMICIN C1AThe risk or severity of adverse effects can be increased when Cyclosporine is combined with GENTAMICIN C1A.Experimental
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Cyclosporine.Investigational
GestodeneThe metabolism of Gestodene can be decreased when combined with Cyclosporine.Approved, Investigational
GestrinoneThe metabolism of Gestrinone can be decreased when combined with Cyclosporine.Approved
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with Cyclosporine.Investigational
GlatiramerThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Glatiramer.Approved, Investigational
GlecaprevirThe serum concentration of Glecaprevir can be increased when it is combined with Cyclosporine.Approved, Investigational
GlipizideThe metabolism of Glipizide can be decreased when combined with Cyclosporine.Approved, Investigational
GLPG-0492GLPG-0492 may increase the hepatotoxic activities of Cyclosporine.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Cyclosporine.Approved, Illicit
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Cyclosporine.Approved
GlycerinThe serum concentration of Cyclosporine can be increased when it is combined with Glycerin.Approved, Investigational
GlycodiazineThe metabolism of Cyclosporine can be increased when combined with Glycodiazine.Approved, Investigational
GolimumabThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Golimumab.Approved
GPI-1485The metabolism of Cyclosporine can be decreased when combined with GPI-1485.Investigational
Gramicidin DThe serum concentration of Gramicidin D can be increased when it is combined with Cyclosporine.Approved
GranisetronThe metabolism of Granisetron can be decreased when combined with Cyclosporine.Approved, Investigational
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Cyclosporine.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Cyclosporine.Approved, Investigational, Withdrawn
GriseofulvinThe serum concentration of Cyclosporine can be decreased when it is combined with Griseofulvin.Approved, Investigational, Vet Approved
GuacetisalThe risk or severity of renal failure and hypertension can be increased when Guacetisal is combined with Cyclosporine.Experimental
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Cyclosporine.Approved, Investigational
GusperimusThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Gusperimus.Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Cyclosporine.Approved, Illicit, Withdrawn
HalcinonideThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Halcinonide.Approved, Investigational, Withdrawn
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Cyclosporine.Approved
HalometasoneThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Halometasone.Experimental
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Cyclosporine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Cyclosporine.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Harmaline is combined with Cyclosporine.Experimental
HE3286The metabolism of HE3286 can be decreased when combined with Cyclosporine.Investigational
HeparinThe risk or severity of hyperkalemia can be increased when Heparin is combined with Cyclosporine.Approved, Investigational
Hepatitis A VaccineThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Cyclosporine.Approved
Hepatitis B Vaccine (Recombinant)The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Cyclosporine.Approved, Withdrawn
HeptabarbitalThe risk or severity of adverse effects can be increased when Heptabarbital is combined with Cyclosporine.Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Cyclosporine.Approved, Illicit, Investigational
HexafluroniumThe risk or severity of adverse effects can be increased when Hexafluronium is combined with Cyclosporine.Approved
HexamethoniumThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Hexamethonium.Experimental
HexapropymateThe risk or severity of adverse effects can be increased when Hexapropymate is combined with Cyclosporine.Experimental
HexobarbitalThe metabolism of Cyclosporine can be increased when combined with Hexobarbital.Approved
HistamineThe metabolism of Histamine can be decreased when combined with Cyclosporine.Approved, Investigational
HM-30181The serum concentration of Cyclosporine can be increased when it is combined with HM-30181.Experimental
Human rabies virus immune globulinThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Cyclosporine.Approved
HycanthoneThe serum concentration of Cyclosporine can be increased when it is combined with Hycanthone.Approved, Investigational
HydracarbazineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Cyclosporine.Experimental
HydrochlorothiazideThe metabolism of Cyclosporine can be increased when combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe metabolism of Hydrocodone can be decreased when combined with Cyclosporine.Approved, Illicit
HydrocortisoneThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Hydrocortisone.Approved, Vet Approved
Hydrocortisone aceponateThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Hydrocortisone aceponate.Experimental, Vet Approved
Hydrocortisone acetateThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Hydrocortisone acetate.Approved, Vet Approved
Hydrocortisone butyrateThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Hydrocortisone butyrate.Approved, Vet Approved
Hydrocortisone cypionateThe metabolism of Hydrocortisone cypionate can be decreased when combined with Cyclosporine.Approved, Vet Approved
Hydrocortisone phosphateThe metabolism of Hydrocortisone phosphate can be decreased when combined with Cyclosporine.Approved, Vet Approved
Hydrocortisone probutateThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Hydrocortisone probutate.Approved, Vet Approved
Hydrocortisone succinateThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Hydrocortisone succinate.Approved
Hydrocortisone valerateThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Hydrocortisone valerate.Approved, Vet Approved
HydroflumethiazideThe metabolism of Cyclosporine can be increased when combined with Hydroflumethiazide.Approved, Investigational
Hydrolyzed CephalothinThe risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Hydrolyzed Cephalothin.Experimental
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Cyclosporine.Approved, Illicit
HydroxychloroquineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Hydroxychloroquine.Approved
HydroxyfasudilThe metabolism of Cyclosporine can be increased when combined with Hydroxyfasudil.Experimental
HydroxyprogesteroneThe metabolism of Hydroxyprogesterone can be decreased when combined with Cyclosporine.Experimental
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be decreased when combined with Cyclosporine.Approved, Investigational
HydroxyureaThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Hydroxyurea.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Cyclosporine.Approved
Hygromycin BThe risk or severity of adverse effects can be increased when Hygromycin B is combined with Cyclosporine.Vet Approved
HypericinThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Hypericin.Investigational
IbandronateThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Cyclosporine is combined with Ibandronate.Approved, Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Ibritumomab tiuxetan.Approved, Investigational
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Cyclosporine.Approved
IbuprofenThe risk or severity of renal failure and hypertension can be increased when Ibuprofen is combined with Cyclosporine.Approved
IbuproxamThe risk or severity of renal failure and hypertension can be increased when Ibuproxam is combined with Cyclosporine.Withdrawn
IcosapentThe risk or severity of renal failure and hypertension can be increased when Icosapent is combined with Cyclosporine.Approved, Nutraceutical
IcotinibThe metabolism of Icotinib can be decreased when combined with Cyclosporine.Approved, Investigational
IdarubicinThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Idarubicin.Approved
IdelalisibThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Idelalisib.Approved
IfenprodilThe risk or severity of adverse effects can be increased when Ifenprodil is combined with Cyclosporine.Approved, Investigational, Withdrawn
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Cyclosporine resulting in a loss in efficacy.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Cyclosporine.Approved
ImagabalinThe risk or severity of adverse effects can be increased when Imagabalin is combined with Cyclosporine.Investigational
ImatinibThe serum concentration of Cyclosporine can be increased when it is combined with Imatinib.Approved
ImidafenacinThe metabolism of Imidafenacin can be decreased when combined with Cyclosporine.Approved, Investigational
ImidaprilThe risk or severity of hyperkalemia can be increased when Imidapril is combined with Cyclosporine.Investigational
Imidazole salicylateThe risk or severity of renal failure and hypertension can be increased when Imidazole salicylate is combined with Cyclosporine.Experimental
ImipenemCyclosporine may increase the neurotoxic activities of Imipenem.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Cyclosporine.Approved
Imipramine oxideThe risk or severity of adverse effects can be increased when Imipramine oxide is combined with Cyclosporine.Experimental
ImiquimodThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Imiquimod.Approved, Investigational
Incadronic acidThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Cyclosporine is combined with Incadronic acid.Approved, Investigational
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Cyclosporine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Indalpine.Investigational, Withdrawn
IndapamideThe metabolism of Cyclosporine can be increased when combined with Indapamide.Approved
IndenololThe risk or severity of hyperkalemia can be increased when Indenolol is combined with Cyclosporine.Withdrawn
IndinavirThe metabolism of Cyclosporine can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Indiplon is combined with Cyclosporine.Investigational
IndobufenThe risk or severity of renal failure and hypertension can be increased when Indobufen is combined with Cyclosporine.Investigational
IndomethacinThe risk or severity of renal failure and hypertension can be increased when Indomethacin is combined with Cyclosporine.Approved, Investigational
IndoprofenThe risk or severity of renal failure and hypertension can be increased when Indoprofen is combined with Cyclosporine.Withdrawn
InfliximabThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Infliximab.Approved
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Cyclosporine.Investigational
Inotuzumab ozogamicinThe serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Cyclosporine.Approved, Investigational
Interferon alfa-n3The risk or severity of adverse effects can be increased when Cyclosporine is combined with Interferon alfa-n3.Approved, Investigational
Interferon alfacon-1The risk or severity of adverse effects can be increased when Cyclosporine is combined with Interferon alfacon-1.Approved, Investigational
IpecacThe metabolism of Ipecac can be decreased when combined with Cyclosporine.Approved, Withdrawn
IpratropiumThe metabolism of Ipratropium can be decreased when combined with Cyclosporine.Approved
IprindoleThe risk or severity of adverse effects can be increased when Iprindole is combined with Cyclosporine.Experimental
IproclozideThe risk or severity of adverse effects can be increased when Iproclozide is combined with Cyclosporine.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Iproniazid is combined with Cyclosporine.Withdrawn
IrbesartanThe risk or severity of hyperkalemia can be increased when Irbesartan is combined with Cyclosporine.Approved, Investigational
IrinotecanThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Irinotecan.Approved, Investigational
IsavuconazoniumThe serum concentration of Cyclosporine can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsepamicinThe risk or severity of adverse effects can be increased when Isepamicin is combined with Cyclosporine.Experimental
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Cyclosporine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Cyclosporine.Approved, Vet Approved
IsoniazidThe metabolism of Cyclosporine can be decreased when combined with Isoniazid.Approved, Investigational
Isosorbide DinitrateThe metabolism of Isosorbide Dinitrate can be decreased when combined with Cyclosporine.Approved, Investigational
Isosorbide MononitrateThe metabolism of Isosorbide Mononitrate can be decreased when combined with Cyclosporine.Approved
IsoxicamThe risk or severity of renal failure and hypertension can be increased when Isoxicam is combined with Cyclosporine.Withdrawn
IsradipineThe metabolism of Isradipine can be decreased when combined with Cyclosporine.Approved, Investigational
ItraconazoleThe metabolism of Cyclosporine can be decreased when combined with Itraconazole.Approved, Investigational
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Cyclosporine.Approved
IvacaftorThe serum concentration of Ivacaftor can be increased when it is combined with Cyclosporine.Approved
IvermectinThe metabolism of Cyclosporine can be decreased when combined with Ivermectin.Approved, Investigational, Vet Approved
IvosidenibThe serum concentration of Ivosidenib can be increased when it is combined with Cyclosporine.Approved, Investigational
IxabepiloneThe metabolism of Cyclosporine can be decreased when combined with Ixabepilone.Approved, Investigational
IxazomibThe metabolism of Ixazomib can be decreased when combined with Cyclosporine.Approved, Investigational
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Cyclosporine.Approved
JosamycinThe metabolism of Cyclosporine can be decreased when combined with Josamycin.Approved, Investigational
KanamycinThe risk or severity of adverse effects can be increased when Kanamycin is combined with Cyclosporine.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of renal failure and hypertension can be increased when Kebuzone is combined with Cyclosporine.Experimental
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Cyclosporine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Cyclosporine.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Cyclosporine.Approved, Investigational
KetoconazoleThe metabolism of Cyclosporine can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of renal failure and hypertension can be increased when Ketoprofen is combined with Cyclosporine.Approved, Vet Approved
KetorolacThe risk or severity of renal failure and hypertension can be increased when Ketorolac is combined with Cyclosporine.Approved
KitasamycinThe metabolism of Cyclosporine can be decreased when combined with Kitasamycin.Experimental
KOS-1584The metabolism of Cyclosporine can be decreased when combined with KOS-1584.Investigational
L-PhenylalanineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with L-Phenylalanine.Approved, Investigational, Nutraceutical
L-TryptophanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Cyclosporine.Approved, Nutraceutical, Withdrawn
LabetalolThe risk or severity of hyperkalemia can be increased when Labetalol is combined with Cyclosporine.Approved
LacidipineThe metabolism of Lacidipine can be decreased when combined with Cyclosporine.Approved, Investigational
LacosamideThe risk or severity of adverse effects can be increased when Lacosamide is combined with Cyclosporine.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Cyclosporine.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Cyclosporine.Approved, Investigational
LandiololThe risk or severity of hyperkalemia can be increased when Landiolol is combined with Cyclosporine.Investigational
LanicemineThe risk or severity of adverse effects can be increased when Lanicemine is combined with Cyclosporine.Investigational
LaniquidarThe serum concentration of Cyclosporine can be increased when it is combined with Laniquidar.Investigational
LanreotideThe serum concentration of Cyclosporine can be decreased when it is combined with Lanreotide.Approved
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Cyclosporine.Approved, Investigational
LapatinibThe serum concentration of Cyclosporine can be increased when it is combined with Lapatinib.Approved, Investigational
LaquinimodThe metabolism of Laquinimod can be decreased when combined with Cyclosporine.Investigational
LatamoxefThe risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Latamoxef.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Cyclosporine.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Leflunomide.Approved, Investigational
LenalidomideThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Lenalidomide.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Cyclosporine.Approved, Investigational
LercanidipineThe serum concentration of Cyclosporine can be increased when it is combined with Lercanidipine.Approved, Investigational
LetermovirThe serum concentration of Letermovir can be increased when it is combined with Cyclosporine.Approved, Investigational
LetrozoleThe metabolism of Letrozole can be decreased when combined with Cyclosporine.Approved, Investigational
LeuprolideThe metabolism of Leuprolide can be decreased when combined with Cyclosporine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Cyclosporine.Approved, Investigational
LevobetaxololThe risk or severity of hyperkalemia can be increased when Levobetaxolol is combined with Cyclosporine.Approved, Investigational
LevobunololThe risk or severity of hyperkalemia can be increased when Levobunolol is combined with Cyclosporine.Approved
LevobupivacaineThe metabolism of Levobupivacaine can be decreased when combined with Cyclosporine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Cyclosporine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Cyclosporine.Approved
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Cyclosporine.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Cyclosporine.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Levomilnacipran.Approved, Investigational
LevonorgestrelThe metabolism of Levonorgestrel can be decreased when combined with Cyclosporine.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Cyclosporine.Approved
LevothyroxineThe metabolism of Levothyroxine can be decreased when combined with Cyclosporine.Approved
LidocaineThe serum concentration of Cyclosporine can be increased when it is combined with Lidocaine.Approved, Vet Approved
LidoflazineThe metabolism of Lidoflazine can be decreased when combined with Cyclosporine.Experimental
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Cyclosporine.Approved
LincomycinThe risk or severity of adverse effects can be increased when Lincomycin is combined with Cyclosporine.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Linezolid.Approved, Investigational
LiothyronineThe metabolism of Liothyronine can be decreased when combined with Cyclosporine.Approved, Vet Approved
LiotrixThe metabolism of Liotrix can be decreased when combined with Cyclosporine.Approved
LisinoprilThe risk or severity of hyperkalemia can be increased when Lisinopril is combined with Cyclosporine.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Cyclosporine.Approved, Investigational
Lithium carbonateThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Lithium carbonate.Approved
Lithium cationThe risk or severity of adverse effects can be increased when Lithium cation is combined with Cyclosporine.Experimental
LobeglitazoneThe metabolism of Lobeglitazone can be decreased when combined with Cyclosporine.Approved, Investigational
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Cyclosporine.Illicit
LofepramineThe risk or severity of adverse effects can be increased when Lofepramine is combined with Cyclosporine.Experimental
LofexidineThe therapeutic efficacy of Cyclosporine can be increased when used in combination with Lofexidine.Approved, Investigational
LomerizineThe serum concentration of Cyclosporine can be increased when it is combined with Lomerizine.Experimental
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Cyclosporine.Approved, Investigational
LomustineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Lomustine.Approved, Investigational
LonafarnibThe serum concentration of Cyclosporine can be increased when it is combined with Lonafarnib.Investigational
LonazolacThe risk or severity of renal failure and hypertension can be increased when Lonazolac is combined with Cyclosporine.Experimental
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Cyclosporine.Approved
LopinavirThe metabolism of Cyclosporine can be decreased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Loprazolam is combined with Cyclosporine.Experimental
LoracarbefThe risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Loracarbef.Investigational, Withdrawn
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Cyclosporine.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Cyclosporine.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Cyclosporine.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Cyclosporine.Approved
LornoxicamThe risk or severity of renal failure and hypertension can be increased when Lornoxicam is combined with Cyclosporine.Approved, Investigational
LorpiprazoleThe serum concentration of Cyclosporine can be increased when it is combined with Lorpiprazole.Approved
LortalamineThe risk or severity of adverse effects can be increased when Lortalamine is combined with Cyclosporine.Experimental
Lorvotuzumab mertansineThe metabolism of Cyclosporine can be decreased when combined with Lorvotuzumab mertansine.Investigational
LosartanThe risk or severity of hyperkalemia can be increased when Losartan is combined with Cyclosporine.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Loteprednol.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Cyclosporine.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Cyclosporine.Approved
LoxoprofenThe risk or severity of renal failure and hypertension can be increased when Loxoprofen is combined with Cyclosporine.Approved, Investigational
LuliconazoleThe serum concentration of Cyclosporine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Cyclosporine can be decreased when it is combined with Lumacaftor.Approved
LumateperoneThe risk or severity of adverse effects can be increased when Lumateperone is combined with Cyclosporine.Investigational
LumefantrineThe metabolism of Lumefantrine can be decreased when combined with Cyclosporine.Approved
LumiracoxibThe risk or severity of renal failure and hypertension can be increased when Lumiracoxib is combined with Cyclosporine.Approved, Investigational
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Cyclosporine.Approved, Investigational
LymecyclineThe risk or severity of adverse effects can be increased when Lymecycline is combined with Cyclosporine.Approved, Investigational
LynestrenolThe metabolism of Lynestrenol can be decreased when combined with Cyclosporine.Approved, Investigational
Lysergic Acid DiethylamideThe metabolism of Lysergic Acid Diethylamide can be decreased when combined with Cyclosporine.Illicit, Investigational, Withdrawn
MacimorelinThe metabolism of Macimorelin can be decreased when combined with Cyclosporine.Approved, Investigational
MacitentanThe metabolism of Macitentan can be decreased when combined with Cyclosporine.Approved
MafenideThe metabolism of Cyclosporine can be increased when combined with Mafenide.Approved, Vet Approved
Magnesium acetateThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Magnesium acetate.Approved
Magnesium acetate tetrahydrateThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Magnesium acetate tetrahydrate.Approved
Magnesium Aluminum SilicateThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Magnesium Aluminum Silicate.Approved
Magnesium aspartateThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Magnesium aspartate.Experimental
Magnesium carbonateThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Magnesium carbonate.Approved, Investigational
Magnesium cationThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Magnesium cation.Approved, Nutraceutical
Magnesium chlorideThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Magnesium chloride.Approved
Magnesium citrateThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Magnesium citrate.Approved
Magnesium gluconateThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Magnesium gluconate.Approved, Investigational
Magnesium glycinateThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Magnesium glycinate.Approved
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Magnesium hydroxide.Approved, Investigational
Magnesium orotateThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Magnesium orotate.Experimental
Magnesium oxideThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Magnesium oxide.Approved
Magnesium phosphateThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Magnesium phosphate.Experimental
Magnesium salicylateThe risk or severity of renal failure and hypertension can be increased when Magnesium salicylate is combined with Cyclosporine.Approved
Magnesium silicateThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Magnesium silicate.Approved
Magnesium stearateThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Magnesium stearate.Investigational
Magnesium sulfateThe therapeutic efficacy of Cyclosporine can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Magnesium Trisilicate.Approved
ManidipineThe metabolism of Manidipine can be decreased when combined with Cyclosporine.Approved, Investigational
MannitolThe risk or severity of nephrotoxicity can be increased when Mannitol is combined with Cyclosporine.Approved, Investigational
Mannitol busulfanThe risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Mannitol busulfan.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Cyclosporine.Approved, Investigational
MaravirocThe metabolism of Maraviroc can be decreased when combined with Cyclosporine.Approved, Investigational
MazindolThe risk or severity of adverse effects can be increased when Mazindol is combined with Cyclosporine.Approved, Investigational
MebanazineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Cyclosporine.Withdrawn
MebendazoleThe metabolism of Mebendazole can be decreased when combined with Cyclosporine.Approved, Vet Approved
MebicarThe risk or severity of adverse effects can be increased when Mebicar is combined with Cyclosporine.Experimental
MebutamateThe risk or severity of adverse effects can be increased when Mebutamate is combined with Cyclosporine.Approved
MebutizideThe metabolism of Cyclosporine can be increased when combined with Mebutizide.Experimental
MecamylamineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Mecamylamine.Approved, Investigational
MechlorethamineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Mechlorethamine.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Cyclosporine.Approved
Meclofenamic acidThe risk or severity of renal failure and hypertension can be increased when Meclofenamic acid is combined with Cyclosporine.Approved, Vet Approved
MedazepamThe risk or severity of adverse effects can be increased when Medazepam is combined with Cyclosporine.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Cyclosporine.Vet Approved
Medical CannabisThe metabolism of Medical Cannabis can be decreased when combined with Cyclosporine.Experimental, Investigational
MedifoxamineThe risk or severity of adverse effects can be increased when Medifoxamine is combined with Cyclosporine.Experimental
MedrogestoneThe metabolism of Cyclosporine can be decreased when combined with Medrogestone.Approved
Medroxyprogesterone acetateThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Cyclosporine.Approved, Investigational
MedrysoneThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of renal failure and hypertension can be increased when Mefenamic acid is combined with Cyclosporine.Approved
MefloquineThe serum concentration of Mefloquine can be increased when it is combined with Cyclosporine.Approved, Investigational
MefrusideThe metabolism of Cyclosporine can be increased when combined with Mefruside.Experimental
Megestrol acetateThe serum concentration of Cyclosporine can be increased when it is combined with Megestrol acetate.Approved, Investigational, Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Cyclosporine.Approved, Nutraceutical, Vet Approved
MelengestrolThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Melengestrol.Vet Approved
MelitracenThe risk or severity of adverse effects can be increased when Melitracen is combined with Cyclosporine.Experimental, Investigational
MeloxicamThe risk or severity of renal failure and hypertension can be increased when Meloxicam is combined with Cyclosporine.Approved, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Cyclosporine.Approved, Investigational
MelphalanMelphalan may increase the nephrotoxic activities of Cyclosporine.Approved
MentholThe metabolism of Menthol can be decreased when combined with Cyclosporine.Approved
MepartricinThe metabolism of Cyclosporine can be decreased when combined with Mepartricin.Experimental
MephenesinThe risk or severity of adverse effects can be increased when Mephenesin is combined with Cyclosporine.Approved
MephenoxaloneThe risk or severity of adverse effects can be increased when Mephenoxalone is combined with Cyclosporine.Experimental
MephenytoinThe risk or severity of adverse effects can be increased when Mephenytoin is combined with Cyclosporine.Investigational, Withdrawn
MepindololThe risk or severity of hyperkalemia can be increased when Mepindolol is combined with Cyclosporine.Experimental
MepolizumabThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Mepolizumab.Approved, Investigational
MeprednisoneThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Meprednisone.Approved, Investigational
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Cyclosporine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Cyclosporine.Experimental
MercaptopurineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Mercaptopurine.Approved
MesalazineThe risk or severity of renal failure and hypertension can be increased when Mesalazine is combined with Cyclosporine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Cyclosporine.Approved, Investigational
MesteroloneMesterolone may increase the hepatotoxic activities of Cyclosporine.Experimental
MestranolThe metabolism of Mestranol can be decreased when combined with Cyclosporine.Approved
MetamizoleThe risk or severity of renal failure and hypertension can be increased when Metamizole is combined with Cyclosporine.Approved, Investigational, Withdrawn
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Cyclosporine.Approved
MetergolineThe metabolism of Metergoline can be decreased when combined with Cyclosporine.Experimental
MethacyclineThe risk or severity of adverse effects can be increased when Methacycline is combined with Cyclosporine.Approved, Investigational
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Cyclosporine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Cyclosporine.Approved, Illicit
MethamphetamineThe risk or severity of adverse effects can be increased when Methamphetamine is combined with Cyclosporine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Cyclosporine.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Cyclosporine.Illicit, Withdrawn
MetharbitalThe risk or severity of adverse effects can be increased when Metharbital is combined with Cyclosporine.Withdrawn
MethimazoleThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Methimazole.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Cyclosporine.Approved, Vet Approved
MethohexitalThe metabolism of Cyclosporine can be increased when combined with Methohexital.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Cyclosporine.Approved
MethotrimeprazineCyclosporine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxsalenThe metabolism of Methoxsalen can be decreased when combined with Cyclosporine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Cyclosporine.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Cyclosporine.Approved
MethyclothiazideThe metabolism of Cyclosporine can be increased when combined with Methyclothiazide.Approved
Methylene blueThe risk or severity of adverse effects can be increased when Methylene blue is combined with Cyclosporine.Approved, Investigational
MethylergometrineThe metabolism of Methylergometrine can be decreased when combined with Cyclosporine.Approved
MethylpentynolThe risk or severity of adverse effects can be increased when Methylpentynol is combined with Cyclosporine.Experimental
MethylphenobarbitalThe metabolism of Cyclosporine can be increased when combined with Methylphenobarbital.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Cyclosporine.Approved, Vet Approved
MethyltestosteroneMethyltestosterone may increase the hepatotoxic activities of Cyclosporine.Approved
MethyprylonThe risk or severity of adverse effects can be increased when Methyprylon is combined with Cyclosporine.Approved, Illicit, Withdrawn
MethysergideThe metabolism of Methysergide can be decreased when combined with Cyclosporine.Approved
MeticraneThe metabolism of Cyclosporine can be increased when combined with Meticrane.Experimental
MetipranololThe risk or severity of hyperkalemia can be increased when Metipranolol is combined with Cyclosporine.Approved
MetoclopramideMetoclopramide can cause an increase in the absorption of Cyclosporine resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
MetocurineThe therapeutic efficacy of Metocurine can be increased when used in combination with Cyclosporine.Approved
Metocurine IodideThe therapeutic efficacy of Metocurine Iodide can be increased when used in combination with Cyclosporine.Approved, Withdrawn
MetolazoneThe metabolism of Cyclosporine can be increased when combined with Metolazone.Approved
MetoprololThe risk or severity of hyperkalemia can be increased when Metoprolol is combined with Cyclosporine.Approved, Investigational
MetreleptinThe serum concentration of Cyclosporine can be decreased when it is combined with Metreleptin.Approved
MetronidazoleThe serum concentration of Cyclosporine can be increased when it is combined with Metronidazole.Approved
MetyrosineCyclosporine may increase the sedative activities of Metyrosine.Approved
MevastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Cyclosporine is combined with Mevastatin.Experimental
MexiletineThe metabolism of Mexiletine can be decreased when combined with Cyclosporine.Approved, Investigational
MianserinThe risk or severity of adverse effects can be increased when Mianserin is combined with Cyclosporine.Approved, Investigational
MibefradilThe metabolism of Cyclosporine can be decreased when combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe serum concentration of Cyclosporine can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MicronomicinThe risk or severity of adverse effects can be increased when Micronomicin is combined with Cyclosporine.Experimental
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Cyclosporine.Approved, Illicit
MidecamycinThe metabolism of Cyclosporine can be decreased when combined with Midecamycin.Approved
MidomafetamineThe risk or severity of adverse effects can be increased when Midomafetamine is combined with Cyclosporine.Experimental, Illicit, Investigational
MidostaurinThe metabolism of Midostaurin can be decreased when combined with Cyclosporine.Approved, Investigational
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Cyclosporine.Approved, Experimental
MifepristoneThe serum concentration of Cyclosporine can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Milnacipran.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Minaprine is combined with Cyclosporine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Cyclosporine.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Minoxidil.Approved, Investigational
MiocamycinThe metabolism of Cyclosporine can be decreased when combined with Miocamycin.Experimental
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Cyclosporine.Approved
MirtazapineCyclosporine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
Mirvetuximab SoravtansineThe metabolism of Cyclosporine can be decreased when combined with Mirvetuximab Soravtansine.Investigational
MitemcinalThe metabolism of Cyclosporine can be decreased when combined with Mitemcinal.Investigational
MitomycinThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Mitomycin.Approved
MitotaneThe serum concentration of Cyclosporine can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Cyclosporine.Approved, Investigational
MivacuriumThe therapeutic efficacy of Mivacurium can be increased when used in combination with Cyclosporine.Approved
MizoribineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Mizoribine.Investigational
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Cyclosporine.Approved, Investigational
ModafinilThe serum concentration of Cyclosporine can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of hyperkalemia can be increased when Moexipril is combined with Cyclosporine.Approved
MofebutazoneThe risk or severity of renal failure and hypertension can be increased when Mofebutazone is combined with Cyclosporine.Experimental
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Cyclosporine.Approved
MometasoneThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Mometasone.Approved, Vet Approved
Mometasone furoateThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Mometasone furoate.Approved, Vet Approved
MonensinThe serum concentration of Cyclosporine can be increased when it is combined with Monensin.Vet Approved
MontelukastThe metabolism of Montelukast can be decreased when combined with Cyclosporine.Approved
MoperoneThe risk or severity of adverse effects can be increased when Moperone is combined with Cyclosporine.Experimental
MoricizineThe risk or severity of adverse effects can be increased when Moricizine is combined with Cyclosporine.Approved, Investigational, Withdrawn
MorniflumateThe risk or severity of renal failure and hypertension can be increased when Morniflumate is combined with Cyclosporine.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Cyclosporine.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Mosapramine is combined with Cyclosporine.Experimental
MoxidectinThe serum concentration of Moxidectin can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
MRK-409The risk or severity of adverse effects can be increased when MRK-409 is combined with Cyclosporine.Experimental
MuromonabThe risk or severity of adverse effects can be increased when Muromonab is combined with Cyclosporine.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Cyclosporine.Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Cyclosporine.Approved, Investigational
NabiximolsThe metabolism of Nabiximols can be decreased when combined with Cyclosporine.Approved, Investigational
NabumetoneThe risk or severity of renal failure and hypertension can be increased when Nabumetone is combined with Cyclosporine.Approved
NadololThe serum concentration of Nadolol can be increased when it is combined with Cyclosporine.Approved
NadroparinThe risk or severity of hyperkalemia can be increased when Nadroparin is combined with Cyclosporine.Approved, Investigational
NafcillinThe metabolism of Cyclosporine can be increased when combined with Nafcillin.Approved, Investigational
NaftopidilThe metabolism of Naftopidil can be decreased when combined with Cyclosporine.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Cyclosporine.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Cyclosporine.Approved
NaloxoneThe metabolism of Cyclosporine can be decreased when combined with Naloxone.Approved, Vet Approved
NaltrexoneThe metabolism of Naltrexone can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
NandroloneNandrolone may increase the hepatotoxic activities of Cyclosporine.Experimental, Investigational
Nandrolone decanoateNandrolone decanoate may increase the hepatotoxic activities of Cyclosporine.Approved, Illicit
NaproxenThe risk or severity of renal failure and hypertension can be increased when Naproxen is combined with Cyclosporine.Approved, Vet Approved
NatalizumabThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Natalizumab.Approved, Investigational
NatamycinThe metabolism of Cyclosporine can be decreased when combined with Natamycin.Approved
NateglinideThe metabolism of Nateglinide can be decreased when combined with Cyclosporine.Approved, Investigational
NeamineThe risk or severity of adverse effects can be increased when Neamine is combined with Cyclosporine.Experimental
NebivololThe risk or severity of hyperkalemia can be increased when Nebivolol is combined with Cyclosporine.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Nefazodone.Approved, Withdrawn
NefiracetamThe risk or severity of adverse effects can be increased when Nefiracetam is combined with Cyclosporine.Investigational
NelarabineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Nelarabine.Approved, Investigational
NelfinavirThe metabolism of Cyclosporine can be decreased when combined with Nelfinavir.Approved
NeocitrullamonThe risk or severity of adverse effects can be increased when Neocitrullamon is combined with Cyclosporine.Experimental
NeomycinThe risk or severity of adverse effects can be increased when Neomycin is combined with Cyclosporine.Approved, Vet Approved
NeosaxitoxinThe therapeutic efficacy of Neosaxitoxin can be increased when used in combination with Cyclosporine.Investigational
NeostigmineThe serum concentration of Neostigmine can be increased when it is combined with Cyclosporine.Approved, Vet Approved
NepafenacThe risk or severity of renal failure and hypertension can be increased when Nepafenac is combined with Cyclosporine.Approved, Investigational
NeratinibThe serum concentration of Cyclosporine can be increased when it is combined with Neratinib.Approved, Investigational
NetilmicinThe risk or severity of adverse effects can be increased when Netilmicin is combined with Cyclosporine.Approved, Investigational
NetoglitazoneThe metabolism of Netoglitazone can be decreased when combined with Cyclosporine.Experimental
NetupitantThe serum concentration of Cyclosporine can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Cyclosporine can be increased when combined with Nevirapine.Approved
NialamideThe risk or severity of adverse effects can be increased when Nialamide is combined with Cyclosporine.Withdrawn
NiaprazineThe risk or severity of adverse effects can be increased when Niaprazine is combined with Cyclosporine.Experimental
NicardipineThe metabolism of Nicardipine can be decreased when combined with Cyclosporine.Approved, Investigational
NicergolineThe metabolism of Nicergoline can be decreased when combined with Cyclosporine.Approved, Investigational
NicotineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Nicotine.Approved
NifedipineThe metabolism of Nifedipine can be decreased when combined with Cyclosporine.Approved
NifenazoneThe risk or severity of renal failure and hypertension can be increased when Nifenazone is combined with Cyclosporine.Experimental
Niflumic AcidThe risk or severity of renal failure and hypertension can be increased when Niflumic Acid is combined with Cyclosporine.Approved
NigericinThe serum concentration of Cyclosporine can be increased when it is combined with Nigericin.Experimental
NiguldipineThe serum concentration of Cyclosporine can be increased when it is combined with Niguldipine.Experimental
NilotinibThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Nilotinib.Approved, Investigational
NiludipineThe metabolism of Niludipine can be decreased when combined with Cyclosporine.Experimental
NilvadipineThe metabolism of Nilvadipine can be decreased when combined with Cyclosporine.Approved, Investigational
NimesulideThe risk or severity of renal failure and hypertension can be increased when Nimesulide is combined with Cyclosporine.Approved, Investigational, Withdrawn
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Cyclosporine.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Cyclosporine.Approved
NisoldipineThe metabolism of Nisoldipine can be decreased when combined with Cyclosporine.Approved
NisoxetineThe risk or severity of adverse effects can be increased when Nisoxetine is combined with Cyclosporine.Experimental
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Cyclosporine.Approved
NitrendipineThe serum concentration of Cyclosporine can be increased when it is combined with Nitrendipine.Approved, Investigational
NitroaspirinThe risk or severity of renal failure and hypertension can be increased when Nitroaspirin is combined with Cyclosporine.Investigational
NitrofurantoinThe serum concentration of Nitrofurantoin can be increased when it is combined with Cyclosporine.Approved, Vet Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Cyclosporine.Approved, Vet Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Cyclosporine.Approved
NomegestrolThe metabolism of Nomegestrol can be decreased when combined with Cyclosporine.Approved
Nomegestrol acetateThe metabolism of Nomegestrol acetate can be decreased when combined with Cyclosporine.Approved, Investigational
NomifensineThe risk or severity of adverse effects can be increased when Nomifensine is combined with Cyclosporine.Withdrawn
NordazepamThe risk or severity of adverse effects can be increased when Nordazepam is combined with Cyclosporine.Approved
NorelgestrominThe metabolism of Norelgestromin can be decreased when combined with Cyclosporine.Approved, Investigational
NorethisteroneThe metabolism of Norethisterone can be decreased when combined with Cyclosporine.Approved
NorethynodrelThe metabolism of Norethynodrel can be decreased when combined with Cyclosporine.Approved
NorfloxacinThe metabolism of Cyclosporine can be decreased when combined with Norfloxacin.Approved
NorgestimateThe metabolism of Norgestimate can be decreased when combined with Cyclosporine.Approved, Investigational
NorgestrelThe metabolism of Norgestrel can be decreased when combined with Cyclosporine.Approved
NorgestrienoneThe metabolism of Norgestrienone can be decreased when combined with Cyclosporine.Experimental
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Cyclosporine.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Cyclosporine.Approved
NS-398The risk or severity of renal failure and hypertension can be increased when NS-398 is combined with Cyclosporine.Experimental
NylidrinThe metabolism of Nylidrin can be decreased when combined with Cyclosporine.Approved
NystatinThe metabolism of Cyclosporine can be decreased when combined with Nystatin.Approved, Vet Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Obinutuzumab.Approved, Investigational
OcrelizumabThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Ocrelizumab.Approved, Investigational
OctamoxinThe risk or severity of adverse effects can be increased when Octamoxin is combined with Cyclosporine.Withdrawn
OctreotideThe serum concentration of Cyclosporine can be decreased when it is combined with Octreotide.Approved, Investigational
OdanacatibThe serum concentration of Odanacatib can be increased when it is combined with Cyclosporine.Investigational
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Cyclosporine.Approved, Investigational
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Cyclosporine.Approved
OleandomycinThe metabolism of Cyclosporine can be decreased when combined with Oleandomycin.Vet Approved
OlmesartanThe risk or severity of hyperkalemia can be increased when Olmesartan is combined with Cyclosporine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Cyclosporine.Approved
OlsalazineThe risk or severity of renal failure and hypertension can be increased when Olsalazine is combined with Cyclosporine.Approved
OmapatrilatThe risk or severity of hyperkalemia can be increased when Omapatrilat is combined with Cyclosporine.Investigational
OmbitasvirThe serum concentration of Cyclosporine can be increased when it is combined with Ombitasvir.Approved, Investigational
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Cyclosporine.Approved
ONT-093The serum concentration of Cyclosporine can be increased when it is combined with ONT-093.Investigational
OpipramolThe risk or severity of adverse effects can be increased when Opipramol is combined with Cyclosporine.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Cyclosporine.Approved, Illicit
OrlistatOrlistat can cause a decrease in the absorption of Cyclosporine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
OrphenadrineCyclosporine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OrvepitantThe risk or severity of adverse effects can be increased when Orvepitant is combined with Cyclosporine.Investigational
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Cyclosporine.Investigational
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Cyclosporine.Approved, Investigational
OtiloniumThe metabolism of Otilonium can be decreased when combined with Cyclosporine.Experimental, Investigational
OxaflozaneThe risk or severity of adverse effects can be increased when Oxaflozane is combined with Cyclosporine.Experimental
OxaliplatinThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Oxaliplatin.Approved, Investigational
OxandroloneOxandrolone may increase the hepatotoxic activities of Cyclosporine.Approved, Investigational
OxaprotilineThe risk or severity of adverse effects can be increased when Oxaprotiline is combined with Cyclosporine.Experimental
OxaprozinThe risk or severity of renal failure and hypertension can be increased when Oxaprozin is combined with Cyclosporine.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Cyclosporine.Approved
OxcarbazepineThe risk or severity of adverse effects can be increased when Oxcarbazepine is combined with Cyclosporine.Approved
OxiracetamThe risk or severity of adverse effects can be increased when Oxiracetam is combined with Cyclosporine.Experimental
OxitriptanThe risk or severity of adverse effects can be increased when Oxitriptan is combined with Cyclosporine.Approved, Investigational, Nutraceutical
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Cyclosporine.Approved
OxybutyninThe metabolism of Oxybutynin can be decreased when combined with Cyclosporine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Oxycodone.Approved, Illicit, Investigational
OxymetholoneOxymetholone may increase the hepatotoxic activities of Cyclosporine.Approved, Illicit
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Cyclosporine.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Oxypertine is combined with Cyclosporine.Experimental
OxyphenbutazoneThe risk or severity of renal failure and hypertension can be increased when Oxyphenbutazone is combined with Cyclosporine.Approved, Withdrawn
OxytetracyclineThe risk or severity of adverse effects can be increased when Oxytetracycline is combined with Cyclosporine.Approved, Investigational, Vet Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Cyclosporine can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe serum concentration of Paliperidone can be decreased when it is combined with Cyclosporine.Approved
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Cyclosporine.Approved, Investigational
PamidronateThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Cyclosporine is combined with Pamidronate.Approved
PancuroniumThe therapeutic efficacy of Pancuronium can be increased when used in combination with Cyclosporine.Approved
PanobinostatThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Panobinostat.Approved, Investigational
PantoprazoleThe serum concentration of Pantoprazole can be increased when it is combined with Cyclosporine.Approved
ParaldehydeCyclosporine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParamethadioneThe risk or severity of adverse effects can be increased when Paramethadione is combined with Cyclosporine.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Paramethasone.Approved
ParecoxibThe risk or severity of renal failure and hypertension can be increased when Parecoxib is combined with Cyclosporine.Approved
PargylineThe risk or severity of adverse effects can be increased when Pargyline is combined with Cyclosporine.Approved
ParicalcitolThe metabolism of Paricalcitol can be decreased when combined with Cyclosporine.Approved, Investigational
ParitaprevirThe serum concentration of Cyclosporine can be increased when it is combined with Paritaprevir.Approved, Investigational
ParnaparinThe risk or severity of hyperkalemia can be increased when Parnaparin is combined with Cyclosporine.Approved, Investigational
ParomomycinThe risk or severity of adverse effects can be increased when Paromomycin is combined with Cyclosporine.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Paroxetine.Approved, Investigational
PasireotideThe serum concentration of Cyclosporine can be decreased when it is combined with Pasireotide.Approved
PatupiloneThe metabolism of Cyclosporine can be decreased when combined with Patupilone.Experimental, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Cyclosporine.Approved
PegaspargaseThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Pegaspargase.Approved, Investigational
Peginterferon alfa-2aThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Peginterferon alfa-2a.Approved, Investigational
Peginterferon alfa-2bThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Peginterferon alfa-2b.Approved
PemetrexedThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Pemetrexed.Approved, Investigational
PenbutololThe risk or severity of hyperkalemia can be increased when Penbutolol is combined with Cyclosporine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with Cyclosporine.Experimental
Penicillin G Acyl-SerineThe risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Penicillin G Acyl-Serine.Experimental
PenimepicyclineThe risk or severity of adverse effects can be increased when Penimepicycline is combined with Cyclosporine.Experimental
PentamidineThe risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Pentamidine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Cyclosporine.Approved, Vet Approved
PentobarbitalThe metabolism of Cyclosporine can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Pentolinium.Approved
PentostatinThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Pentostatin.Approved, Investigational
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Cyclosporine.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Cyclosporine.Approved, Investigational
PergolideThe metabolism of Pergolide can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved, Withdrawn
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Cyclosporine.Approved, Investigational
PerindoprilThe risk or severity of hyperkalemia can be increased when Perindopril is combined with Cyclosporine.Approved
PerindoprilatThe risk or severity of hyperkalemia can be increased when Perindoprilat is combined with Cyclosporine.Experimental
PermethrinThe metabolism of Permethrin can be decreased when combined with Cyclosporine.Approved, Investigational
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Cyclosporine.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Cyclosporine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Cyclosporine.Approved
PhenacemideThe risk or severity of adverse effects can be increased when Phenacemide is combined with Cyclosporine.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Cyclosporine.Withdrawn
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Cyclosporine.Experimental
PhencyclidineThe risk or severity of adverse effects can be increased when Phencyclidine is combined with Cyclosporine.Illicit
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Cyclosporine.Approved
PhenethylamineThe risk or severity of adverse effects can be increased when Phenethylamine is combined with Cyclosporine.Experimental
PheneturideThe risk or severity of adverse effects can be increased when Pheneturide is combined with Cyclosporine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Phenibut is combined with Cyclosporine.Experimental
PheniprazineThe risk or severity of adverse effects can be increased when Pheniprazine is combined with Cyclosporine.Withdrawn
PhenobarbitalThe metabolism of Cyclosporine can be increased when combined with Phenobarbital.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Cyclosporine.Experimental
PhenothiazineThe serum concentration of Phenothiazine can be increased when it is combined with Cyclosporine.Vet Approved
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be decreased when combined with Cyclosporine.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Cyclosporine.Withdrawn
PhenprobamateThe risk or severity of adverse effects can be increased when Phenprobamate is combined with Cyclosporine.Experimental
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Cyclosporine.Approved, Investigational
PhensuximideThe risk or severity of adverse effects can be increased when Phensuximide is combined with Cyclosporine.Approved
PhenylbutazoneThe risk or severity of renal failure and hypertension can be increased when Phenylbutazone is combined with Cyclosporine.Approved, Vet Approved
PhenytoinThe metabolism of Cyclosporine can be increased when combined with Phenytoin.Approved, Vet Approved
PhthalylsulfathiazoleThe metabolism of Cyclosporine can be increased when combined with Phthalylsulfathiazole.Experimental
PibrentasvirThe serum concentration of Pibrentasvir can be increased when it is combined with Cyclosporine.Approved, Investigational
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Cyclosporine.Approved, Investigational
PimavanserinThe risk or severity of adverse effects can be increased when Pimavanserin is combined with Cyclosporine.Approved, Investigational
PimecrolimusThe metabolism of Cyclosporine can be decreased when combined with Pimecrolimus.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Cyclosporine.Approved
PinacidilThe metabolism of Pinacidil can be decreased when combined with Cyclosporine.Approved
PinaveriumThe metabolism of Pinaverium can be decreased when combined with Cyclosporine.Approved
PinazepamThe risk or severity of adverse effects can be increased when Pinazepam is combined with Cyclosporine.Experimental
PindololThe risk or severity of hyperkalemia can be increased when Pindolol is combined with Cyclosporine.Approved, Investigational
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Cyclosporine.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Cyclosporine.Approved, Investigational
PipecuroniumThe therapeutic efficacy of Pipecuronium can be increased when used in combination with Cyclosporine.Approved
PiperaquineThe metabolism of Piperaquine can be decreased when combined with Cyclosporine.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Cyclosporine.Approved, Investigational
PirarubicinThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Pirarubicin.Investigational
PiretanideThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Piretanide.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Pirfenidone.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Cyclosporine.Approved, Investigational
PirlimycinThe risk or severity of adverse effects can be increased when Pirlimycin is combined with Cyclosporine.Vet Approved
PirlindoleThe risk or severity of adverse effects can be increased when Pirlindole is combined with Cyclosporine.Approved
PiroxicamThe risk or severity of renal failure and hypertension can be increased when Piroxicam is combined with Cyclosporine.Approved, Investigational
PirprofenThe risk or severity of renal failure and hypertension can be increased when Pirprofen is combined with Cyclosporine.Experimental
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Cyclosporine.Approved
PitolisantThe serum concentration of Cyclosporine can be decreased when it is combined with Pitolisant.Approved, Investigational
PivagabineThe risk or severity of adverse effects can be increased when Pivagabine is combined with Cyclosporine.Investigational
PivhydrazineThe risk or severity of adverse effects can be increased when Pivhydrazine is combined with Cyclosporine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Cyclosporine.Approved
PlazomicinThe risk or severity of adverse effects can be increased when Plazomicin is combined with Cyclosporine.Approved, Investigational
PodofiloxThe metabolism of Podofilox can be decreased when combined with Cyclosporine.Approved
Polymyxin B SulfateThe risk or severity of adverse effects can be increased when Polymyxin B Sulfate is combined with Cyclosporine.Approved, Vet Approved
PolythiazideThe metabolism of Cyclosporine can be increased when combined with Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Pomalidomide.Approved
PonatinibThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Ponatinib.Approved, Investigational
PosaconazoleThe metabolism of Cyclosporine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
Potassium acetateThe risk or severity of hyperkalemia can be increased when Potassium acetate is combined with Cyclosporine.Approved, Investigational
Potassium bicarbonateThe risk or severity of hyperkalemia can be increased when Potassium bicarbonate is combined with Cyclosporine.Approved
Potassium cationThe risk or severity of hyperkalemia can be increased when Potassium cation is combined with Cyclosporine.Approved, Investigational
Potassium ChlorideThe risk or severity of hyperkalemia can be increased when Potassium Chloride is combined with Cyclosporine.Approved, Withdrawn
Potassium CitrateThe risk or severity of hyperkalemia can be increased when Potassium Citrate is combined with Cyclosporine.Approved, Investigational, Vet Approved
PractololThe risk or severity of hyperkalemia can be increased when Practolol is combined with Cyclosporine.Approved
PralatrexateThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Pralatrexate.Approved, Investigational
PramipexoleCyclosporine may increase the sedative activities of Pramipexole.Approved, Investigational
PranoprofenThe risk or severity of renal failure and hypertension can be increased when Pranoprofen is combined with Cyclosporine.Experimental, Investigational
PrasteroneThe metabolism of Prasterone can be decreased when combined with Cyclosporine.Approved, Investigational, Nutraceutical
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Cyclosporine.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Cyclosporine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Cyclosporine.Approved, Illicit
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Cyclosporine.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe serum concentration of Cyclosporine can be decreased when it is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe serum concentration of the active metabolites of Prednisone can be increased when Prednisone is used in combination with Cyclosporine.Approved, Vet Approved
PrednylideneThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Prednylidene.Experimental
PregabalinThe therapeutic efficacy of Cyclosporine can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PregnenoloneThe metabolism of Pregnenolone can be decreased when combined with Cyclosporine.Approved, Experimental, Investigational
PrenylamineThe metabolism of Prenylamine can be decreased when combined with Cyclosporine.Withdrawn
PridinolThe risk or severity of adverse effects can be increased when Pridinol is combined with Cyclosporine.Experimental
PrimaquineThe serum concentration of Cyclosporine can be increased when it is combined with Primaquine.Approved
PrimidoneThe metabolism of Cyclosporine can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe metabolism of Cyclosporine can be increased when combined with Probenecid.Approved, Investigational
ProcainamideThe risk or severity of adverse effects can be increased when Procainamide is combined with Cyclosporine.Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Cyclosporine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Procarbazine.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Cyclosporine.Approved, Vet Approved
ProgabideThe risk or severity of adverse effects can be increased when Progabide is combined with Cyclosporine.Approved, Investigational
ProgesteroneThe serum concentration of Cyclosporine can be increased when it is combined with Progesterone.Approved, Vet Approved
ProglumetacinThe risk or severity of renal failure and hypertension can be increased when Proglumetacin is combined with Cyclosporine.Experimental
ProguanilThe metabolism of Proguanil can be decreased when combined with Cyclosporine.Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Cyclosporine.Approved, Vet Approved
PromegestoneThe metabolism of Promegestone can be decreased when combined with Cyclosporine.Experimental
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Cyclosporine.Approved, Investigational
PropacetamolThe risk or severity of renal failure and hypertension can be increased when Propacetamol is combined with Cyclosporine.Approved, Investigational
PropanididThe risk or severity of adverse effects can be increased when Propanidid is combined with Cyclosporine.Experimental
PropericiazineThe risk or severity of adverse effects can be increased when Propericiazine is combined with Cyclosporine.Approved, Investigational
PropiomazineThe risk or severity of adverse effects can be increased when Propiomazine is combined with Cyclosporine.Approved
PropiopromazineThe risk or severity of adverse effects can be increased when Propiopromazine is combined with Cyclosporine.Vet Approved
PropiverineThe metabolism of Propiverine can be decreased when combined with Cyclosporine.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Cyclosporine.Approved, Investigational, Vet Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Cyclosporine.Approved, Investigational
PropylthiouracilThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Propylthiouracil.Approved, Investigational
PropyphenazoneThe risk or severity of renal failure and hypertension can be increased when Propyphenazone is combined with Cyclosporine.Experimental
ProquazoneThe risk or severity of renal failure and hypertension can be increased when Proquazone is combined with Cyclosporine.Experimental
ProthipendylThe risk or severity of adverse effects can be increased when Prothipendyl is combined with Cyclosporine.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Cyclosporine.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Proxibarbal is combined with Cyclosporine.Experimental
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Cyclosporine.Approved
PseudoephedrineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Pseudoephedrine.Approved
PsilocybineThe risk or severity of adverse effects can be increased when Psilocybine is combined with Cyclosporine.Investigational
PuromycinThe risk or severity of adverse effects can be increased when Puromycin is combined with Cyclosporine.Experimental
PyrantelThe therapeutic efficacy of Pyrantel can be increased when used in combination with Cyclosporine.Approved, Vet Approved
PyrazinamideThe serum concentration of Cyclosporine can be increased when it is combined with Pyrazinamide.Approved, Investigational
PyrithyldioneThe risk or severity of adverse effects can be increased when Pyrithyldione is combined with Cyclosporine.Experimental
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Cyclosporine.Approved, Illicit
QuercetinThe serum concentration of Cyclosporine can be increased when it is combined with Quercetin.Experimental, Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Cyclosporine.Approved
QuinacrineThe serum concentration of Cyclosporine can be increased when it is combined with Quinacrine.Approved, Investigational
QuinaprilThe risk or severity of hyperkalemia can be increased when Quinapril is combined with Cyclosporine.Approved, Investigational
QuinaprilatThe risk or severity of hyperkalemia can be increased when Quinaprilat is combined with Cyclosporine.Experimental
QuinethazoneThe metabolism of Cyclosporine can be increased when combined with Quinethazone.Approved
QuingestanolThe metabolism of Quingestanol can be decreased when combined with Cyclosporine.Experimental
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Cyclosporine.Approved, Investigational
QuinineThe metabolism of Cyclosporine can be increased when combined with Quinine.Approved
QuinupramineThe risk or severity of adverse effects can be increased when Quinupramine is combined with Cyclosporine.Experimental
QuinupristinThe serum concentration of Cyclosporine can be increased when it is combined with Quinupristin.Approved
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Cyclosporine.Approved, Investigational
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Cyclosporine.Approved, Investigational
RacloprideThe risk or severity of adverse effects can be increased when Raclopride is combined with Cyclosporine.Investigational
RaloxifeneThe metabolism of Raloxifene can be decreased when combined with Cyclosporine.Approved, Investigational
RaltitrexedThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Raltitrexed.Approved, Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Cyclosporine.Approved, Investigational
RamiprilThe risk or severity of hyperkalemia can be increased when Ramipril is combined with Cyclosporine.Approved
RamiprilatThe risk or severity of hyperkalemia can be increased when Ramiprilat is combined with Cyclosporine.Experimental
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Cyclosporine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Cyclosporine.Approved, Investigational
RapacuroniumThe therapeutic efficacy of Rapacuronium can be increased when used in combination with Cyclosporine.Withdrawn
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Cyclosporine.Approved
ReboxetineThe risk or severity of adverse effects can be increased when Reboxetine is combined with Cyclosporine.Approved, Investigational
RegorafenibThe serum concentration of Regorafenib can be increased when it is combined with Cyclosporine.Approved
RemacemideThe risk or severity of adverse effects can be increased when Remacemide is combined with Cyclosporine.Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Cyclosporine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Cyclosporine.Approved, Withdrawn
RepaglinideThe serum concentration of Repaglinide can be increased when it is combined with Cyclosporine.Approved, Investigational
ReposalThe risk or severity of adverse effects can be increased when Reposal is combined with Cyclosporine.Approved
RescinnamineThe risk or severity of hyperkalemia can be increased when Rescinnamine is combined with Cyclosporine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Cyclosporine.Approved, Investigational
RetapamulinThe metabolism of Retapamulin can be decreased when combined with Cyclosporine.Approved
Reversin 121The serum concentration of Cyclosporine can be increased when it is combined with Reversin 121.Experimental
ReviparinThe risk or severity of hyperkalemia can be increased when Reviparin is combined with Cyclosporine.Approved, Investigational
Rhodamine 6GThe serum concentration of Rhodamine 6G can be increased when it is combined with Cyclosporine.Experimental
RibostamycinThe risk or severity of adverse effects can be increased when Ribostamycin is combined with Cyclosporine.Approved, Investigational
RidaforolimusThe metabolism of Cyclosporine can be decreased when combined with Ridaforolimus.Investigational
RifabutinThe metabolism of Rifabutin can be decreased when combined with Cyclosporine.Approved, Investigational
RifampicinThe risk or severity of liver damage can be increased when Rifampicin is combined with Cyclosporine.Approved
RifamycinThe metabolism of Cyclosporine can be increased when combined with Rifamycin.Investigational
RifapentineThe metabolism of Cyclosporine can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Cyclosporine.Approved, Investigational
RilonaceptThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Rilonacept.Approved, Investigational
RiluzoleThe risk or severity of adverse effects can be increased when Riluzole is combined with Cyclosporine.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Rimexolone.Approved
RimonabantThe metabolism of Rimonabant can be decreased when combined with Cyclosporine.Approved, Investigational
RindopepimutThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Cyclosporine.Investigational
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Cyclosporine.Approved
RisedronateThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Cyclosporine is combined with Risedronate.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Cyclosporine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Ritanserin.Investigational
RitonavirThe serum concentration of Cyclosporine can be increased when it is combined with Ritonavir.Approved, Investigational
RituximabThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Rituximab.Approved
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Cyclosporine.Approved
RivoglitazoneThe metabolism of Rivoglitazone can be decreased when combined with Cyclosporine.Experimental, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Rizatriptan.Approved
RobenacoxibThe risk or severity of renal failure and hypertension can be increased when Robenacoxib is combined with Cyclosporine.Experimental, Vet Approved
RocuroniumThe therapeutic efficacy of Rocuronium can be increased when used in combination with Cyclosporine.Approved
RofecoxibThe risk or severity of renal failure and hypertension can be increased when Rofecoxib is combined with Cyclosporine.Approved, Investigational, Withdrawn
RoflumilastRoflumilast may increase the immunosuppressive activities of Cyclosporine.Approved
RokitamycinThe metabolism of Cyclosporine can be decreased when combined with Rokitamycin.Experimental
RolapitantThe serum concentration of Cyclosporine can be increased when it is combined with Rolapitant.Approved, Investigational
RolipramThe risk or severity of adverse effects can be increased when Rolipram is combined with Cyclosporine.Investigational
RolitetracyclineThe risk or severity of adverse effects can be increased when Rolitetracycline is combined with Cyclosporine.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Cyclosporine.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Cyclosporine.Vet Approved
RonifibrateThe risk or severity of renal failure can be increased when Cyclosporine is combined with Ronifibrate.Experimental
RopiniroleCyclosporine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Cyclosporine.Approved
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Cyclosporine.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Cyclosporine.Approved
Rotavirus VaccineThe therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Cyclosporine.Approved
RotigotineCyclosporine may increase the sedative activities of Rotigotine.Approved
RoxithromycinThe metabolism of Roxithromycin can be decreased when combined with Cyclosporine.Approved, Investigational, Withdrawn
RP-5063The risk or severity of adverse effects can be increased when RP-5063 is combined with Cyclosporine.Investigational
Rubella virus vaccineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Cyclosporine.Approved, Investigational
RucaparibThe serum concentration of Rucaparib can be increased when it is combined with Cyclosporine.Approved, Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Cyclosporine.Approved
RupatadineThe metabolism of Rupatadine can be decreased when combined with Cyclosporine.Approved
RuxolitinibThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Ruxolitinib.Approved
SafinamideThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Safinamide.Approved, Investigational
SafrazineThe risk or severity of adverse effects can be increased when Safrazine is combined with Cyclosporine.Withdrawn
SagopiloneThe metabolism of Cyclosporine can be decreased when combined with Sagopilone.Investigational
SalicylamideThe risk or severity of renal failure and hypertension can be increased when Salicylamide is combined with Cyclosporine.Approved
Salicylic acidThe risk or severity of renal failure and hypertension can be increased when Salicylic acid is combined with Cyclosporine.Approved, Investigational, Vet Approved
SalinomycinThe serum concentration of Cyclosporine can be increased when it is combined with Salinomycin.Vet Approved
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Cyclosporine.Approved
Salmonella typhi ty2 vi polysaccharide antigenThe therapeutic efficacy of Salmonella typhi ty2 vi polysaccharide antigen can be decreased when used in combination with Cyclosporine.Approved
Salmonella typhi Ty21a live antigenThe risk or severity of infection can be increased when Salmonella typhi Ty21a live antigen is combined with Cyclosporine.Approved
Salmonella typhi Ty21a live antigenThe therapeutic efficacy of Salmonella typhi Ty21a live antigen can be decreased when used in combination with Cyclosporine.Approved
SalsalateThe risk or severity of renal failure and hypertension can be increased when Salsalate is combined with Cyclosporine.Approved
SaprisartanThe risk or severity of hyperkalemia can be increased when Saprisartan is combined with Cyclosporine.Experimental
SaquinavirThe metabolism of Cyclosporine can be decreased when combined with Saquinavir.Approved, Investigational
SaralasinThe risk or severity of hyperkalemia can be increased when Saralasin is combined with Cyclosporine.Investigational
SaredutantThe risk or severity of adverse effects can be increased when Saredutant is combined with Cyclosporine.Investigational
SarilumabThe therapeutic efficacy of Cyclosporine can be decreased when used in combination with Sarilumab.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Cyclosporine.Approved
SC-236The risk or severity of renal failure and hypertension can be increased when SC-236 is combined with Cyclosporine.Experimental, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Cyclosporine.Approved, Investigational
SecobarbitalThe metabolism of Cyclosporine can be increased when combined with Secobarbital.Approved, Vet Approved
SecukinumabThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Secukinumab.Approved
SelamectinThe metabolism of Cyclosporine can be decreased when combined with Selamectin.Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Cyclosporine.Approved, Investigational, Vet Approved
SeletracetamThe metabolism of Seletracetam can be decreased when combined with Cyclosporine.Investigational
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Cyclosporine.Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Cyclosporine.Approved
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Cyclosporine.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Sertraline.Approved
SetrobuvirThe metabolism of Cyclosporine can be increased when combined with Setrobuvir.Investigational
SevelamerThe serum concentration of Cyclosporine can be decreased when it is combined with Sevelamer.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Cyclosporine.Approved, Vet Approved
SibutramineThe risk or severity of adverse effects can be increased when Sibutramine is combined with Cyclosporine.Approved, Illicit, Investigational, Withdrawn
SildenafilThe metabolism of Cyclosporine can be increased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Cyclosporine.Approved
SiltuximabThe serum concentration of Cyclosporine can be decreased when it is combined with Siltuximab.Approved, Investigational
Silver sulfadiazineThe metabolism of Cyclosporine can be increased when combined with Silver sulfadiazine.Approved, Vet Approved
SimeprevirThe serum concentration of Cyclosporine can be increased when it is combined with Simeprevir.Approved
SimfibrateThe risk or severity of renal failure can be increased when Cyclosporine is combined with Simfibrate.Experimental
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Cyclosporine.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Cyclosporine.Approved, Investigational
SisomicinThe risk or severity of adverse effects can be increased when Sisomicin is combined with Cyclosporine.Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Cyclosporine.Approved, Investigational
SitaxentanThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Sitaxentan.Approved, Investigational, Withdrawn
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Cyclosporine.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Cyclosporine.Approved
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Cyclosporine.Approved
SolithromycinThe metabolism of Cyclosporine can be decreased when combined with Solithromycin.Investigational
SomatostatinThe serum concentration of Cyclosporine can be decreased when it is combined with Somatostatin.Approved, Investigational
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Cyclosporine.Approved, Investigational
SorafenibThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Sorafenib.Approved, Investigational
SotalolThe risk or severity of hyperkalemia can be increased when Sotalol is combined with Cyclosporine.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Cyclosporine.Approved, Investigational
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Cyclosporine.Experimental
SpiramycinThe metabolism of Spiramycin can be decreased when combined with Cyclosporine.Approved
SpiraprilThe risk or severity of hyperkalemia can be increased when Spirapril is combined with Cyclosporine.Approved
SpironolactoneThe risk or severity of hyperkalemia can be increased when Spironolactone is combined with Cyclosporine.Approved
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Cyclosporine.Investigational
St. John's WortThe serum concentration of Cyclosporine can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StanoloneStanolone may increase the hepatotoxic activities of Cyclosporine.Illicit, Investigational
Stanolone acetateThe serum concentration of Stanolone acetate can be increased when it is combined with Cyclosporine.Experimental
StanozololStanozolol may increase the hepatotoxic activities of Cyclosporine.Approved, Vet Approved
StaurosporineThe serum concentration of Cyclosporine can be increased when it is combined with Staurosporine.Experimental
SteproninThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Stepronin.Approved
StiripentolThe serum concentration of Cyclosporine can be increased when it is combined with Stiripentol.Approved
StreptomycinThe risk or severity of adverse effects can be increased when Streptomycin is combined with Cyclosporine.Approved, Vet Approved
StreptozocinThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Streptozocin.Approved, Investigational
StyramateThe risk or severity of adverse effects can be increased when Styramate is combined with Cyclosporine.Experimental
SuccinylcholineThe therapeutic efficacy of Succinylcholine can be increased when used in combination with Cyclosporine.Approved
SuccinylsulfathiazoleThe metabolism of Cyclosporine can be increased when combined with Succinylsulfathiazole.Experimental
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Cyclosporine.Approved, Investigational
SulfacetamideThe metabolism of Cyclosporine can be increased when combined with Sulfacetamide.Approved
SulfachlorpyridazineThe metabolism of Cyclosporine can be increased when combined with Sulfachlorpyridazine.Vet Approved
SulfacytineThe metabolism of Cyclosporine can be increased when combined with Sulfacytine.Approved
SulfadiazineThe metabolism of Cyclosporine can be increased when combined with Sulfadiazine.Approved, Investigational, Vet Approved
SulfadicramideThe metabolism of Cyclosporine can be increased when combined with Sulfadicramide.Experimental
SulfadimethoxineThe metabolism of Cyclosporine can be increased when combined with Sulfadimethoxine.Approved, Vet Approved
SulfadoxineThe metabolism of Cyclosporine can be increased when combined with Sulfadoxine.Approved, Investigational
SulfaethoxypyridazineThe metabolism of Cyclosporine can be increased when combined with Sulfaethoxypyridazine.Vet Approved
SulfaguanidineThe metabolism of Cyclosporine can be increased when combined with Sulfaguanidine.Experimental
SulfaisodimidineThe metabolism of Cyclosporine can be increased when combined with Sulfaisodimidine.Experimental
SulfamazoneThe metabolism of Cyclosporine can be increased when combined with Sulfamazone.Experimental
SulfamerazineThe metabolism of Cyclosporine can be increased when combined with Sulfamerazine.Approved, Vet Approved
SulfameterThe metabolism of Cyclosporine can be increased when combined with Sulfameter.Approved
SulfamethazineThe metabolism of Cyclosporine can be increased when combined with Sulfamethazine.Approved, Investigational, Vet Approved
SulfamethizoleThe metabolism of Cyclosporine can be increased when combined with Sulfamethizole.Approved, Investigational, Vet Approved
SulfamethoxazoleThe metabolism of Cyclosporine can be increased when combined with Sulfamethoxazole.Approved
SulfamethoxypyridazineThe metabolism of Cyclosporine can be increased when combined with Sulfamethoxypyridazine.Experimental
SulfametomidineThe metabolism of Cyclosporine can be increased when combined with Sulfametomidine.Experimental
SulfametopyrazineThe metabolism of Cyclosporine can be increased when combined with Sulfametopyrazine.Approved, Withdrawn
SulfamoxoleThe metabolism of Cyclosporine can be increased when combined with Sulfamoxole.Approved
SulfanilamideThe metabolism of Cyclosporine can be increased when combined with Sulfanilamide.Approved
SulfanitranThe metabolism of Cyclosporine can be increased when combined with Sulfanitran.Vet Approved
SulfaperinThe metabolism of Cyclosporine can be increased when combined with Sulfaperin.Experimental
SulfaphenazoleThe metabolism of Cyclosporine can be increased when combined with Sulfaphenazole.Approved
SulfapyridineThe metabolism of Cyclosporine can be increased when combined with Sulfapyridine.Approved
SulfaquinoxalineThe metabolism of Cyclosporine can be increased when combined with Sulfaquinoxaline.Vet Approved
SulfasalazineThe risk or severity of renal failure and hypertension can be increased when Sulfasalazine is combined with Cyclosporine.Approved
SulfathiazoleThe metabolism of Cyclosporine can be increased when combined with Sulfathiazole.Approved, Vet Approved
SulfathioureaThe metabolism of Cyclosporine can be increased when combined with Sulfathiourea.Experimental
SulfatolamideThe metabolism of Cyclosporine can be increased when combined with Sulfatolamide.Experimental
SulfinpyrazoneThe serum concentration of Cyclosporine can be decreased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe metabolism of Cyclosporine can be increased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of renal failure and hypertension can be increased when Sulindac is combined with Cyclosporine.Approved, Investigational
SulodexideThe risk or severity of hyperkalemia can be increased when Sulodexide is combined with Cyclosporine.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Cyclosporine.Approved, Investigational
SulthiameThe risk or severity of adverse effects can be increased when Sulthiame is combined with Cyclosporine.Experimental
SultoprideThe risk or severity of adverse effects can be increased when Sultopride is combined with Cyclosporine.Experimental
SumatriptanThe metabolism of Cyclosporine can be increased when combined with Sumatriptan.Approved, Investigational
SunitinibThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Sunitinib.Approved, Investigational
SuprofenThe risk or severity of renal failure and hypertension can be increased when Suprofen is combined with Cyclosporine.Approved, Withdrawn
SuvorexantCyclosporine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
SuxibuzoneThe risk or severity of renal failure and hypertension can be increased when Suxibuzone is combined with Cyclosporine.Experimental
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Cyclosporine.Approved
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Cyclosporine.Approved
TacrineThe serum concentration of Tacrine can be increased when it is combined with Cyclosporine.Investigational, Withdrawn
TacrolimusTacrolimus may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational
TadalafilThe metabolism of Tadalafil can be decreased when combined with Cyclosporine.Approved, Investigational
TalbutalThe risk or severity of adverse effects can be increased when Talbutal is combined with Cyclosporine.Approved, Illicit
TalinololThe serum concentration of Talinolol can be increased when it is combined with Cyclosporine.Investigational
TalniflumateThe risk or severity of renal failure and hypertension can be increased when Talniflumate is combined with Cyclosporine.Approved
TalopramThe risk or severity of adverse effects can be increased when Talopram is combined with Cyclosporine.Experimental
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Cyclosporine.Approved
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Cyclosporine.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Tandospirone is combined with Cyclosporine.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Cyclosporine.Approved
TariquidarThe serum concentration of Cyclosporine can be increased when it is combined with Tariquidar.Investigational
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Cyclosporine.Approved, Investigational
TasosartanThe risk or severity of hyperkalemia can be increased when Tasosartan is combined with Cyclosporine.Approved
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be decreased when combined with Cyclosporine.Experimental
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Cyclosporine.Experimental
TecemotideThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Cyclosporine.Investigational
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Cyclosporine.Approved, Investigational
Tedizolid phosphateThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Tedizolid phosphate.Approved
TelaprevirThe serum concentration of Cyclosporine can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Cyclosporine can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of hyperkalemia can be increased when Telmisartan is combined with Cyclosporine.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Cyclosporine.Approved, Investigational
TemocaprilThe risk or severity of hyperkalemia can be increased when Temocapril is combined with Cyclosporine.Experimental, Investigational
TemozolomideThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Temozolomide.Approved, Investigational
TenidapThe risk or severity of renal failure and hypertension can be increased when Tenidap is combined with Cyclosporine.Experimental
TeniposideThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Teniposide.Approved
TenofovirThe serum concentration of Tenofovir can be increased when it is combined with Cyclosporine.Experimental, Investigational
Tenofovir alafenamideThe serum concentration of Tenofovir alafenamide can be increased when it is combined with Cyclosporine.Approved
Tenofovir disoproxilThe serum concentration of Tenofovir disoproxil can be increased when it is combined with Cyclosporine.Approved, Investigational
TenoxicamThe risk or severity of renal failure and hypertension can be increased when Tenoxicam is combined with Cyclosporine.Approved
TepoxalinThe risk or severity of renal failure and hypertension can be increased when Tepoxalin is combined with Cyclosporine.Vet Approved
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
TerfenadineThe serum concentration of Terfenadine can be increased when it is combined with Cyclosporine.Approved, Withdrawn
TergurideThe metabolism of Terguride can be decreased when combined with Cyclosporine.Experimental
TeriflunomideThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Teriflunomide.Approved
TerodilineThe metabolism of Terodiline can be decreased when combined with Cyclosporine.Experimental
TertatololThe risk or severity of hyperkalemia can be increased when Tertatolol is combined with Cyclosporine.Experimental
TesmilifeneThe serum concentration of Cyclosporine can be increased when it is combined with Tesmilifene.Investigational
TestosteroneTestosterone may increase the hepatotoxic activities of Cyclosporine.Approved, Investigational
Testosterone cypionateTestosterone cypionate may increase the hepatotoxic activities of Cyclosporine.Approved
Testosterone enanthateTestosterone enanthate may increase the hepatotoxic activities of Cyclosporine.Approved
Testosterone propionateTestosterone propionate may increase the hepatotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved, Withdrawn
Testosterone undecanoateTestosterone undecanoate may increase the hepatotoxic activities of Cyclosporine.Approved, Investigational
TetracyclineThe risk or severity of adverse effects can be increased when Tetracycline is combined with Cyclosporine.Approved, Vet Approved
TetraethylammoniumThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Tetraethylammonium.Experimental, Investigational
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Cyclosporine.Investigational
TetrandrineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Tetrandrine.Experimental
TetrazepamThe risk or severity of adverse effects can be increased when Tetrazepam is combined with Cyclosporine.Experimental
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Cyclosporine.Investigational
TezacaftorThe metabolism of Tezacaftor can be decreased when combined with Cyclosporine.Approved, Investigational
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with Cyclosporine.Investigational
ThalidomideCyclosporine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Theophylline can be decreased when combined with Cyclosporine.Approved
ThiamylalThe metabolism of Cyclosporine can be increased when combined with Thiamylal.Approved, Vet Approved
ThiazinamThe risk or severity of adverse effects can be increased when Thiazinam is combined with Cyclosporine.Experimental
ThiethylperazineThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Cyclosporine.Withdrawn
ThiocolchicosideThe risk or severity of adverse effects can be increased when Thiocolchicoside is combined with Cyclosporine.Approved, Investigational
ThiopentalThe metabolism of Cyclosporine can be increased when combined with Thiopental.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Thiopropazate is combined with Cyclosporine.Experimental
ThioproperazineThe risk or severity of adverse effects can be increased when Thioproperazine is combined with Cyclosporine.Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Cyclosporine.Approved, Withdrawn
ThiotepaThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Thiotepa.Approved, Investigational
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Cyclosporine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Cyclosporine.Approved, Investigational
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Cyclosporine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Tiapride is combined with Cyclosporine.Approved, Investigational
Tiaprofenic acidThe risk or severity of renal failure and hypertension can be increased when Tiaprofenic acid is combined with Cyclosporine.Approved
TiclopidineThe metabolism of Ticlopidine can be decreased when combined with Cyclosporine.Approved
TigecyclineThe risk or severity of adverse effects can be increased when Tigecycline is combined with Cyclosporine.Approved
TildipirosinThe metabolism of Cyclosporine can be decreased when combined with Tildipirosin.Vet Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Cyclosporine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Cyclosporine.Experimental
TilmicosinThe metabolism of Cyclosporine can be decreased when combined with Tilmicosin.Investigational, Vet Approved
Tiludronic acidThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Cyclosporine is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Cyclosporine.Approved
TinidazoleThe metabolism of Tinidazole can be decreased when combined with Cyclosporine.Approved, Investigational
TinoridineThe risk or severity of renal failure and hypertension can be increased when Tinoridine is combined with Cyclosporine.Investigational
TinzaparinThe risk or severity of hyperkalemia can be increased when Tinzaparin is combined with Cyclosporine.Approved
TioguanineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Tioguanine.Approved
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Cyclosporine.Approved
TipifarnibThe serum concentration of Cyclosporine can be increased when it is combined with Tipifarnib.Investigational
TipranavirThe metabolism of Cyclosporine can be decreased when combined with Tipranavir.Approved, Investigational
TixocortolThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Tixocortol.Approved, Withdrawn
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Cyclosporine.Approved, Investigational
TobramycinThe risk or severity of adverse effects can be increased when Tobramycin is combined with Cyclosporine.Approved, Investigational
TocilizumabThe serum concentration of Cyclosporine can be decreased when it is combined with Tocilizumab.Approved
TocofersolanThe metabolism of Tocofersolan can be decreased when combined with Cyclosporine.Approved
TocopherolThe metabolism of Tocopherol can be decreased when combined with Cyclosporine.Approved, Investigational
TofacitinibThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Tofacitinib.Approved, Investigational
TofacitinibCyclosporine may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TofisopamThe risk or severity of adverse effects can be increased when Tofisopam is combined with Cyclosporine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Cyclosporine.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of renal failure and hypertension can be increased when Tolfenamic Acid is combined with Cyclosporine.Approved, Investigational
TolmetinThe risk or severity of renal failure and hypertension can be increased when Tolmetin is combined with Cyclosporine.Approved
ToloxatoneThe risk or severity of adverse effects can be increased when Toloxatone is combined with Cyclosporine.Approved
TolperisoneThe risk or severity of adverse effects can be increased when Tolperisone is combined with Cyclosporine.Approved, Investigational
TolterodineThe metabolism of Tolterodine can be decreased when combined with Cyclosporine.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Cyclosporine.Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Cyclosporine.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Cyclosporine.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Torasemide.Approved
ToremifeneThe serum concentration of Cyclosporine can be increased when it is combined with Toremifene.Approved, Investigational
TositumomabThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Tositumomab.Approved, Investigational
TrabectedinThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Trabectedin.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Cyclosporine.Approved, Investigational
TramiprosateThe risk or severity of adverse effects can be increased when Tramiprosate is combined with Cyclosporine.Investigational
TrandolaprilThe risk or severity of hyperkalemia can be increased when Trandolapril is combined with Cyclosporine.Approved
TranilastThe metabolism of Tranilast can be decreased when combined with Cyclosporine.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Cyclosporine.Approved, Investigational
TrastuzumabThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Trastuzumab.Approved, Investigational
Trastuzumab emtansineThe metabolism of Cyclosporine can be decreased when combined with Trastuzumab emtansine.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Trazodone.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamcinoloneThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Triamcinolone.Approved, Vet Approved
TriamtereneThe risk or severity of hyperkalemia can be increased when Triamterene is combined with Cyclosporine.Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Cyclosporine.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tricaine methanesulfonate is combined with Cyclosporine.Vet Approved
TrichlormethiazideThe metabolism of Cyclosporine can be increased when combined with Trichlormethiazide.Approved, Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Trichloroethylene is combined with Cyclosporine.Approved
TriclofosThe risk or severity of adverse effects can be increased when Triclofos is combined with Cyclosporine.Withdrawn
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Cyclosporine.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Trifluperidol is combined with Cyclosporine.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Cyclosporine.Approved, Vet Approved
TrifluridineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Trifluridine.Approved, Investigational
TrilostaneThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Trilostane.Approved, Investigational, Vet Approved, Withdrawn
TrimebutineThe metabolism of Trimebutine can be decreased when combined with Cyclosporine.Approved
TrimethadioneThe risk or severity of adverse effects can be increased when Trimethadione is combined with Cyclosporine.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Trimethaphan.Approved, Investigational
TrimethoprimThe serum concentration of Cyclosporine can be increased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Cyclosporine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Cyclosporine.Approved
TriptolideThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Triptolide.Investigational
TrofosfamideThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Trofosfamide.Investigational
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Cyclosporine.Investigational, Withdrawn
Trolamine salicylateThe risk or severity of renal failure and hypertension can be increased when Trolamine salicylate is combined with Cyclosporine.Approved
TroleandomycinThe metabolism of Cyclosporine can be decreased when combined with Troleandomycin.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Tubocurarine.Approved
TylosinThe metabolism of Cyclosporine can be decreased when combined with Tylosin.Vet Approved
TylvalosinThe metabolism of Cyclosporine can be decreased when combined with Tylvalosin.Vet Approved
Typhoid VaccineThe therapeutic efficacy of Typhoid Vaccine can be decreased when used in combination with Cyclosporine.Approved
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Cyclosporine.Approved, Investigational, Nutraceutical
UdenafilThe metabolism of Udenafil can be decreased when combined with Cyclosporine.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Cyclosporine.Approved
UlobetasolThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Ulobetasol.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Cyclosporine.Approved
UstekinumabThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Ustekinumab.Approved, Investigational
ValbenazineThe metabolism of Valbenazine can be decreased when combined with Cyclosporine.Approved, Investigational
ValdecoxibThe risk or severity of renal failure and hypertension can be increased when Valdecoxib is combined with Cyclosporine.Approved, Investigational, Withdrawn
ValerianThe risk or severity of adverse effects can be increased when Valerian is combined with Cyclosporine.Approved, Experimental, Investigational
ValinomycinThe serum concentration of Valinomycin can be increased when it is combined with Cyclosporine.Experimental
ValnoctamideThe risk or severity of adverse effects can be increased when Valnoctamide is combined with Cyclosporine.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Cyclosporine.Approved, Investigational
ValpromideThe risk or severity of adverse effects can be increased when Valpromide is combined with Cyclosporine.Experimental
ValsartanThe risk or severity of hyperkalemia can be increased when Valsartan is combined with Cyclosporine.Approved, Investigational
ValspodarThe serum concentration of Valspodar can be increased when it is combined with Cyclosporine.Investigational
VancomycinThe risk or severity of adverse effects can be increased when Vancomycin is combined with Cyclosporine.Approved
VandetanibThe metabolism of Vandetanib can be decreased when combined with Cyclosporine.Approved
VanoxerineThe metabolism of Vanoxerine can be decreased when combined with Cyclosporine.Investigational
VapreotideThe serum concentration of Cyclosporine can be decreased when it is combined with Vapreotide.Approved, Investigational
VardenafilThe metabolism of Vardenafil can be decreased when combined with Cyclosporine.Approved
Varicella Zoster Vaccine (Live/Attenuated)The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/Attenuated) is combined with Cyclosporine.Approved
Varicella Zoster Vaccine (Live/Attenuated)The therapeutic efficacy of Varicella Zoster Vaccine (Live/Attenuated) can be decreased when used in combination with Cyclosporine.Approved
VecuroniumThe therapeutic efficacy of Vecuronium can be increased when used in combination with Cyclosporine.Approved
VedolizumabThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Vedolizumab.Approved
VelpatasvirThe serum concentration of Velpatasvir can be increased when it is combined with Cyclosporine.Approved, Investigational
VemurafenibThe serum concentration of Cyclosporine can be increased when it is combined with Vemurafenib.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Cyclosporine.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Veralipride is combined with Cyclosporine.Experimental
VerapamilThe metabolism of Cyclosporine can be decreased when combined with Verapamil.Approved
Vibrio cholerae CVD 103-HgR strain live antigenThe risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Cyclosporine.Approved, Investigational
Vibrio cholerae CVD 103-HgR strain live antigenThe therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Cyclosporine.Approved, Investigational
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Cyclosporine.Investigational
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Cyclosporine.Approved
VilanterolThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Vilanterol.Approved
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Cyclosporine.Approved
ViloxazineThe risk or severity of adverse effects can be increased when Viloxazine is combined with Cyclosporine.Approved, Investigational, Withdrawn
VinbarbitalThe risk or severity of adverse effects can be increased when Vinbarbital is combined with Cyclosporine.Experimental
VinblastineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Vinblastine.Approved
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Cyclosporine.Approved, Investigational
VindesineThe serum concentration of Vindesine can be increased when it is combined with Cyclosporine.Approved, Investigational
VinflunineThe serum concentration of Vinflunine can be increased when it is combined with Cyclosporine.Approved, Investigational
VinorelbineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Vinorelbine.Approved, Investigational
VinpocetineThe risk or severity of adverse effects can be increased when Vinpocetine is combined with Cyclosporine.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Vinyl ether is combined with Cyclosporine.Experimental
VinylbitalThe risk or severity of adverse effects can be increased when Vinylbital is combined with Cyclosporine.Experimental
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Cyclosporine.Approved, Investigational
Vitamin EThe serum concentration of Cyclosporine can be decreased when it is combined with Vitamin E.Approved, Nutraceutical, Vet Approved
VoacamineThe serum concentration of Cyclosporine can be increased when it is combined with Voacamine.Approved, Investigational
VoclosporinThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Voclosporin.Investigational
VorapaxarThe serum concentration of Cyclosporine can be increased when it is combined with Vorapaxar.Approved
VoriconazoleThe metabolism of Cyclosporine can be decreased when combined with Voriconazole.Approved, Investigational
VorinostatThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Vorinostat.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Cyclosporine.Approved, Investigational
VoxilaprevirThe serum concentration of Voxilaprevir can be increased when it is combined with Cyclosporine.Approved, Investigational
WarfarinThe metabolism of Warfarin can be decreased when combined with Cyclosporine.Approved
WIN 55212-2The metabolism of WIN 55212-2 can be decreased when combined with Cyclosporine.Experimental
WortmanninThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Wortmannin.Experimental
XipamideThe metabolism of Cyclosporine can be increased when combined with Xipamide.Experimental
XP19986The risk or severity of adverse effects can be increased when XP19986 is combined with Cyclosporine.Investigational
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Cyclosporine.Vet Approved
Yellow Fever VaccineThe risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Cyclosporine.Approved, Investigational
Yellow Fever VaccineThe therapeutic efficacy of Yellow Fever Vaccine can be decreased when used in combination with Cyclosporine.Approved, Investigational
YohimbineThe serum concentration of Cyclosporine can be increased when it is combined with Yohimbine.Approved, Investigational, Vet Approved
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Cyclosporine.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Cyclosporine.Approved, Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Cyclosporine.Approved, Illicit, Investigational
ZaltoprofenThe risk or severity of renal failure and hypertension can be increased when Zaltoprofen is combined with Cyclosporine.Approved, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Cyclosporine.Approved
ZidovudineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Zidovudine.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Cyclosporine.Approved, Investigational, Withdrawn
ZimelidineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Cyclosporine.Approved
ZofenoprilThe risk or severity of hyperkalemia can be increased when Zofenopril is combined with Cyclosporine.Experimental
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Cyclosporine.Vet Approved
Zoledronic acidThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Cyclosporine is combined with Zoledronic acid.Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Zolmitriptan.Approved, Investigational
ZolpidemCyclosporine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZomepiracThe risk or severity of renal failure and hypertension can be increased when Zomepirac is combined with Cyclosporine.Withdrawn
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Cyclosporine.Approved, Investigational
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Cyclosporine.Approved
ZosuquidarThe serum concentration of Cyclosporine can be increased when it is combined with Zosuquidar.Investigational
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Cyclosporine.Approved, Investigational, Withdrawn
ZuclopenthixolThe serum concentration of Zuclopenthixol can be increased when it is combined with Cyclosporine.Approved, Investigational
Food Interactions
  • Avoid salt substitutes containing potassium.
  • Avoid taking with grapefruit or grapefruit juice as grapefruit can significantly increase serum levels of this product.
  • Red wine may reduce cyclosporine levels due to increased metabolism, therefore it appears prudent to avoid red wine (white wine does not appear to affect cyclosporine metabolism).
  • When taken with a meal, AUC and Cmax of cyclosporine modified decreased.

References

Synthesis Reference

Hans Dietl, "Pharmaceutical preparation containing cyclosporine(s) for intravenous administration and a process for its production." U.S. Patent US5527537, issued October, 1990.

US5527537
General References
  1. Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, Michelassi F, Hanauer S: Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994 Jun 30;330(26):1841-5. [PubMed:8196726]
  2. Husi H, Schorgendorfer K, Stempfer G, Taylor P, Walkinshaw MD: Prediction of substrate-specific pockets in cyclosporin synthetase. FEBS Lett. 1997 Sep 15;414(3):532-6. [PubMed:9323029]
  3. Link [Link]
External Links
KEGG Drug
D00184
KEGG Compound
C05086
PubChem Compound
5284373
PubChem Substance
46508198
ChemSpider
4447449
BindingDB
50022815
ChEBI
4031
ChEMBL
CHEMBL160
Therapeutic Targets Database
DNC001177
PharmGKB
PA449167
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Cyclosporine
ATC Codes
S01XA18 — CiclosporinL04AD01 — Ciclosporin
AHFS Codes
  • 52:08.92 — Anti-inflammatory Agents, Miscellaneous
  • 92:44.00 — Immunosuppressive Agents
FDA label
Download (176 KB)
MSDS
Download (83.2 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myelogenous Leukaemia (AML) / Agnogenic Myeloid Metaplasia / Chronic Chronic myelogenous leukemia / Lymphoid Malignancies / Lymphoma, Hodgkins / Myelodysplastic Syndromes / Non-Hodgkin's Lymphoma, Relapsed / Refractory Chronic Lymphocytic Leukemia / Refractory Hodgkin Lymphoma / Refractory Non-Hodgkin's lymphoma / Relapsed Chronic Lymphocytic Leukemia1
0TerminatedTreatmentAllogeneic peripheral haematopoietic stem cell transplant / Neuroepithelial Tumor / Tumors, Solid1
1Active Not RecruitingTreatmentAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Acute, secondary Myeloid Leukemia / Chronic Myelomonocytic Leukemia / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Refractory Anemia With Excess Blasts1
1Active Not RecruitingTreatmentAdenosine Deaminase Deficiency / Autosomal Recessive Disorder / Immune System Disorder / Purine-Nucleoside Phosphorylase Deficiency / Severe Combined Immunodeficiency / Severe Combined Immunodeficiency With Absence of T and B Cells / X-linked Severe Combined Immunodeficiency1
1Active Not RecruitingTreatmentAdult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Chronic Myelomonocytic Leukemia / De Novo Myelodysplastic Syndromes / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Excess Blasts in Transformation / Refractory Anemia With Ringed Sideroblasts / Refractory Cytopenia With Multilineage Dysplasia / Secondary Myelodysplastic Syndromes / Untreated Adult Acute Myeloid Leukemia1
1Active Not RecruitingTreatmentRecurrent Colorectal Carcinoma / Solid Neoplasms / Stage IIIA Colorectal Cancer / Stage IIIA Colorectal Cancer AJCC v7 / Stage IIIB Colorectal Cancer / Stage IIIB Colorectal Cancer AJCC v7 / Stage IIIC Colorectal Cancer / Stage IIIC Colorectal Cancer AJCC v7 / Stage IVA Colorectal Cancer / Stage IVA Colorectal Cancer AJCC v7 / Stage IVB Colorectal Cancer / Stage IVB Colorectal Cancer AJCC v71
1CompletedNot AvailableDry Eye Syndromes1
1CompletedNot AvailableHealthy Volunteers4
1CompletedBasic ScienceDrug Interactions / Healthy Volunteers1
1CompletedBasic ScienceHealthy Volunteers4
1CompletedBasic ScienceHealthy Volunteers / Pharmacokinetics1
1CompletedBasic ScienceHealthy Volunteers / Pharmacokinetics / Venous Thromboembolism (VTE)1
1CompletedBasic ScienceHepatitis C Viral Infection1
1CompletedOtherPurpura, Thrombocytopenic, Idiopathic1
1CompletedPreventionHealthy Volunteers1
1CompletedSupportive CareChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Precancerous/Nonmalignant Condition1
1CompletedTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome / Acute, secondary Myeloid Leukemia / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Burkitt Lymphoma / Childhood Chronic Myelogenous Leukemia / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Childhood Myelodysplastic Syndromes / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Chronic Phase Chronic Myelogenous Leukemia / Contiguous Stage II Adult Burkitt Lymphoma / Contiguous Stage II Adult Diffuse Large Cell Lymphoma / Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Contiguous Stage II Adult Lymphoblastic Lymphoma / Contiguous Stage II Grade 3 Follicular Lymphoma / Contiguous Stage II Mantle Cell Lymphoma / De Novo Myelodysplastic Syndromes / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Leukemia, Prolymphocytic / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Burkitt Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Noncontiguous Stage II Adult Lymphoblastic Lymphoma / Noncontiguous Stage II Grade 3 Follicular Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Anemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Excess Blasts in Transformation / Refractory Chronic Lymphocytic Leukemia / Refractory Multiple Myeloma / Secondary Myelodysplastic Syndromes / Splenic Marginal Zone Lymphoma / Stage I Adult Burkitt Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Mixed Cell Lymphoma / Stage I Adult Immunoblastic Large Cell Lymphoma / Stage I Adult Lymphoblastic Lymphoma / Stage I Childhood Lymphoblastic Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage I Mantle Cell Lymphoma / Stage II Childhood Lymphoblastic Lymphoma / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Childhood Lymphoblastic Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Childhood Lymphoblastic Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma1
1CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemia Acute Myeloid Leukemia (AML)1
1CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Multiple Myeloma (MM) / Myelodysplastic Syndrome1
1CompletedTreatmentAdult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Childhood Acute Myeloid Leukemia in Remission / Childhood Myelodysplastic Syndromes / Congenital Hypoplastic Anemia / Previously Treated Myelodysplastic Syndromes1
1CompletedTreatmentAnemias / Leukemia, T-Cell / Lymphocytosis / Neutropenias / Thrombocytopenias1
1CompletedTreatmentCholesterol1
1CompletedTreatmentChronic Graft Versus Host Disease1
1CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection / Immunosuppression / Transplantation, Organ1
1CompletedTreatmentAcute, secondary Myeloid Leukemia / Chronic Myelomonocytic Leukemia / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Refractory Anemia With Excess Blasts / Refractory Cytopenia With Multilineage Dysplasia / Refractory Cytopenia With Multilineage Dysplasia and Ringed Sideroblasts1
1CompletedTreatmentChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
1CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
1CompletedTreatmentCongenital Hypoplastic Anemia1
1CompletedTreatmentDiabetes Mellitus (DM) / Type 2 Diabetes Mellitus1
1CompletedTreatmentDrug/Agent Toxicity by Tissue/Organ / Malignant Lymphomas / Neutropenias / Small Intestine Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentEnd Stage Renal Disease (ESRD) / Multiple Myeloma (MM)1
1CompletedTreatmentHealthy Volunteers3
1CompletedTreatmentHepatitis C Virus (HCV)1
1CompletedTreatmentHereditary Angioedema1
1CompletedTreatmentLeukemia Acute Myeloid Leukemia (AML) / Leukemia Lymphoblastic, Acute / Recurrent Neoplasm1
1CompletedTreatmentMetastatic Breast Cancer (MBC)1
1CompletedTreatmentNeoplasms, Brain / Tumors, Central Nervous System1
1CompletedTreatmentNeuroblastomas / Sarcomas / Unspecified Childhood Solid Tumor, Protocol Specific1
1CompletedTreatmentOsteogenesis Imperfecta1
1CompletedTreatmentPsoriasis1
1CompletedTreatmentRenal Replacement Therapies1
1RecruitingTreatmentCD30-Positive Neoplastic Cells Present / Recurrent Hodgkin Lymphoma / Refractory Hodgkin Lymphoma1
1RecruitingTreatmentGraft Versus Host Disease (GVHD) / Sickle Cell Disorders1
1SuspendedTreatmentPlasma Cell Myeloma / Refractory Plasma Cell Myeloma1
1TerminatedTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Chronic Phase Chronic Myelogenous Leukemia / Relapsing Chronic Myelogenous Leukemia1
1TerminatedTreatmentAplastic Anaemia (AA)1
1TerminatedTreatmentCardiac Surgical Procedures1
1TerminatedTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Secondary Myelofibrosis1
1TerminatedTreatmentRefractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
1TerminatedTreatmentRheumatoid Arthritis1
1Unknown StatusSupportive CareGraft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes1
1Unknown StatusTreatmentCancer, Breast2
1Unknown StatusTreatmentMalignant Lymphomas2
1Unknown StatusTreatmentMelanoma (Skin)1
1Unknown StatusTreatmentProstate Cancer1
1Unknown StatusTreatmentUnspecified Childhood Solid Tumor, Protocol Specific1
1, 2Active Not RecruitingTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Grade III Lymphomatoid Granulomatosis / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Burkitt Lymphoma / Childhood Chronic Myelogenous Leukemia / Childhood Diffuse Large Cell Lymphoma / Childhood Grade III Lymphomatoid Granulomatosis / Childhood Immunoblastic Large Cell Lymphoma / Childhood Myelodysplastic Syndromes / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Childhood Renal Cell Carcinoma / Chronic Myelomonocytic Leukemia / Chronic Phase Chronic Myelogenous Leukemia / Clear Cell Renal Cell Carcinoma / Contiguous Stage II Adult Burkitt Lymphoma / Contiguous Stage II Adult Diffuse Large Cell Lymphoma / Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Contiguous Stage II Adult Lymphoblastic Lymphoma / Contiguous Stage II Grade 3 Follicular Lymphoma / Contiguous Stage II Mantle Cell Lymphoma / De Novo Myelodysplastic Syndromes / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Juvenile Myelomonocytic Leukemia / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Burkitt Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Noncontiguous Stage II Adult Lymphoblastic Lymphoma / Noncontiguous Stage II Grade 3 Follicular Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Noncutaneous Extranodal Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Post-Transplant Lymphoproliferative Disorder / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Refractory Anemia / Refractory Anemia With Ringed Sideroblasts / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia / Refractory Multiple Myeloma / Relapsing Chronic Myelogenous Leukemia / Renal Cell Cancer, Recurrent / Splenic Marginal Zone Lymphoma / Stage I Adult Burkitt Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Mixed Cell Lymphoma / Stage I Adult Immunoblastic Large Cell Lymphoma / Stage I Adult Lymphoblastic Lymphoma / Stage I Adult T-Cell Leukemia/Lymphoma / Stage I Childhood Anaplastic Large Cell Lymphoma / Stage I Childhood Large Cell Lymphoma / Stage I Childhood Lymphoblastic Lymphoma / Stage I Childhood Small Noncleaved Cell Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage I Mantle Cell Lymphoma / Stage II Adult T-Cell Leukemia/Lymphoma / Stage II Childhood Anaplastic Large Cell Lymphoma / Stage II Childhood Large Cell Lymphoma / Stage II Childhood Lymphoblastic Lymphoma / Stage II Childhood Small Noncleaved Cell Lymphoma / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Adult T-Cell Leukemia/Lymphoma / Stage III Childhood Anaplastic Large Cell Lymphoma / Stage III Childhood Large Cell Lymphoma / Stage III Childhood Lymphoblastic Lymphoma / Stage III Childhood Small Noncleaved Cell Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Adult T-Cell Leukemia/Lymphoma / Stage IV Childhood Anaplastic Large Cell Lymphoma / Stage IV Childhood Large Cell Lymphoma / Stage IV Childhood Lymphoblastic Lymphoma / Stage IV Childhood Small Noncleaved Cell Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Renal Cell Cancer / T-Cell Large Granular Lymphocyte Leukemia / Type 1 Papillary Renal Cell Carcinoma / Type 2 Papillary Renal Cell Carcinoma / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Adult Acute Myeloid Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia / Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies / Waldenström's Macroglobulinemia (WM)1
1, 2Active Not RecruitingTreatmentAcute Undifferentiated Leukemia (AUL) / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Childhood Burkitt Lymphoma / Childhood Diffuse Large Cell Lymphoma / Childhood Grade III Lymphomatoid Granulomatosis / Childhood Immunoblastic Large Cell Lymphoma / Childhood Myelodysplastic Syndromes / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Chronic Myelomonocytic Leukemia / Cutaneous B-Cell Non-Hodgkin Lymphoma / De Novo Myelodysplastic Syndromes / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Juvenile Myelomonocytic Leukemia / Malignant mast cell neoplasm / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Myeloid/NK-cell Acute Leukemia / Nodal marginal zone B-cell lymphomas / Noncutaneous Extranodal Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Post-Transplant Lymphoproliferative Disorder / Previously Treated Myelodysplastic Syndromes / Primary Systemic Amyloidosis / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia / Refractory Multiple Myeloma / Renal Cell Cancer, Recurrent / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Stage II Multiple Myeloma / Stage III Multiple Myeloma / T-Cell Large Granular Lymphocyte Leukemia / Testicular Lymphoma / Waldenström's Macroglobulinemia (WM)1
1, 2Active Not RecruitingTreatmentAdult Acute Myeloid Leukemia in Remission / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Myelodysplastic Syndrome / Childhood Renal Cell Carcinoma / Chronic Myelomonocytic Leukemia / Clear Cell Renal Cell Carcinoma / De Novo Myelodysplastic Syndrome / Metastatic Renal Cell Cancer / Previously Treated Myelodysplastic Syndromes / Progression of Multiple Myeloma or Plasma Cell Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult Non-Hodgkin Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Non-Hodgkin Lymphoma / Refractory Anemia / Refractory Anemia With Ringed Sideroblasts / Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Renal Medullary Carcinoma / Type 1 Papillary Renal Cell Carcinoma / Type 2 Papillary Renal Cell Carcinoma / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Adult Acute Myeloid Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
1, 2Active Not RecruitingTreatmentComplete Atypical DiGeorge Anomaly / Complete Atypical DiGeorge Syndrome / Complete DiGeorge Anomaly / Complete DiGeorge Syndrome / DiGeorge Anomaly1
1, 2Active Not RecruitingTreatmentLeukemia, Acute / Lymphoma, Hodgkins / Multiple Myeloma (MM) / Myelodysplastic Syndrome / Non-Hodgkin's Disease1
1, 2Active Not RecruitingTreatmentChronic, recurrent Lymphocytic Leukemia / Leukemia, Prolymphocytic / Recurrent Adult Hodgkin's Lymphoma / Recurrent Childhood Hodgkin Lymphoma / Recurrent Childhood Non-Hodgkin Lymphoma / Recurrent Non-Hodgkin Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hodgkin Lymphoma / Refractory Non-Hodgkin's lymphoma / Refractory Small Lymphocytic Lymphoma / T-cell chronic lymphocytic leukaemia / T-Cell Prolymphocytic Leukemia1
1, 2Active Not RecruitingTreatmentRefractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
1, 2Active Not RecruitingTreatmentRenal Cell Cancer, Recurrent / Stage IV Renal Cell Cancer1
1, 2CompletedPreventionTransplant, Kidney1
1, 2CompletedSupportive CareChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
1, 2CompletedTreatmentAcute Myelogenous Leukaemia (AML)1
1, 2CompletedTreatmentAplastic Anaemia (AA) / Neutropenias / Pancytopenia / Severe Aplastic Anemia (SAA)1
1, 2CompletedTreatmentBeta Thalassemia-Major / Sickle Cell Disorders1
1, 2CompletedTreatmentCNI Side Effects1
1, 2CompletedTreatmentCancer, Breast / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Renal Cancers1
1, 2CompletedTreatmentChronic Lymphocytic Leukaemia (CLL) / Leukemias / Malignant Lymphomas1
1, 2CompletedTreatmentChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms / Precancerous Conditions1
1, 2CompletedTreatmentChronic Myeloproliferative Disorders / Leukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
1, 2CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
1, 2CompletedTreatmentChronic Rejection of Lung Transplant / Decreased Immunologic Activity / Disorders Related to Lung Transplantation / Obliterative Bronchiolitis1
1, 2CompletedTreatmentCongenital Hypoplastic Anemia1
1, 2CompletedTreatmentDiabetes, Diabetes Mellitus Type 1 / Hypoglycemia1
1, 2CompletedTreatmentDry Eye Syndromes1
1, 2CompletedTreatmentLeukemias3
1, 2CompletedTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
1, 2CompletedTreatmentLeukemias / Myelodysplastic Syndromes1
1, 2CompletedTreatmentPsoriasis2
1, 2CompletedTreatmentRefractory Multiple Myeloma1
1, 2CompletedTreatmentRenal Cancers1
1, 2CompletedTreatmentSickle Cell Disorders1
1, 2CompletedTreatmentType 1 Mucopolysaccharidosis1
1, 2RecruitingTreatmentAcute Lymphoblastic Leukemia in Remission / Acute myeloid leukaemia (in remission) / Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / CD45-Positive Neoplastic Cells Present / Chronic Myelomonocytic Leukemia / Myelodysplastic Syndrome With Excess Blasts / Recurrent Adult Acute Myeloid Leukemia / Refractory Adult Acute Lymphoblastic Leukemia1
1, 2RecruitingTreatmentCongenital Hypoplastic Anemia1
1, 2RecruitingTreatmentHemophagocytic Lymphohistiocytosis (HLH)1
1, 2TerminatedTreatmentAdult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Recurrent Adult Acute Myeloid Leukemia1
1, 2TerminatedTreatmentLeukemias1
1, 2Unknown StatusTreatmentAplastic Anaemia (AA)1
1, 2Unknown StatusTreatmentEnd-Stage Renal Disease (ESRD) / Renal Failure1
1, 2WithdrawnSupportive CareGraft Versus Host Disease (GVHD) / Leukemias / Myelodysplastic Syndromes1
1, 2WithdrawnTreatmentChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Myelodysplastic Syndromes / Nonmalignant Neoplasm1
1, 2WithdrawnTreatmentLeukemias1
2Active Not RecruitingTreatmentAccelerated Phase of Disease / Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Chronic Phase of Disease / Recurrent Disease1
2Active Not RecruitingTreatmentAcute Biphenotypic Leukemia (ABL) / Acute Lymphoblastic Leukaemias (ALL) / Aggressive Non-Hodgkin Lymphoma / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Chronic, recurrent Lymphocytic Leukemia / Indolent Non-Hodgkin's Lymphomas / Leukemia Acute Myeloid Leukemia (AML) / Malignant Lymphoma, Large Cell Type / Malignant Lymphomas / Mixed Phenotype Acute Leukemia (MPAL) / Myelodysplastic Syndrome / Myeloproliferative Neoplasms / Recurrent Follicular Lymphoma / Recurrent Lymphoplasmacytic Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Plasma Cell Myeloma / Recurrent Small Lymphocytic Lymphoma / Recurrent T-Cell Non-Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Refractory Follicular Lymphoma / Refractory Hodgkin Lymphoma / Refractory Lymphoplasmacytic Lymphoma / Refractory Mantle Cell Lymphoma / Refractory Small Lymphocytic Lymphoma / T-Cell Non-Hodgkin Lymphoma1
2Active Not RecruitingTreatmentAcute Biphenotypic Leukemia (ABL) / Acute erythroid leukemia / Acute Lymphoblastic Leukemia in Remission / Acute Megakaryoblastic Leukemia / Acute myeloid leukaemia (in remission) / Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Acute, secondary Myeloid Leukemia / Blasts Under 10 Percent of Bone Marrow Nucleated Cells / Blasts Under 5 Percent of Bone Marrow Nucleated Cells / Chronic Chronic myelogenous leukemia / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Mixed Phenotype Acute Leukemia (MPAL) / Myelodysplastic Syndrome / Myelodysplastic Syndrome With Excess Blasts / Pancytopenia / Refractory Anemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Excess Blasts in Transformation1
2Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Graft Versus Host Disease (GVHD) / Leukemia Acute Myeloid Leukemia (AML) / Lymphoma, Hodgkins / Myelodysplastic/Myeloproliferative Neoplasms / Non-Hodgkin's Lymphoma (NHL) / Plasma Cell Myeloma / Waldenström's Macroglobulinemia (WM)1
2Active Not RecruitingTreatmentAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome / Acute, secondary Myeloid Leukemia / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b)1
2Active Not RecruitingTreatmentAcute Undifferentiated Leukemia (AUL) / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Burkitt Lymphoma / Childhood Chronic Myelogenous Leukemia / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Childhood Myelodysplastic Syndromes / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Chronic Myelomonocytic Leukemia / Chronic Phase Chronic Myelogenous Leukemia / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Juvenile Myelomonocytic Leukemia / Malignant mast cell neoplasm / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Nodal marginal zone B-cell lymphomas / Noncutaneous Extranodal Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia / Refractory Multiple Myeloma / Relapsing Chronic Myelogenous Leukemia / Secondary Myelodysplastic Syndromes / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Testicular Lymphoma / Waldenström's Macroglobulinemia (WM)1
2Active Not RecruitingTreatmentAcute myeloid leukaemia (in remission) / Congenital Hypoplastic Anemia / De Novo Myelodysplastic Syndrome / Previously Treated Myelodysplastic Syndromes1
2Active Not RecruitingTreatmentAdult Acute Lymphoblastic Leukemia in Remission / Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 / Blastic Phase / Blastic Phase Chronic Myelogenous Leukemia / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Chronic Phase Chronic Myelogenous Leukemia / Chronic Phase of Disease / Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia / Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Disease / Relapsing Chronic Myelogenous Leukemia1
2Active Not RecruitingTreatmentAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Childhood Burkitt Lymphoma / Childhood Chronic Myelogenous Leukemia / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Chronic Phase Chronic Myelogenous Leukemia / Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Contiguous Stage II Grade 1 Follicular Lymphoma / Contiguous Stage II Grade 2 Follicular Lymphoma / Contiguous Stage II Marginal Zone Lymphoma / Contiguous Stage II Small Lymphocytic Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Noncontiguous Stage II Grade 1 Follicular Lymphoma / Noncontiguous Stage II Grade 2 Follicular Lymphoma / Noncontiguous Stage II Marginal Zone Lymphoma / Noncontiguous Stage II Small Lymphocytic Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Previously Treated Myelodysplastic Syndromes / Progressive Hairy Cell Leukemia, Initial Treatment / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia / Refractory Multiple Myeloma / Relapsing Chronic Myelogenous Leukemia / Splenic Marginal Zone Lymphoma / Stage I Adult Diffuse Small Cleaved Cell Lymphoma / Stage I Childhood Anaplastic Large Cell Lymphoma / Stage I Childhood Large Cell Lymphoma / Stage I Cutaneous T-cell Non-Hodgkin Lymphoma / Stage I Grade 1 Follicular Lymphoma / Stage I Grade 2 Follicular Lymphoma / Stage I Mantle Cell Lymphoma / Stage I Marginal Zone Lymphoma / Stage I Mycosis Fungoides/Sezary Syndrome / Stage I Small Lymphocytic Lymphoma / Stage II Childhood Anaplastic Large Cell Lymphoma / Stage II Childhood Large Cell Lymphoma / Stage II Cutaneous T-cell Non-Hodgkin Lymphoma / Stage II Mycosis Fungoides/Sezary Syndrome / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Childhood Anaplastic Large Cell Lymphoma / Stage III Childhood Large Cell Lymphoma / Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Mycosis Fungoides/Sezary Syndrome / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Childhood Anaplastic Large Cell Lymphoma / Stage IV Childhood Large Cell Lymphoma / Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Mycosis Fungoides/Sezary Syndrome / Stage IV Small Lymphocytic Lymphoma / T-Cell Large Granular Lymphocyte Leukemia / Waldenström's Macroglobulinemia (WM)1
2Active Not RecruitingTreatmentAcute, secondary Myeloid Leukemia / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Childhood Myelodysplastic Syndromes / Chronic Myelomonocytic Leukemia / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Excess Blasts in Transformation / Refractory Anemia With Ringed Sideroblasts / Refractory Cytopenia With Multilineage Dysplasia / Secondary Myelodysplastic Syndromes1
2Active Not RecruitingTreatmentAplastic Anaemia (AA) / Bone Marrow Failure / Haemoglobinuria / Hemolytic Anemia / Paroxysmal Hemoglobinuria / Paroxysmal Nocturnal Haemoglobinuria (PNH) / Proteinuria / Thrombosis / Urination Disorders2
2Active Not RecruitingTreatmentAtypical Chronic Myeloid Leukemia, BCR-ABL1 Negative / Chronic Myelomonocytic Leukemia / De Novo Myelodysplastic Syndrome / Essential Thrombocythemia (ET) / Myeloproliferative Neoplasms / Paroxysmal Nocturnal Haemoglobinuria (PNH) / Polycythemia Vera (PV) / Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase / Primary Myelofibrosis / Refractory Anemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Ring Sideroblasts / Refractory Cytopenia With Multilineage Dysplasia / Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts1
2Active Not RecruitingTreatmentChronic Granulomatous Disease (CGD)1
2Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Leukemia, Prolymphocytic / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Stage III Chronic Lymphocytic Leukemia / Stage III Small Lymphocytic Lymphoma / Stage IV Chronic Lymphocytic Leukemia / Stage IV Small Lymphocytic Lymphoma / T-Cell Large Granular Lymphocyte Leukemia1
2Active Not RecruitingTreatmentChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases / Precancerous/Nonmalignant Condition1
2Active Not RecruitingTreatmentChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
2Active Not RecruitingTreatmentImmunodeficiency Syndrome / Non-Cancer Diagnosis1
2Active Not RecruitingTreatmentLeukemias1
2Active Not RecruitingTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma (MM) / Myelodysplastic Syndromes / Plasma Cell Neoplasms / Renal Cancers1
2Active Not RecruitingTreatmentLeukemias / Myelodysplastic Syndromes1
2Active Not RecruitingTreatmentMalignant Lymphomas1
2Active Not RecruitingTreatmentMyocardial Reperfusion Injury1
2Active Not RecruitingTreatmentRefractory Plasma Cell Myeloma1
2Active Not RecruitingTreatmentRetinoblastoma1
2CompletedPreventionAcute Kidney Injury (AKI)1
2CompletedPreventionChronic Lung Diseases1
2CompletedPreventionGraft Versus Host Disease (GVHD)1
2CompletedPreventionGraft Versus Host Disease (GVHD) / Hematopoietic Stem Cell Transplantation (HSCT)1
2CompletedPreventionRejection, Transplant / Transplantation, Kidney / Transplantation, Renal1
2CompletedPreventionTransplantation, Kidney2
2CompletedSupportive CareAccelerated Phase Chronic Myelogenous Leukemia / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Grade III Lymphomatoid Granulomatosis / B-Cell Chronic Lymphocytic Leukemia / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Chronic Myelomonocytic Leukemia / Chronic Phase Chronic Myelogenous Leukemia / Contiguous Stage II Adult Burkitt Lymphoma / Contiguous Stage II Adult Diffuse Large Cell Lymphoma / Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Contiguous Stage II Adult Lymphoblastic Lymphoma / Contiguous Stage II Grade 1 Follicular Lymphoma / Contiguous Stage II Grade 2 Follicular Lymphoma / Contiguous Stage II Grade 3 Follicular Lymphoma / Contiguous Stage II Mantle Cell Lymphoma / Contiguous Stage II Marginal Zone Lymphoma / Contiguous Stage II Small Lymphocytic Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Graft Versus Host Disease (GVHD) / Intraocular Lymphoma / Myelodysplastic Syndrome With Isolated Del(5q) / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Burkitt Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Noncontiguous Stage II Adult Lymphoblastic Lymphoma / Noncontiguous Stage II Grade 1 Follicular Lymphoma / Noncontiguous Stage II Grade 2 Follicular Lymphoma / Noncontiguous Stage II Grade 3 Follicular Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Marginal Zone Lymphoma / Noncontiguous Stage II Small Lymphocytic Lymphoma / Post-Transplant Lymphoproliferative Disorder / Primary Central Nervous System Hodgkin Lymphoma / Primary Central Nervous System Non-Hodgkin Lymphoma / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Anemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Ringed Sideroblasts / Refractory Chronic Lymphocytic Leukemia / Refractory Cytopenia With Multilineage Dysplasia / Refractory Hairy Cell Leukemia / Relapsing Chronic Myelogenous Leukemia / Secondary Central Nervous System Hodgkin Lymphoma / Secondary Central Nervous System Non-Hodgkin Lymphoma / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Stage I Adult Burkitt Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Mixed Cell Lymphoma / Stage I Adult Diffuse Small Cleaved Cell Lymphoma / Stage I Adult Hodgkin Lymphoma / Stage I Adult Immunoblastic Large Cell Lymphoma / Stage I Adult Lymphoblastic Lymphoma / Stage I Chronic Lymphocytic Leukemia / Stage I Grade 1 Follicular Lymphoma / Stage I Grade 2 Follicular Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage I Mantle Cell Lymphoma / Stage I Marginal Zone Lymphoma / Stage I Small Lymphocytic Lymphoma / Stage II Adult Hodgkin Lymphoma / Stage II Chronic Lymphocytic Leukemia / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Chronic Lymphocytic Leukemia / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Chronic Lymphocytic Leukemia / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Small Lymphocytic Lymphoma / Testicular Lymphoma / Waldenström's Macroglobulinemia (WM)1
2CompletedSupportive CareAnemias / Leukemias / Neutropenias / Thrombocytopenias1
2CompletedTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Acute Promyelocytic Leukemia (M3) / Adult Erythroleukemia (M6a) / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Adult Pure Erythroid Leukemia (M6b) / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Burkitt's Lymphoma / Childhood Acute Erythroleukemia (M6) / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Megakaryocytic Leukemia (M7) / Childhood Acute Monoblastic Leukemia (M5a) / Childhood Acute Monocytic Leukemia (M5b) / Childhood Acute Myeloblastic Leukemia With Maturation (M2) / Childhood Acute Myeloblastic Leukemia Without Maturation (M1) / Childhood Acute Myeloid Leukemia in Remission / Childhood Acute Myelomonocytic Leukemia (M4) / Childhood Acute Promyelocytic Leukemia (M3) / Childhood Chronic Myelogenous Leukemia / Childhood Myelodysplastic Syndromes / Chronic Phase Chronic Myelogenous Leukemia / Cutaneous B-Cell Non-Hodgkin Lymphoma / De Novo Myelodysplastic Syndromes / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Peripheral T-Cell Lymphoma (PTCL) / Post-Transplant Lymphoproliferative Disorder / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult Non-Hodgkin Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Refractory Multiple Myeloma / Relapsing Chronic Myelogenous Leukemia / Secondary Myelodysplastic Syndromes / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Testicular Lymphoma / Waldenström's Macroglobulinemia (WM)1
2CompletedTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Acute, secondary Myeloid Leukemia / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Myeloid Leukemia in Remission / Adult Erythroleukemia (M6a) / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Adult Pure Erythroid Leukemia (M6b) / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Blastic Phase Chronic Myelogenous Leukemia / Childhood Acute Erythroleukemia (M6) / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Megakaryocytic Leukemia (M7) / Childhood Acute Myeloid Leukemia in Remission / Childhood Burkitt Lymphoma / Childhood Chronic Myelogenous Leukemia / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Childhood Myelodysplastic Syndromes / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Chronic Myelomonocytic Leukemia / Chronic Phase Chronic Myelogenous Leukemia / Cutaneous B-Cell Non-Hodgkin Lymphoma / De Novo Myelodysplastic Syndromes / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Noncutaneous Extranodal Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Philadelphia Chromosome Negative Chronic Myelogenous Leukemia / Post-Transplant Lymphoproliferative Disorder / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Relapsing Chronic Myelogenous Leukemia / Secondary Myelodysplastic Syndromes / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Stage III Multiple Myeloma / Testicular Lymphoma / Waldenström's Macroglobulinemia (WM)1
2CompletedTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Chronic Myelogenous Leukemia / Childhood Myelodysplastic Syndromes / Chronic Phase Chronic Myelogenous Leukemia / De Novo Myelodysplastic Syndromes / Previously Treated Myelodysplastic Syndromes / Refractory Anemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Excess Blasts in Transformation / Relapsing Chronic Myelogenous Leukemia / Secondary Myelodysplastic Syndromes1
2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myelogenous Leukaemia (AML) / Chronic Chronic myelogenous leukemia / Chronic Lymphocytic Leukaemia (CLL) / Myelodysplastic Syndrome1
2CompletedTreatmentAcute Lymphocytic Leukemia (ALL) / Acute Myelogenous Leukaemia (AML) / Chronic Chronic myelogenous leukemia / Chronic Lymphocytic Leukaemia (CLL) / Hodgkins Disease (HD) / Multiple Myeloma (MM) / Myelodysplastic Syndromes / Non-Hodgkin's Lymphoma (NHL) / Peripheral T-Cell Lymphoma (PTCL)1
2CompletedTreatmentAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome / Acute, secondary Myeloid Leukemia / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Erythroleukemia (M6a) / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Adult Pure Erythroid Leukemia (M6b) / B-cell Adult Acute Lymphoblastic Leukemia / B-cell Childhood Acute Lymphoblastic Leukemia / Blastic Phase Chronic Myelogenous Leukemia / Burkitt's Lymphoma / Childhood Acute Erythroleukemia (M6) / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Megakaryocytic Leukemia (M7) / Childhood Acute Minimally Differentiated Myeloid Leukemia (M0) / Childhood Acute Monoblastic Leukemia (M5a) / Childhood Acute Monocytic Leukemia (M5b) / Childhood Acute Myeloid Leukemia in Remission / Childhood Chronic Myelogenous Leukemia / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Childhood Myelodysplastic Syndromes / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Chronic Myelomonocytic Leukemia / Chronic Phase Chronic Myelogenous Leukemia / Cutaneous B-Cell Non-Hodgkin Lymphoma / De Novo Myelodysplastic Syndromes / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Juvenile Myelomonocytic Leukemia / Leukemia, Prolymphocytic / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Nodal marginal zone B-cell lymphomas / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Relapsing Chronic Myelogenous Leukemia / Secondary Myelodysplastic Syndromes / Secondary Myelofibrosis / Splenic Marginal Zone Lymphoma / Stage I Chronic Lymphocytic Leukemia / Stage II Chronic Lymphocytic Leukemia / Stage III Chronic Lymphocytic Leukemia / Stage IV Chronic Lymphocytic Leukemia / T-cell Adult Acute Lymphoblastic Leukemia / T-cell Childhood Acute Lymphoblastic Leukemia / T-Cell Large Granular Lymphocyte Leukemia / Waldenström's Macroglobulinemia (WM)1
2CompletedTreatmentAdrenoleukodystrophy (ALD) / Alpha Mannosidosis / Aspartylglucosaminuria / Fucosidosis / Hunter Syndrome / Hurler's Syndrome / Krabbe's Disease / Metachromatic Leukodystrophy (MLD) / Mucopolysaccharidosis / Mucopolysaccharidosis VI / Peroxisomal Disorders / Sly Syndrome / Sphingolipidoses1
2CompletedTreatmentAdult Acute Lymphoblastic Leukemia in Remission / Childhood Acute Lymphoblastic Leukemia in Remission / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Lymphoblastic Leukemia1
2CompletedTreatmentAdult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22)1
2CompletedTreatmentAll / Aplastic Anaemia (AA) / CLL / CML Chronic Phase, Accelerated Phase, or Blast Crisis / Leukemia Acute Myeloid Leukemia (AML) / Multiple Myeloma (MM) / MYELOPROLIFERATIVE DISORDER (P Vera, CMML, ET) / RELAPSED NON-HODGKIN'S OR HODGKIN'S LYMPHOMA / Smith-Magenis Syndrome1
2CompletedTreatmentAnemias / Bone Marrow Transplant Failure / Myelodysplastic Syndromes (MDS) / Myeloid Leukemias / Myeloproliferative Disorders / Neural Tube Defects (NTDs)1
2CompletedTreatmentAplastic Anaemia (AA)5
2CompletedTreatmentAplastic Anaemia (AA) / Congenital Hypoplastic Anemia1
2CompletedTreatmentAplastic Anaemia (AA) / Myelodysplastic Syndrome1
2CompletedTreatmentAplastic Anaemia (AA) / Severe Aplastic Anemia (SAA)1
2CompletedTreatmentAtopic Dermatitis (AD)1
2CompletedTreatmentB-Cell Chronic Lymphocytic Leukemia / Nodal marginal zone B-cell lymphomas / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Splenic Marginal Zone Lymphoma / Waldenström's Macroglobulinemia (WM)1
2CompletedTreatmentB-Cell Prolymphocytic Leukemia / Chronic Lymphocytic Leukaemia (CLL) / Chronic, recurrent Lymphocytic Leukemia / Leukemia, Prolymphocytic / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / T-Cell Prolymphocytic Leukemia1
2CompletedTreatmentBeta-Thalassemia / Hematologic Diseases / Hematopoietic Stem Cell Transplantation (HSCT) / Sickle Cell Disorders1
2CompletedTreatmentBladder Ca / Bony/Soft Tissue Sarcoma / Breast Ca / Cholangiocarcinomas / Colon/Rectal Ca / Esophageal/Gastric Ca / Hepatocellular Ca / Neoplasms Metastasis / Ovarian Ca / Pancreatic Ca / Prostate Ca1
2CompletedTreatmentBlood Cancers / CLL / Graft Versus Host Disease (GVHD) / Hodgkins Disease (HD) / Leukemias / Malignancies / NHL / Smith-Magenis Syndrome1
2CompletedTreatmentBlood Cancers / Leukemias1
2CompletedTreatmentBlood and Marrow Transplant (BMT) / Multiple Myeloma (MM) / Transplantation, Autologous / Transplantation, Homologous1
2CompletedTreatmentBrittle Nail Syndrome1
2CompletedTreatmentCancer of the Ovary / Cancer, Breast / Fallopian Tube Cancer / Primary Peritoneal Cancer1
2CompletedTreatmentCancer, Breast1
2CompletedTreatmentCardiovascular Disease (CVD) / Heart Diseases / Myocarditis1
2CompletedTreatmentCervical Cancers / Vaginal Cancers1
2CompletedTreatmentChediak-Higashi Syndrome / Griscelli Syndrome / Histiocytosis, Langerhans-Cell / Immunologic Deficiency Syndromes / Lymphohistiocytosis, Hemophagocytic / X-Linked Lymphoproliferative Disorders1
2CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection1
2CompletedTreatmentChronic Myeloproliferative Disorders / Leukemias / Myelodysplastic/Myeloproliferative Diseases1
2CompletedTreatmentColorectal Cancers1
2CompletedTreatmentCongenital Amegakaryocytic Thrombocytopenia / Congenital Hypoplastic Anemia / Leukemias / Myelodysplastic Syndromes / Severe Congenital Neutropenia1
2CompletedTreatmentCongenital Hypoplastic Anemia / Hematologic Diseases1
2CompletedTreatmentConjunctivitis, Seasonal Allergic1
2CompletedTreatmentCytopaenia1
2CompletedTreatmentDisease, Chronic / Leukemia, Acute / Leukemias / Malignant Lymphomas / Myelodysplasia1
2CompletedTreatmentDry Eye Syndrome (DES)1
2CompletedTreatmentDry Eye Syndromes2
2CompletedTreatmentGiant Cell Myocarditis / Myocarditis1
2CompletedTreatmentGlomerulonephritis minimal lesion / Systemic Lupus Erythematosus (SLE)1
2CompletedTreatmentGraft Versus Host Disease (GVHD)1
2CompletedTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes1
2CompletedTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
2CompletedTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Myelodysplastic Syndromes / Neuroblastomas1
2CompletedTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Myelodysplastic Syndromes1
2CompletedTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Myelodysplastic Syndromes / Thymic Carcinoma1
2CompletedTreatmentHansen's Disease3
2CompletedTreatmentHematologic Diseases / Myelodysplastic Syndromes1
2CompletedTreatmentHepatocellular,Carcinoma1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections2
2CompletedTreatmentImmunosuppresion / Neutropenias / Pancytopenia / Thrombocytopenias1
2CompletedTreatmentInterstitial Cystitis1
2CompletedTreatmentKeratoconjunctivitis Sicca1
2CompletedTreatmentKeratoconjunctivitis Sicca / Sjögren's Syndrome1
2CompletedTreatmentLeukemia, Mast-Cell / Mantle Cell Lymphoma (MCL)1
2CompletedTreatmentLeukemias7
2CompletedTreatmentLeukemias / Malignant Lymphomas2
2CompletedTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes2
2CompletedTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
2CompletedTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
2CompletedTreatmentLeukemias / Malignant Lymphomas / Myelodysplastic Syndromes1
2CompletedTreatmentLeukemias / Malignant Lymphomas / Myelodysplastic Syndromes / Myelodysplastic-Myeloproliferative Diseases1
2CompletedTreatmentLeukemias / Myelodysplastic Syndromes5
2CompletedTreatmentLeukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
2CompletedTreatmentLiver Diseases / Transplantation, Liver1
2CompletedTreatmentMelanoma (Skin)1
2CompletedTreatmentMild to Moderate Ulcerative Colitis1
2CompletedTreatmentMultiple Myeloma (MM)1
2CompletedTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
2CompletedTreatmentMyelodysplastic Syndrome3
2CompletedTreatmentOnychoclasis1
2CompletedTreatmentOpen Angle Glaucoma (OAG)1
2CompletedTreatmentPeriodontitis1
2CompletedTreatmentPterygium1
2CompletedTreatmentSarcomas1
2CompletedTreatmentSevere Aplastic Anemia (SAA)1
2CompletedTreatmentTransplantation, Kidney3
2CompletedTreatmentTransplantation, Renal1
2Not Yet RecruitingPreventionGraft Versus Host Disease (GVHD)1
2Not Yet RecruitingTreatmentAcute Lymphoblastic Leukemia in Remission / Acute myeloid leukaemia (in remission) / Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Acute, recurrent Myeloid Leukemia / Agnogenic Myeloid Metaplasia / Blasts 5 Percent or Less of Bone Marrow Nucleated Cells / Chronic Myelomonocytic Leukemia / Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Donor / Minimal Residual Disease / Myelodysplastic Syndrome / Myeloproliferative Neoplasms / Recurrent Hodgkin Lymphoma / Recurrent Non-Hodgkin Lymphoma / Refractory Acute Myeloid Leukemia / Therapy-Related Acute Myeloid Leukemia1
2Not Yet RecruitingTreatmentEye Dryness1
2Not Yet RecruitingTreatmentLeukemia, Acute / Smith-Magenis Syndrome1
2RecruitingPreventionAdult Acute Lymphoblastic Leukemia / Adult Acute Myeloid Leukemia / Adult Diffuse Large B-Cell Lymphoma / Aggressive Non-Hodgkin Lymphoma / Aggressive, recurrent Adult Non-Hodgkin Lymphoma / Blasts Under 5 Percent of Bone Marrow Nucleated Cells / Childhood Acute Lymphoblastic Leukemia / Childhood Acute Myeloid Leukemia / Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Childhood Diffuse Large B -Cell Lymphoma / Chronic Lymphocytic Leukaemia (CLL) / Chronic, recurrent Lymphocytic Leukemia / DS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma / Leukemia, Prolymphocytic / Loss of Chromosome 17p / Myelodysplastic/Myeloproliferative Neoplasms / Non-Hodgkin's Lymphoma (NHL) / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Hodgkin Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Non-Hodgkin Lymphoma / Recurrent Plasma Cell Myeloma / Recurrent Small Lymphocytic Lymphoma / Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Stage I Adult Hodgkin Lymphoma / Stage I Aggressive Adult Non-Hodgkin Lymphoma / Stage I Childhood Hodgkin Lymphoma / Stage I Chronic Lymphocytic Leukemia / Stage I Diffuse Large B-Cell Lymphoma / Stage I Mantle Cell Lymphoma / Stage I Small Lymphocytic Lymphoma / Stage II Adult Hodgkin Lymphoma / Stage II Childhood Hodgkin Lymphoma / Stage II Chronic Lymphocytic Leukemia / Stage II Contiguous Adult Aggressive Non-Hodgkin Lymphoma / Stage II Contiguous Mantle Cell Lymphoma / Stage II Diffuse Large B-Cell Lymphoma / Stage II Non-Contiguous Aggressive Adult Non-Hodgkin Lymphoma / Stage II Non-Contiguous Mantle Cell Lymphoma / Stage II Small Lymphocytic Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage III Aggressive Adult Non-Hodgkin Lymphoma / Stage III Childhood Hodgkin Lymphoma / Stage III Chronic Lymphocytic Leukemia / Stage III Diffuse Large B-Cell Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Aggressive Adult Non-Hodgkin Lymphoma / Stage IV Childhood Hodgkin Lymphoma / Stage IV Chronic Lymphocytic Leukemia / Stage IV Diffuse Large B-Cell Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Small Lymphocytic Lymphoma / T-cell chronic lymphocytic leukaemia / T-Cell Prolymphocytic Leukemia / Waldenström's Macroglobulinemia (WM)1
2RecruitingPreventionGraft Versus Host Disease (GVHD) / Hematopoietic Stem Cell Transplantation (HSCT)1
2RecruitingTreatmentAcute Biphenotypic Leukemia (ABL) / Acute Lymphoblastic Leukemia in Remission / Acute myeloid leukaemia (in remission) / Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Adult Acute Lymphoblastic Leukemia in Complete Remission / Adult Acute Myeloid Leukemia in Remission / Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Aggressive Non-Hodgkin Lymphoma / Agnogenic Myeloid Metaplasia / B Acute Lymphoblastic Leukemia With t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1) / Blasts Under 5 Percent of Bone Marrow Nucleated Cells / Burkitt's Lymphoma / Childhood Acute Lymphoblastic Leukemia in Complete Remission / Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Chronic, recurrent Lymphocytic Leukemia / Leukemia, Prolymphocytic / Lymphoma, Lymphoblastic / Mantle Cell Lymphoma (MCL) / Myelodysplastic Syndrome With Excess Blasts / Pancytopenia / Plasma Cell Myeloma / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Recurrent Follicular Lymphoma / Recurrent Lymphoplasmacytic Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Anemia With Excess Blasts1
2RecruitingTreatmentAcute Biphenotypic Leukemia (ABL) / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Myelodysplastic Syndrome / Blasts Under 5 Percent of Bone Marrow Nucleated Cells / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Childhood Myelodysplastic Syndrome / Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Myelodysplastic Syndrome With Excess Blasts-2 / RAEB-2 / Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Refractory Anemia With Excess Blasts / Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Aggressive Non-Hodgkin Lymphoma / Chronic Lymphocytic Leukaemia (CLL) / Chronic, recurrent Lymphocytic Leukemia / Hematopoietic Cell Transplantation Recipient / Leukemia Acute Myeloid Leukemia (AML) / Leukemia, Prolymphocytic / Loss of Chromosome 17p / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Mantle Cell Lymphoma (MCL) / Myelodysplastic Syndrome / Myelodysplastic/Myeloproliferative Neoplasms / Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Recurrent Hodgkin Lymphoma / Recurrent Plasma Cell Myeloma / Recurrent Small Lymphocytic Lymphoma / Recurrent Waldenstrom Macroglobulinemia / T-cell chronic lymphocytic leukaemia1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemia Acute Myeloid Leukemia (AML) / Leukemia, Acute / Leukemias / Lymphoma, Hodgkins / Myelodysplastic Syndromes / Myelodysplastic-Myeloproliferative Diseases / Myeloproliferative Disorders / Non Hodgkin Lymphoma (NHL)1
2RecruitingTreatmentAcute Lymphocytic Leukemia (ALL) / Agnogenic Myeloid Metaplasia / Chronic Chronic myelogenous leukemia / Chronic Lymphocytic Leukaemia (CLL) / Leukemia Acute Myeloid Leukemia (AML) / Leukemia, Prolymphocytic / Leukemias / Malignant Lymphomas / Multiple Myeloma (MM) / Myelodysplastic Syndromes / Non-Hodgkin's Lymphoma (NHL) / Refractory Anemia / Smith-Magenis Syndrome1
2RecruitingTreatmentAdult Acute Lymphoblastic Leukemia / Adult Acute Myeloid Leukemia / Adult Diffuse Large B-Cell Lymphoma / Adult Myelodysplastic Syndrome / Adult Non-Hodgkin's Lymphoma / Aggressive Non-Hodgkin Lymphoma / Childhood Acute Lymphoblastic Leukemia / Childhood Acute Myeloid Leukemia / Childhood Diffuse Large B -Cell Lymphoma / Childhood Diffuse Large B-Cell Lymphoma / Childhood Myelodysplastic Syndrome / Childhood Non-Hodgkin's Lymphoma / Chronic Lymphocytic Leukaemia (CLL) / Chronic Lymphocytic Leukemia in Remission / Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Chronic, recurrent Lymphocytic Leukemia / Hematopoietic and Lymphoid Cell Neoplasm / Leukemia, Prolymphocytic / Mantle Cell Lymphoma (MCL) / Plasma Cell Myeloma / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / T-cell chronic lymphocytic leukaemia / T-Cell Prolymphocytic Leukemia / Waldenström's Macroglobulinemia (WM)1
2RecruitingTreatmentAplastic Anaemia (AA)2
2RecruitingTreatmentAplastic Anaemia (AA) / Dyskeratosis Congenita / Hoyeraal Hreidarsson Syndrome / Revesz Syndrome1
2RecruitingTreatmentAplastic Anaemia (AA) / Hypoplastic Myelodysplastic Syndrome1
2RecruitingTreatmentAutoimmune Diseases / Glomerular Diseases / Glomerulonephritis minimal lesion / Glomerulonephritis, Membranous / Proteinuria1
2RecruitingTreatmentB-cell Non-Hodgkin's Lymphomas / Chronic Lymphocytic Leukaemia (CLL) / Leukemia Acute Myeloid Leukemia (AML) / Lymphoma, Hodgkins / Myelodysplastic Syndrome / Myeloproliferative Neoplasms / T-Cell Non-Hodgkin Lymphoma1
2RecruitingTreatmentBone Marrow Transplant Failure / Cutaneous T-Cell Lymphoma (CTCL) / Lymphoma, T-Cell, Cutaneous / Mycoses / Non-Hodgkin's Lymphoma (NHL) / Sezary Syndrome1
2RecruitingTreatmentAcute, secondary Myeloid Leukemia / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Myelodysplastic Syndrome / De Novo Myelodysplastic Syndrome / Leukemias / Myelodysplastic Syndromes / Previously Treated Myelodysplastic Syndromes / Recurrent Childhood Acute Myeloid Leukemia / Refractory Anemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Excess Blasts in Transformation / Secondary Myelodysplastic Syndromes1
2RecruitingTreatmentDelayed Graft Function / Transplant, Kidney1
2RecruitingTreatmentEpidermolysis Bullosa1
2RecruitingTreatmentHematopoietic Cell Transplantation Recipient / Non-Malignant1
2RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML)1
2RecruitingTreatmentLeukemias1
2RecruitingTreatmentPost-Transplant Lymphoproliferative Disorder / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent B-Cell Non-Hodgkin Lymphoma / Recurrent Burkitt Lymphoma / Refractory B-Cell Non-Hodgkin Lymphoma / Refractory Burkitt Lymphoma / Refractory Diffuse Large B Cell Lymphoma1
2RecruitingTreatmentRefractory Non-Hodgkin's lymphoma / Relapsed Non Hodgkin Lymphoma1
2RecruitingTreatmentSevere Aplastic Anemia (SAA)1
2TerminatedPreventionCardiopulmonary Bypass / Coronary Artery Bypass Surgery1
2TerminatedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Chronic Lymphocytic Leukaemia (CLL) / Hodgkins Disease (HD) / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndromes / Non-Hodgkin's Lymphoma (NHL)1
2TerminatedTreatmentBlood and Marrow Transplant (BMT) / Diffuse Large B-Cell / Lymphoma, B-Cell / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Lymphomas: Non-Hodgkin / Malignant Lymphoma, Non-Hodgkin / Non-Hodgkin's Lymphoma (NHL)1
2TerminatedTreatmentCancer, Breast1
2TerminatedTreatmentChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes1
2TerminatedTreatmentChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes1
2TerminatedTreatmentChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms / Unusual Cancers of Childhood1
2TerminatedTreatmentChronic Myeloproliferative Disorders / Leukemias / Myelodysplastic/Myeloproliferative Diseases1
2TerminatedTreatmentDry Eye Syndromes1
2TerminatedTreatmentEnd-Stage Renal Disease (ESRD)1
2TerminatedTreatmentLeukemia, Large Granular Lymphocytic / LGL Leukemia1
2TerminatedTreatmentLeukemias1
2TerminatedTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
2TerminatedTreatmentLeukemias / Myelodysplastic Syndromes1
2TerminatedTreatmentMalignant Lymphomas2
2TerminatedTreatmentNon-Hodgkin's Lymphoma (NHL)1
2TerminatedTreatmentPediatric Liver Transplantation1
2TerminatedTreatmentRenal Cancers1
2TerminatedTreatmentUnrecognized Condition: Mature B or T-cell Neoplasm1
2Unknown StatusPreventionGraft Versus Host Disease (GVHD)1
2Unknown StatusTreatmentCyclosporin Overdose / Idiopathic Membranous Nephropathy / Proteinuria / Spontaneous Remission / Steroid Nephropathy1
2Unknown StatusTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Precancerous Conditions1
2Unknown StatusTreatmentHematopoietic/Lymphoid Cancer1
2Unknown StatusTreatmentHuman Immunodeficiency Virus (HIV) Infections1
2Unknown StatusTreatmentLeber's Hereditary Optic Neuropathy (LHON)1
2Unknown StatusTreatmentLeukemias1
2Unknown StatusTreatmentLeukemias / Malignant Lymphomas1
2Unknown StatusTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes1
2Unknown StatusTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
2Unknown StatusTreatmentMalignant Lymphomas2
2Unknown StatusTreatmentNonmalignant Neoplasm1
2Unknown StatusTreatmentRefractory Follicular Lymphoma1
2Unknown StatusTreatmentRenal Cancers2
2WithdrawnPreventionTransplantation, Kidney1
2WithdrawnSupportive CareGraft Versus Host Disease (GVHD) / Leukemias / Myelodysplastic Syndromes1
2WithdrawnTreatmentDiabetes, Diabetes Mellitus Type 11
2WithdrawnTreatmentLacrimation increased1
2WithdrawnTreatmentMalignant Lymphomas1
2WithdrawnTreatmentNeuroblastomas1
2WithdrawnTreatmentPsoriasis1
2, 3Active Not RecruitingTreatmentChronic Graft Versus Host Disease1
2, 3Active Not RecruitingTreatmentIdiopathic Membranous Nephropathy1
2, 3CompletedNot AvailableConjunctivitis, Vernal1
2, 3CompletedPreventionGraft Versus Host Disease (GVHD)1
2, 3CompletedTreatmentFamilial Lipoprotein Lipase Deficiency1
2, 3CompletedTreatmentHTLV I Associated Myelopathies1
2, 3CompletedTreatmentHansen's Disease1
2, 3CompletedTreatmentLeukemias / Malignant Lymphomas / Myelodysplastic Syndromes1
2, 3CompletedTreatmentMalignant Lymphomas1
2, 3CompletedTreatmentVernal Keratoconjunctivitis1
2, 3Not Yet RecruitingTreatmentRecurrent Miscarriages1
2, 3RecruitingTreatmentChronic Myeloid Leukemia (CML)1
2, 3RecruitingTreatmentDry Eye Syndrome (DES)1
2, 3RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML)1
2, 3Unknown StatusTreatmentChronic Graft Versus Host Disease1
2, 3Unknown StatusTreatmentFamilial Lipoprotein Lipase Deficiency1
2, 3Unknown StatusTreatmentOsteopetrosis1
2, 3WithdrawnTreatmentTransplantation, Kidney1
3Active Not RecruitingTreatmentAcute Lymphoblastic Leukemia in Remission / Acute myeloid leukaemia (in remission) / Aggressive Non-Hodgkin Lymphoma / Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Hematopoietic and Lymphoid Cell Neoplasm / Indolent Non-Hodgkin's Lymphomas / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Mantle Cell Lymphoma (MCL) / Myelodysplastic/Myeloproliferative Neoplasms / Plasma Cell Myeloma / Refractory Chronic Lymphocytic Leukemia / Refractory Hodgkin Lymphoma / Waldenström's Macroglobulinemia (WM)1
3Active Not RecruitingTreatmentFailing Renal Allograft / Transplant, Kidney1
3Active Not RecruitingTreatmentThrombotic Thrombocytopenic Purpura (TTP)1
3Active Not RecruitingTreatmentTransplantation, Kidney1
3CompletedNot AvailableDry Eye Syndromes2
3CompletedPreventionChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
3CompletedPreventionDe Novo Kidney Transplant Recipients / Transplantation, Renal1
3CompletedPreventionGraft Versus Host Disease (GVHD) / Survival1
3CompletedPreventionImmunosuppression / Obliterative Bronchiolitis1
3CompletedPreventionLung Transplant1
3CompletedPreventionPediatric Kidney Transplantation1
3CompletedPreventionTransplantation, Kidney1
3CompletedPreventionTransplantation, Renal1
3CompletedSupportive CareGraft Versus Host Disease (GVHD)1
3CompletedSupportive CareGraft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas1
3CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Aggressive Non-Hodgkin Lymphoma / Chronic Lymphocytic Leukaemia (CLL) / Chronic, recurrent Lymphocytic Leukemia / Hematopoietic and Lymphoid Cell Neoplasm / Indolent Non-Hodgkin's Lymphomas / Leukemia Acute Myeloid Leukemia (AML) / Leukemia, Prolymphocytic / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Mantle Cell Lymphoma (MCL) / Myelodysplastic Syndrome / Myeloproliferative Neoplasms / Recurrent Plasma Cell Myeloma / Refractory Chronic Lymphocytic Leukemia / Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Refractory Hodgkin Lymphoma / Small Lymphocytic Lymphoma (SLL) / T-cell chronic lymphocytic leukaemia / Waldenström's Macroglobulinemia (WM)1
3CompletedTreatmentAcute Lymphocytic Leukemia (ALL) / Acute Myelogenous Leukaemia (AML) / Chronic Chronic myelogenous leukemia / Myelodysplastic Syndrome / Natural Killer Cell Lymphoblastic Leukemia/Lymphoma1
3CompletedTreatmentAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome / Acute Myeloid Leukemia/Transient Myeloproliferative Disorder / Acute, secondary Myeloid Leukemia / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Childhood Acute Myeloid Leukemia in Remission / Childhood Myelodysplastic Syndromes / De Novo Myelodysplastic Syndromes / Myelodysplastic Syndrome With Isolated Del(5q) / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes1
3CompletedTreatmentAcute atopic conjunctivitis1
3CompletedTreatmentAortic Valvular Surgery1
3CompletedTreatmentAtopic Dermatitis (AD)1
3CompletedTreatmentBehcet's Syndrome / Diffuse posterior uveitis / Panuveitis / Vasculitis Retinal1
3CompletedTreatmentCancer, Breast1
3CompletedTreatmentChildhood Acute Lymphoblastic Leukemia in Remission / Recurrent Childhood Acute Lymphoblastic Leukemia1
3CompletedTreatmentChronic Plaque Psoriasis1
3CompletedTreatmentChronic Renal Failure (CRF) / Transplantation, Kidney1
3CompletedTreatmentDry Eye Syndrome (DES)1
3CompletedTreatmentDry Eye Syndromes3
3CompletedTreatmentGlomerulosclerosis, Focal Segmental1
3CompletedTreatmentGraft Versus Host Disease (GVHD) / Malignant Lymphomas1
3CompletedTreatmentGraft Versus Host Disease (GVHD) / Renal Failure1
3CompletedTreatmentGraft Versus Host Disease (GVHD) / Transplantation, Kidney1
3CompletedTreatmentHeart Diseases / Heart Transplantation1
3CompletedTreatmentHeart Transplantation1
3CompletedTreatmentHepatocellular,Carcinoma1
3CompletedTreatmentKeratoconjunctivitis Sicca1
3CompletedTreatmentLeukemias1
3CompletedTreatmentLeukemias / Myelodysplastic Syndromes1
3CompletedTreatmentLymphohistiocytosis, Hemophagocytic1
3CompletedTreatmentLymphoma, Hodgkins / Non-Hodgkin's Lymphoma (NHL)1
3CompletedTreatmentModerate to Severe Dry Eye Syndrome1
3CompletedTreatmentMyelodysplastic Syndromes1
3CompletedTreatmentOrgan Transplantation, Renal Transplantation1
3CompletedTreatmentPsoriasis1
3CompletedTreatmentRejection, Transplant1
3CompletedTreatmentRejection, Transplant / Transplantation, Kidney1
3CompletedTreatmentRenal Interstitial Fibrosis1
3CompletedTreatmentST Elevation Acute Myocardial Infarction2
3CompletedTreatmentSevere Atopic Dermatitis2
3CompletedTreatmentSkin Cancers / Transplantation, Kidney1
3CompletedTreatmentTransplantation Infection1
3CompletedTreatmentTransplantation, Kidney3
3CompletedTreatmentTransplantation, Liver1
3CompletedTreatmentTransplantation, Renal3
3Enrolling by InvitationTreatmentDry Eye Syndrome (DES)1
3Not Yet RecruitingTreatmentMembranoproliferative Glomerulonephritis1
3Not Yet RecruitingTreatmentStevens Johnson Syndrome / Toxic Epidermal Necrolyses1
3RecruitingTreatmentAcquired Aplastic Anemia1
3RecruitingTreatmentBehçet's Disease / Uveitis1
3RecruitingTreatmentGlomerulonephritis, Membranous1
3RecruitingTreatmentHand Eczema1
3RecruitingTreatmentSevere Aplastic Anemia (SAA)1
3TerminatedSupportive CareGraft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas1
3TerminatedTreatmentAnti-r-HuEpo Associated PRCA Subjects1
3TerminatedTreatmentChronic Hepatitis C Virus (HCV) Infection / Evidence of Liver Transplantation1
3TerminatedTreatmentEnd-Stage Renal Disease (ESRD) / Transplantation, Kidney1
3TerminatedTreatmentGraft Versus Host Disease (GVHD)1
3TerminatedTreatmentLeukemia Acute Myeloid Leukemia (AML) / Leukemias / Myeloid Leukemias1
3TerminatedTreatmentLeukemias1
3TerminatedTreatmentTransplantation, Kidney1
3Unknown StatusTreatmentColorectal Cancers1
3Unknown StatusTreatmentDry Eye Syndromes1
3Unknown StatusTreatmentJuvenile Dermatomyositis1
3Unknown StatusTreatmentNonneoplastic Condition1
3WithdrawnTreatmentDiabetes, Diabetes Mellitus Type 12
3WithdrawnTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas1
3WithdrawnTreatmentImmune Thrombocytopenia1
4CompletedNot AvailableCataracts / Eye Dryness1
4CompletedNot AvailableEndothelial Graft Rejection1
4CompletedNot AvailableFunction of Renal Transplant1
4CompletedNot AvailablePterygia1
4CompletedBasic ScienceEnd Stage Renal Disease (ESRD)1
4CompletedDiagnosticHeart and Lung Transplant1
4CompletedPreventionDisorder Related to Cardiac Transplantation1
4CompletedPreventionTransplantation, Kidney1
4CompletedSupportive CareHepatitis C Viral Infection / Renal Allograft1
4CompletedTreatmentAdult Primary Kidney Transplantation1
4CompletedTreatmentAqueous Deficient Dry Eye Disease / Evaporative Dry Eye Disease / Primary Sjogren's Syndrome / Secondary Sjogren's Syndrome1
4CompletedTreatmentChronic Kidney Disease (CKD) / End Stage Renal Disease (ESRD) / Hemodialysis-dependent patients / Renal Replacement Therapies / Transplantation, Renal1
4CompletedTreatmentChronic Renal Allograft Failure / Transplantation, Renal1
4CompletedTreatmentChronic Renal Failure (CRF)1
4CompletedTreatmentComplications of Transplanted Organs and Tissue / Diabetes Mellitus Nos New Onset1
4CompletedTreatmentDiabetic Nephropathies / Transplant, Kidney / Type 2 Diabetes Mellitus1
4CompletedTreatmentDisease Severity / OSDI / Progression, Disease / Schirmers / Staining1
4CompletedTreatmentDry Eye Syndrome (DES) / Keratoconjunctivitis Sicca1
4CompletedTreatmentDry Eye Syndromes2
4CompletedTreatmentEnd Stage Liver Diseases / Hepatitis C Viral Infection / Transplantation, Liver1
4CompletedTreatmentEnd Stage Renal Disease (ESRD) / Transplantation, Renal1
4CompletedTreatmentEye Dryness1
4CompletedTreatmentGraft Versus Host Disease (GVHD)1
4CompletedTreatmentGraft Versus Host Disease (GVHD) / Renal Failure1
4CompletedTreatmentHeart Transplantation2
4CompletedTreatmentHepatitis C Viral Infection1
4CompletedTreatmentHepatitis C Viral Infection / Transplantation, Liver1
4CompletedTreatmentInflammatory Reaction1
4CompletedTreatmentKidney Transplantation, Renal Transplantation1
4CompletedTreatmentMyelodysplastic Syndrome1
4CompletedTreatmentPlanned Kidney Transplantation1
4CompletedTreatmentPolyomavirus Infections1
4CompletedTreatmentPsoriasis2
4CompletedTreatmentRenal Function and Chronic Allograft Vasculopathy1
4CompletedTreatmentRenal Transplanted Recipients1
4CompletedTreatmentRheumatoid Arthritis1
4CompletedTreatmentRosaceas1
4CompletedTreatmentStevens Johnson Syndrome1
4CompletedTreatmentTransplantation, Kidney4
4CompletedTreatmentTransplantation, Liver2
4CompletedTreatmentTransplantation, Renal2
4CompletedTreatmentUveitis1
4Not Yet RecruitingTreatmentAplastic Anaemia (AA)1
4Not Yet RecruitingTreatmentDisorder Related to Renal Transplantation / Immunosuppression Related Infectious Disease / Virus Diseases1
4Not Yet RecruitingTreatmentSjögren's Syndrome1
4RecruitingPreventionBeta-Thalassemia Major1
4RecruitingPreventionGraft Versus Host Disease, Acute1
4RecruitingTreatmentCorneal Inflammation1
4RecruitingTreatmentDisorder Related to Bone Marrow Transplantation / Leukemia Acute Myeloid Leukemia (AML)1
4RecruitingTreatmentIdiopathic Membranous Nephropathy1
4RecruitingTreatmentSevere Aplastic Anemia (SAA)1
4TerminatedPreventionHeart Transplantation / Renal Function Abnormal1
4TerminatedPreventionHepatitis C Viral Infection / Transplantation, Liver1
4TerminatedPreventionSkin Cancers / Transplantation, Kidney1
4TerminatedPreventionTransplantation, Renal1
4TerminatedTreatmentAtopic Dermatitis (AD)1
4TerminatedTreatmentCardiac Transplantation / High Blood Pressure (Hypertension)1
4TerminatedTreatmentKidney Transplant Rejection1
4TerminatedTreatmentTransplantation, Renal1
4Unknown StatusPreventionChronic Allograft Nephropathy (CAN)1
4Unknown StatusPreventionDiabetes Mellitus (DM) / Rejection, Transplant1
4Unknown StatusPreventionImmunosuppression / Transplantation, Kidney / Transplantations2
4Unknown StatusTreatmentChronic Renal Failure (CRF) / Immunosuppression / Interstitial Fibrosis (IF) / Transplantations1
4Unknown StatusTreatmentDry Eye Syndromes / HIV Seropositivity1
4Unknown StatusTreatmentImmunosuppression / Transplant, Kidney1
4Unknown StatusTreatmentPsoriasis1
4Unknown StatusTreatmentTransplantation, Renal1
4WithdrawnTreatmentCardiovascular Disease (CVD) / Cardiovascular Outcomes / Kidney Transplant Recipients / Transplantation, Kidney1
4WithdrawnTreatmentDry Eye Syndrome (DES)1
4WithdrawnTreatmentKidney Graft Dysfunction1
Not AvailableActive Not RecruitingTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / B-Cell Chronic Lymphocytic Leukemia / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Chronic Myelogenous Leukemia / Childhood Myelodysplastic Syndromes / Childhood Renal Cell Carcinoma / Chronic Phase Chronic Myelogenous Leukemia / Clear Cell Renal Cell Carcinoma / De Novo Myelodysplastic Syndromes / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Nodal marginal zone B-cell lymphomas / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Hodgkin's Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia / Refractory Multiple Myeloma / Relapsing Chronic Myelogenous Leukemia / Splenic Marginal Zone Lymphoma / Stage III Renal Cell Cancer / Stage IV Renal Cell Cancer / T-Cell Large Granular Lymphocyte Leukemia / Type 1 Papillary Renal Cell Carcinoma / Type 2 Papillary Renal Cell Carcinoma / Waldenström's Macroglobulinemia (WM)1
Not AvailableActive Not RecruitingTreatmentAcute Myeloid Leukemia/Transient Myeloproliferative Disorder / Acute Undifferentiated Leukemia (AUL) / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Burkitt Lymphoma / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Childhood Myelodysplastic Syndromes / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Chronic Myelomonocytic Leukemia / Cutaneous B-Cell Non-Hodgkin Lymphoma / De Novo Myelodysplastic Syndromes / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Juvenile Myelomonocytic Leukemia / Malignant mast cell neoplasm / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Nodal marginal zone B-cell lymphomas / Noncutaneous Extranodal Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Post-Transplant Lymphoproliferative Disorder / Previously Treated Myelodysplastic Syndromes / Primary Systemic Amyloidosis / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia / Refractory Multiple Myeloma / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Stage II Multiple Myeloma / Stage III Multiple Myeloma / T-Cell Large Granular Lymphocyte Leukemia / Testicular Lymphoma / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Adult Acute Myeloid Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia / Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies / Waldenström's Macroglobulinemia (WM)1
Not AvailableActive Not RecruitingTreatmentAdult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Noncutaneous Extranodal Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia / Refractory Multiple Myeloma / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Stage II Multiple Myeloma / Stage III Multiple Myeloma / Testicular Lymphoma / Waldenström's Macroglobulinemia (WM)1
Not AvailableActive Not RecruitingTreatmentLeukemias / Malignant Lymphomas / Myelodysplastic Syndromes1
Not AvailableActive Not RecruitingTreatmentMalignant Lymphomas1
Not AvailableAvailableNot AvailableComplete DiGeorge Anomaly / Complete DiGeorge Syndrome / DiGeorge Anomaly / DiGeorge's syndrome1
Not AvailableCompletedNot AvailableDiabetes, Diabetes Mellitus Type 1 / Islet Transplantation1
Not AvailableCompletedNot AvailableDry Eye Syndrome (DES)1
Not AvailableCompletedNot AvailableHealthy Volunteers2
Not AvailableCompletedNot AvailableKeratoconjunctivitis Sicca1
Not AvailableCompletedOtherHealthy Volunteers1
Not AvailableCompletedPreventionEye Dryness2
Not AvailableCompletedSupportive CareChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
Not AvailableCompletedTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Acute Undifferentiated Leukemia (AUL) / Acute, secondary Myeloid Leukemia / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Grade III Lymphomatoid Granulomatosis / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Aggressive NK-cell Leukemia / AIDS-Related Diffuse Large Cell Lymphoma / AIDS-Related Diffuse Mixed Cell Lymphoma / AIDS-Related Diffuse Small Cleaved Cell Lymphoma / AIDS-related Immunoblastic Large Cell Lymphoma / AIDS-Related Lymphoblastic Lymphoma / AIDS-related Peripheral/Systemic Lymphoma / AIDS-related Primary CNS Lymphoma / AIDS-related Small Noncleaved Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Blastic Phase Chronic Myelogenous Leukemia / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Burkitt Lymphoma / Childhood Chronic Myelogenous Leukemia / Childhood Diffuse Large Cell Lymphoma / Childhood Grade III Lymphomatoid Granulomatosis / Childhood Immunoblastic Large Cell Lymphoma / Childhood Myelodysplastic Syndromes / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Chronic Eosinophilic Leukemia (CEL) / Chronic Myelomonocytic Leukemia / Chronic Neutrophilic Leukemia / Chronic Phase Chronic Myelogenous Leukemia / Contiguous Stage II Adult Burkitt Lymphoma / Contiguous Stage II Adult Diffuse Large Cell Lymphoma / Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Contiguous Stage II Adult Lymphoblastic Lymphoma / Contiguous Stage II Grade 1 Follicular Lymphoma / Contiguous Stage II Grade 2 Follicular Lymphoma / Contiguous Stage II Grade 3 Follicular Lymphoma / Contiguous Stage II Mantle Cell Lymphoma / Contiguous Stage II Marginal Zone Lymphoma / Contiguous Stage II Small Lymphocytic Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Essential Thrombocythemia (ET) / Extramedullary Plasmacytoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / HIV-associated Hodgkin Lymphoma / Human Immunodeficiency Virus (HIV) Infections / Intraocular Lymphoma / Isolated Plasmacytoma of Bone / Juvenile Myelomonocytic Leukemia / Leukemia, Prolymphocytic / Malignant mast cell neoplasm / Meningeal Chronic Myelogenous Leukemia / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Myeloid/NK-cell Acute Leukemia / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Burkitt Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Noncontiguous Stage II Adult Lymphoblastic Lymphoma / Noncontiguous Stage II Grade 1 Follicular Lymphoma / Noncontiguous Stage II Grade 2 Follicular Lymphoma / Noncontiguous Stage II Grade 3 Follicular Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Marginal Zone Lymphoma / Noncontiguous Stage II Small Lymphocytic Lymphoma / Noncutaneous Extranodal Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Polycythemia Vera (PV) / Post-Transplant Lymphoproliferative Disorder / Previously Treated Myelodysplastic Syndromes / Primary Central Nervous System Lymphoma (PCNSL) / Primary Myelofibrosis / Primary Systemic Amyloidosis / Progressive Hairy Cell Leukemia, Initial Treatment / Secondary Myelodysplastic Syndromes / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Stage 0 Chronic Lymphocytic Leukemia / Stage I Adult Burkitt Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Mixed Cell Lymphoma / Stage I Adult Diffuse Small Cleaved Cell Lymphoma / Stage I Adult Hodgkin Lymphoma / Stage I Adult Immunoblastic Large Cell Lymphoma / Stage I Adult Lymphoblastic Lymphoma / Stage I Adult T-Cell Leukemia/Lymphoma / Stage I Childhood Anaplastic Large Cell Lymphoma / Stage I Childhood Hodgkin Lymphoma / Stage I Childhood Large Cell Lymphoma / Stage I Childhood Lymphoblastic Lymphoma / Stage I Childhood Small Noncleaved Cell Lymphoma / Stage I Chronic Lymphocytic Leukemia / Stage I Cutaneous T-cell Non-Hodgkin Lymphoma / Stage I Grade 1 Follicular Lymphoma / Stage I Grade 2 Follicular Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage I Mantle Cell Lymphoma / Stage I Marginal Zone Lymphoma / Stage I Multiple Myeloma / Stage I Small Lymphocytic Lymphoma / Stage IA Mycosis Fungoides/Sezary Syndrome / Stage IB Mycosis Fungoides/Sezary Syndrome / Stage II Adult Hodgkin Lymphoma / Stage II Adult T-Cell Leukemia/Lymphoma / Stage II Childhood Anaplastic Large Cell Lymphoma / Stage II Childhood Hodgkin Lymphoma / Stage II Childhood Large Cell Lymphoma / Stage II Childhood Lymphoblastic Lymphoma / Stage II Childhood Small Noncleaved Cell Lymphoma / Stage II Chronic Lymphocytic Leukemia / Stage II Cutaneous T-cell Non-Hodgkin Lymphoma / Stage II Multiple Myeloma / Stage IIA Mycosis Fungoides/Sezary Syndrome / Stage IIB Mycosis Fungoides/Sezary Syndrome / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Adult T-Cell Leukemia/Lymphoma / Stage III Childhood Anaplastic Large Cell Lymphoma / Stage III Childhood Hodgkin Lymphoma / Stage III Childhood Large Cell Lymphoma / Stage III Childhood Lymphoblastic Lymphoma / Stage III Childhood Small Noncleaved Cell Lymphoma / Stage III Chronic Lymphocytic Leukemia / Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Multiple Myeloma / Stage III Small Lymphocytic Lymphoma / Stage IIIA Mycosis Fungoides/Sezary Syndrome / Stage IIIB Mycosis Fungoides/Sezary Syndrome / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Adult T-Cell Leukemia/Lymphoma / Stage IV Childhood Anaplastic Large Cell Lymphoma / Stage IV Childhood Hodgkin Lymphoma / Stage IV Childhood Large Cell Lymphoma / Stage IV Childhood Lymphoblastic Lymphoma / Stage IV Childhood Small Noncleaved Cell Lymphoma / Stage IV Chronic Lymphocytic Leukemia / Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Small Lymphocytic Lymphoma / Stage IVA Mycosis Fungoides/Sezary Syndrome / Stage IVB Mycosis Fungoides/Sezary Syndrome / T-Cell Large Granular Lymphocyte Leukemia / Testicular Lymphoma / Unspecified Adult Solid Tumor, Protocol Specific / Unspecified Childhood Solid Tumor, Protocol Specific / Waldenström's Macroglobulinemia (WM)1
Not AvailableCompletedTreatmentAtopic Dermatitis (AD)1
Not AvailableCompletedTreatmentAtopic Keratoconjunctivitis1
Not AvailableCompletedTreatmentBlood and Marrow Transplant (BMT) / Graft Versus Host Disease (GVHD)1
Not AvailableCompletedTreatmentChronic Allograft Nephropathy (CAN) / Transplantation, Kidney1
Not AvailableCompletedTreatmentChronic Granulomatous Disease (CGD) / Metabolism, Inborn Errors1
Not AvailableCompletedTreatmentChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
Not AvailableCompletedTreatmentChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Myelodysplastic Syndromes1
Not AvailableCompletedTreatmentContact Lens Wearers With Dry Eye Syndrome1
Not AvailableCompletedTreatmentDiabetes, Diabetes Mellitus Type 11
Not AvailableCompletedTreatmentGlaucoma1
Not AvailableCompletedTreatmentHeart Transplantation2
Not AvailableCompletedTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Nonmalignant Neoplasm / Unspecified Adult Solid Tumor, Protocol Specific1
Not AvailableCompletedTreatmentLiving Donors / Transplantation, Kidney1
Not AvailableCompletedTreatmentLysosomal Storage Diseases / Peroxisomal Disorders1
Not AvailableCompletedTreatmentMyocarditis1
Not AvailableCompletedTreatmentTransplant, Kidney1
Not AvailableNot Yet RecruitingDiagnosticDry Eye Syndrome (DES) / Tear Film Insufficiency1
Not AvailableRecruitingOtherSevere Aplastic Anemia (SAA)1
Not AvailableRecruitingPreventionImmunosuppression / Renal Failure1
Not AvailableRecruitingTreatmentAcute Lymphocytic Leukemia (ALL) / Agnogenic Myeloid Metaplasia / Burkitt's Lymphoma / Chronic Chronic myelogenous leukemia / Chronic Lymphocytic Leukaemia (CLL) / Follicular Lymphoma (FL) / Leukemia Acute Myeloid Leukemia (AML) / Leukemia, Plasma Cell / Leukemia, Prolymphocytic / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Lymphoma, Lymphoblastic / Lymphoplasmacytic Lymphoma / Mantle Cell Lymphoma (MCL) / Marginal Zone B-Cell Lymphoma / Multiple Myeloma (MM) / Myelodysplasia / Non-Hodgkin's Lymphoma (NHL) / Small Lymphocytic Lymphoma (SLL)1
Not AvailableRecruitingTreatmentAllografts / Transplantation, Lung1
Not AvailableRecruitingTreatmentBlasts 10 Percent or More of Bone Marrow Nucleated Cells / Chronic Myelomonocytic Leukemia-2 / High Grade Malignant Neoplasm / Myelodysplastic Syndrome / Myelodysplastic Syndrome With Excess Blasts-2 / Myeloid Neoplasm / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Refractory Acute Myeloid Leukemia1
Not AvailableRecruitingTreatmentChronic Myeloid Leukemia (CML) / Leukemia, Acute / Myelodysplastic Syndrome1
Not AvailableRecruitingTreatmentCorneal Graft Rejection1
Not AvailableTerminatedTreatmentAcute Lymphocytic Leukemia (ALL) / Acute Myelogenous Leukaemia (AML) / Agnogenic Myeloid Metaplasia / Chronic Chronic myelogenous leukemia / Chronic Lymphocytic Leukaemia (CLL) / Hodgkins Disease (HD) / Mantle Cell Lymphoma (MCL) / Multiple Myeloma (MM) / Myelodysplasia / Non-Hodgkin's Lymphoma (NHL)1
Not AvailableTerminatedTreatmentBruton's agammaglobulinemia / Chediak-Higashi Syndrome / Chronic Granulomatous Disease (CGD) / Common Variable Immunodeficiency / Familial Erythrophagocytic Lymphohistiocytosis / Graft Versus Host Disease (GVHD) / Immunologic Deficiency Syndromes / Leukocyte Adhesion Deficiency Syndrome / Lymphohistiocytosis, Hemophagocytic / Severe Combined Immunodeficiency / Virus-Associated Hemophagocytic Syndrome / Wiskott-Aldrich Syndrome (WAS) / X-Linked Hyper IgM Syndrome / X-Linked Lymphoproliferative Syndrome1
Not AvailableTerminatedTreatmentChronic Myeloproliferative Disorders / Congenital Hypoplastic Anemia / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
Not AvailableTerminatedTreatmentChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma (MM) / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
Not AvailableTerminatedTreatmentChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases / Sarcomas1
Not AvailableTerminatedTreatmentLeukemias / Malignant Lymphomas1
Not AvailableUnknown StatusNot AvailableAcquired Haemophilia1
Not AvailableUnknown StatusNot AvailableIdiopathic Membranous Nephropathy1
Not AvailableUnknown StatusNot AvailableKeratoconus1
Not AvailableUnknown StatusPreventionGraft Versus Host Disease (GVHD) / Hematopoietic Stem Cell Transplantation (HSCT)1
Not AvailableUnknown StatusSupportive CareGraft Versus Host Disease (GVHD) / Leukemias1
Not AvailableUnknown StatusTreatmentAnemia, Hemolytic, Autoimmune / Autoimmune Thrombocytopenic Purpura / Churg-Strauss Syndrome (CSS) / Giant Cells Arteritis / Graft Versus Host Disease (GVHD) / Granulomatosis With Polyangiitis / Polyarteritis Nodosa / Pure Red Cell Aplasia / Purpura, Schoenlein-Henoch / Rheumatoid Arthritis / Rheumatoid Arthritis, Juvenile / Systemic Lupus Erythematosus (SLE) / Takayasu's Disease / Vasculitis, Hypersensitivity1
Not AvailableUnknown StatusTreatmentAplastic Anaemia (AA) / Graft Versus Host Disease (GVHD)1
Not AvailableUnknown StatusTreatmentChediak-Higashi Syndrome / Familial Erythrophagocytic Lymphohistiocytosis / Graft Versus Host Disease (GVHD) / Lymphohistiocytosis, Hemophagocytic / Virus-Associated Hemophagocytic Syndrome / X-Linked Lymphoproliferative Syndrome1
Not AvailableUnknown StatusTreatmentLeukemias1

Pharmacoeconomics

Manufacturers
  • Apotex inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Pliva inc
  • Sandoz inc
  • Abbott laboratories
  • Novartis pharmaceuticals corp
  • Allergan inc
  • Bedford laboratories div ben venue laboratories inc
  • Pharmaforce inc
  • Novex pharma
  • Watson laboratories inc
  • Wockhardt eu operations (swiss) ag
Packagers
  • Abbott Laboratories Ltd.
  • Allergan Inc.
  • Amerisource Health Services Corp.
  • Apotex Inc.
  • Banner Pharmacaps Inc.
  • Bedford Labs
  • Ben Venue Laboratories Inc.
  • Cardinal Health
  • Catalent Pharma Solutions
  • Draxis Specialty Pharmaceuticals Inc.
  • Eon Labs
  • Ivax Pharmaceuticals
  • Lake Erie Medical and Surgical Supply
  • Medisca Inc.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Novartis AG
  • Paddock Labs
  • Physicians Total Care Inc.
  • Pliva Inc.
  • R.P. Scherer GmbH and Co. KG
  • Sandhills Packaging Inc.
  • Sangstat Medical Corp.
  • Santec Chemicals Corp.
  • Swiss Caps Ag
  • Teva Pharmaceutical Industries Ltd.
  • Torpharm Inc.
  • Watson Pharmaceuticals
  • Wockhardt Ltd.
Dosage forms
FormRouteStrength
LiquidOphthalmic.0005 g/100mL
LiquidTopical.25 g/100mL
Capsule, gelatin coatedOral100 mg/1
Capsule, gelatin coatedOral25 mg/1
Injection, solutionIntravenous50 mg/mL
SolutionOral100 mg/mL
Capsule, liquid filledOral100 mg/1
Capsule, liquid filledOral25 mg/1
Capsule, liquid filledOral50 mg/1
EmulsionOphthalmic1 mg/mL
CapsuleOral100 mg/1
CapsuleOral25 mg/1
CapsuleOral50 mg/1
CapsuleOral100 mg
CapsuleOral10 mg
CapsuleOral25 mg
CapsuleOral50 mg
SolutionOral100 mg
EmulsionOphthalmic.5 mg/mL
EmulsionOphthalmic0.05 %
InjectionIntravenous50 mg/mL
LiquidIntravenous50 mg
LiquidOral100 mg
Prices
Unit descriptionCostUnit
SandIMMUNE 100 mg/ml Solution 50ml Bottle499.62USD bottle
Neoral 100 mg/ml Solution 50ml Bottle346.14USD bottle
CycloSPORINE Modified 100 mg/ml Solution 50ml Bottle311.53USD bottle
SandIMMUNE 30 100 mg capsule Box308.69USD box
Restasis 30 0.05% Emulsion 1 Box = 30 Containers205.99USD box
Neoral 30 100 mg capsule Box190.54USD box
CycloSPORINE Modified 30 100 mg capsule Box171.48USD box
Gengraf 30 100 mg capsule Box159.94USD box
SandIMMUNE 30 25 mg capsule Box77.33USD box
Neoral 30 25 mg capsule Box47.69USD box
SandIMMUNE 50 mg/ml Solution 5ml Ampule46.38USD ampule
Gengraf 30 25 mg capsule Box42.99USD box
CycloSPORINE Modified 30 25 mg capsule Box42.9USD box
Cyclosporine a powder25.2USD g
Sandimmune 100 mg capsule9.89USD capsule
Sandimmune 50 mg/ml ampul7.71USD ml
Cyclosporine 100 mg capsule6.46USD capsule
Neoral 100 mg gelatn capsule6.11USD capsule
Cyclosporine 100 mg softgel5.5USD softgel capsule
Cyclosporine modif 100 mg softgel5.5USD softgel capsule
Cyclosporine modif 100 mg capsule5.49USD capsule
Cyclosporine 50 mg/ml amp5.45USD ml
Cyclosporine 50 mg/ml vial5.28USD ml
Gengraf 100 mg capsule5.28USD capsule
Restasis 0.05% eye emulsion4.49USD each
Cyclosporine 50 mg softgel2.74USD softgel capsule
Sandimmune 25 mg capsule2.48USD capsule
Cyclosporine 25 mg capsule1.56USD capsule
Neoral 25 mg gelatin capsule1.53USD capsule
Cyclosporine 25 mg softgel1.38USD softgel capsule
Gengraf 25 mg capsule1.32USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5985321No1994-09-262014-09-26Us
US4839342No1992-08-022009-08-02Us
CA2108018No2003-04-152012-04-16Canada
CA1332150No1994-09-272011-09-27Canada
US8633162No2004-08-272024-08-27Us
US8648048No2004-08-272024-08-27Us
US9248191No2004-08-272024-08-27Us
US8629111No2004-08-272024-08-27Us
US8642556No2004-08-272024-08-27Us
US8685930No2004-08-272024-08-27Us
US8561859No2012-04-162032-04-16Us
US9676525No2014-02-072034-02-07Us
US8292129No2011-02-252031-02-25Us
US9669974No2014-05-112034-05-11Us

Properties

State
Liquid
Experimental Properties
PropertyValueSource
melting point (°C)148-151 °CNot Available
Caco2 permeability-6.05ADME Research, USCD
Predicted Properties
PropertyValueSource
logP3.64ChemAxon
pKa (Strongest Acidic)11.83ChemAxon
pKa (Strongest Basic)-2.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count12ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area278.8 Å2ChemAxon
Rotatable Bond Count15ChemAxon
Refractivity327.14 m3·mol-1ChemAxon
Polarizability133.6 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8727
Blood Brain Barrier-0.9659
Caco-2 permeable-0.6994
P-glycoprotein substrateSubstrate0.8463
P-glycoprotein inhibitor IInhibitor0.8685
P-glycoprotein inhibitor IINon-inhibitor0.5992
Renal organic cation transporterNon-inhibitor0.9485
CYP450 2C9 substrateNon-substrate0.8628
CYP450 2D6 substrateNon-substrate0.8823
CYP450 3A4 substrateSubstrate0.6407
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.923
CYP450 2D6 inhibitorNon-inhibitor0.9265
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.6112
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9968
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.8948
BiodegradationNot ready biodegradable0.9244
Rat acute toxicity2.8788 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9815
hERG inhibition (predictor II)Non-inhibitor0.9214
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as cyclosporins. These are cyclic depsipeptides containing the cyclosporin backbone.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Peptidomimetics
Sub Class
Peptoid-peptide hybrids
Direct Parent
Cyclosporins
Alternative Parents
Oligopeptides / Macrolactams / Alpha amino acids and derivatives / Tertiary carboxylic acid amides / Secondary carboxylic acid amides / Secondary alcohols / Lactams / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds
show 3 more
Substituents
Cyclosporin-backbone / Alpha-oligopeptide / Macrolactam / Alpha-amino acid or derivatives / Tertiary carboxylic acid amide / Carboxamide group / Lactam / Secondary alcohol / Secondary carboxylic acid amide / Carboxylic acid derivative
show 12 more
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
homodetic cyclic peptide (CHEBI:4031)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Binder
General Function
Not Available
Specific Function
Likely involved in the mobilization of calcium as a result of the TCR/CD3 complex interaction. Binds to cyclophilin B.
Gene Name
CAMLG
Uniprot ID
P49069
Uniprot Name
Calcium signal-modulating cyclophilin ligand
Molecular Weight
32952.255 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Bernasconi R, Solda T, Galli C, Pertel T, Luban J, Molinari M: Cyclosporine A-sensitive, cyclophilin B-dependent endoplasmic reticulum-associated degradation. PLoS One. 2010 Sep 28;5(9). pii: e13008. doi: 10.1371/journal.pone.0013008. [PubMed:20927389]
  4. Yamashita H, Ito T, Kato H, Asai S, Tanaka H, Nagai H, Inagaki N: Comparison of the efficacy of tacrolimus and cyclosporine A in a murine model of dinitrofluorobenzene-induced atopic dermatitis. Eur J Pharmacol. 2010 Oct 25;645(1-3):171-6. doi: 10.1016/j.ejphar.2010.07.031. Epub 2010 Aug 3. [PubMed:20674565]
  5. Galat A, Bua J: Molecular aspects of cyclophilins mediating therapeutic actions of their ligands. Cell Mol Life Sci. 2010 Oct;67(20):3467-88. doi: 10.1007/s00018-010-0437-0. Epub 2010 Jul 4. [PubMed:20602248]
  6. Lee J, Kim SS: Current implications of cyclophilins in human cancers. J Exp Clin Cancer Res. 2010 Jul 19;29:97. doi: 10.1186/1756-9966-29-97. [PubMed:20637127]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Calcium ion binding
Specific Function
Regulatory subunit of calcineurin, a calcium-dependent, calmodulin stimulated protein phosphatase. Confers calcium sensitivity (By similarity).
Gene Name
PPP3R2
Uniprot ID
Q96LZ3
Uniprot Name
Calcineurin subunit B type 2
Molecular Weight
19533.065 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Yamashita H, Ito T, Kato H, Asai S, Tanaka H, Nagai H, Inagaki N: Comparison of the efficacy of tacrolimus and cyclosporine A in a murine model of dinitrofluorobenzene-induced atopic dermatitis. Eur J Pharmacol. 2010 Oct 25;645(1-3):171-6. doi: 10.1016/j.ejphar.2010.07.031. Epub 2010 Aug 3. [PubMed:20674565]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Virion binding
Specific Function
PPIases accelerate the folding of proteins. It catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides.
Gene Name
PPIA
Uniprot ID
P62937
Uniprot Name
Peptidyl-prolyl cis-trans isomerase A
Molecular Weight
18012.42 Da
References
  1. Keckesova Z, Ylinen LM, Towers GJ: Cyclophilin A renders human immunodeficiency virus type 1 sensitive to Old World monkey but not human TRIM5 alpha antiviral activity. J Virol. 2006 May;80(10):4683-90. [PubMed:16641261]
  2. Patwardhan AM, Jeske NA, Price TJ, Gamper N, Akopian AN, Hargreaves KM: The cannabinoid WIN 55,212-2 inhibits transient receptor potential vanilloid 1 (TRPV1) and evokes peripheral antihyperalgesia via calcineurin. Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11393-8. Epub 2006 Jul 18. [PubMed:16849427]
  3. Redell JB, Zhao J, Dash PK: Acutely increased cyclophilin a expression after brain injury: a role in blood-brain barrier function and tissue preservation. J Neurosci Res. 2007 Jul;85(9):1980-8. [PubMed:17461417]
  4. Schaller T, Ylinen LM, Webb BL, Singh S, Towers GJ: Fusion of cyclophilin A to Fv1 enables cyclosporine-sensitive restriction of human and feline immunodeficiency viruses. J Virol. 2007 Sep;81(18):10055-63. Epub 2007 Jul 3. [PubMed:17609268]
  5. Lee J, Kim SS: Current implications of cyclophilins in human cancers. J Exp Clin Cancer Res. 2010 Jul 19;29:97. doi: 10.1186/1756-9966-29-97. [PubMed:20637127]
  6. Stegmann CM, Luhrmann R, Wahl MC: The crystal structure of PPIL1 bound to cyclosporine A suggests a binding mode for a linear epitope of the SKIP protein. PLoS One. 2010 Apr 2;5(4):e10013. doi: 10.1371/journal.pone.0010013. [PubMed:20368803]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Peptidyl-prolyl cis-trans isomerase activity
Specific Function
PPIases accelerate the folding of proteins. It catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides. Involved in regulation of the mitochondrial permeability trans...
Gene Name
PPIF
Uniprot ID
P30405
Uniprot Name
Peptidyl-prolyl cis-trans isomerase F, mitochondrial
Molecular Weight
22040.09 Da
References
  1. Handschumacher RE, Harding MW, Rice J, Drugge RJ, Speicher DW: Cyclophilin: a specific cytosolic binding protein for cyclosporin A. Science. 1984 Nov 2;226(4674):544-7. [PubMed:6238408]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inducer
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inducer
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Details
3. Cytochrome P450 3A4
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Ekins S, Bravi G, Wikel JH, Wrighton SA: Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33. [PubMed:10490933]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Details
4. Cytochrome P450 2C19
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Details
6. Cytochrome P450 2C9
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Details
7. Cytochrome P450 2D6
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Romiti N, Tramonti G, Chieli E: Influence of different chemicals on MDR-1 P-glycoprotein expression and activity in the HK-2 proximal tubular cell line. Toxicol Appl Pharmacol. 2002 Sep 1;183(2):83-91. [PubMed:12387747]
  2. Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR, Kim RB: Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos. 2000 Jun;28(6):655-60. [PubMed:10820137]
  3. Tiberghien F, Kurome T, Takesako K, Didier A, Wenandy T, Loor F: Aureobasidins: structure-activity relationships for the inhibition of the human MDR1 P-glycoprotein ABC-transporter. J Med Chem. 2000 Jun 29;43(13):2547-56. [PubMed:10891114]
  4. Gao J, Murase O, Schowen RL, Aube J, Borchardt RT: A functional assay for quantitation of the apparent affinities of ligands of P-glycoprotein in Caco-2 cells. Pharm Res. 2001 Feb;18(2):171-6. [PubMed:11405287]
  5. Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5. [PubMed:11716514]
  6. Leonessa F, Kim JH, Ghiorghis A, Kulawiec RJ, Hammer C, Talebian A, Clarke R: C-7 analogues of progesterone as potent inhibitors of the P-glycoprotein efflux pump. J Med Chem. 2002 Jan 17;45(2):390-8. [PubMed:11784143]
  7. Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA: Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol Pharmacol. 2002 May;61(5):964-73. [PubMed:11961113]
  8. Tang F, Horie K, Borchardt RT: Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa? Pharm Res. 2002 Jun;19(6):765-72. [PubMed:12134945]
  9. Kumar S, Kwei GY, Poon GK, Iliff SA, Wang Y, Chen Q, Franklin RB, Didolkar V, Wang RW, Yamazaki M, Chiu SH, Lin JH, Pearson PG, Baillie TA: Pharmacokinetics and interactions of a novel antagonist of chemokine receptor 5 (CCR5) with ritonavir in rats and monkeys: role of CYP3A and P-glycoprotein. J Pharmacol Exp Ther. 2003 Mar;304(3):1161-71. [PubMed:12604693]
  10. Horie K, Tang F, Borchardt RT: Isolation and characterization of Caco-2 subclones expressing high levels of multidrug resistance protein efflux transporter. Pharm Res. 2003 Feb;20(2):161-8. [PubMed:12636153]
  11. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25. [PubMed:12699389]
  12. Atkinson DE, Greenwood SL, Sibley CP, Glazier JD, Fairbairn LJ: Role of MDR1 and MRP1 in trophoblast cells, elucidated using retroviral gene transfer. Am J Physiol Cell Physiol. 2003 Sep;285(3):C584-91. Epub 2003 Apr 30. [PubMed:12724138]
  13. Hamada A, Miyano H, Watanabe H, Saito H: Interaction of imatinib mesilate with human P-glycoprotein. J Pharmacol Exp Ther. 2003 Nov;307(2):824-8. Epub 2003 Sep 15. [PubMed:12975485]
  14. Corea G, Fattorusso E, Lanzotti V, Taglialatela-Scafati O, Appendino G, Ballero M, Simon PN, Dumontet C, Di Pietro A: Modified jatrophane diterpenes as modulators of multidrug resistance from Euphorbia dendroides L. Bioorg Med Chem. 2003 Nov 17;11(23):5221-7. [PubMed:14604686]
  15. Rao US, Scarborough GA: Direct demonstration of high affinity interactions of immunosuppressant drugs with the drug binding site of the human P-glycoprotein. Mol Pharmacol. 1994 Apr;45(4):773-6. [PubMed:7514263]
  16. Pouliot JF, L'Heureux F, Liu Z, Prichard RK, Georges E: Reversal of P-glycoprotein-associated multidrug resistance by ivermectin. Biochem Pharmacol. 1997 Jan 10;53(1):17-25. [PubMed:8960059]
  17. Kuhnel JM, Perrot JY, Faussat AM, Marie JP, Schwaller MA: Functional assay of multidrug resistant cells using JC-1, a carbocyanine fluorescent probe. Leukemia. 1997 Jul;11(7):1147-55. [PubMed:9205004]
  18. Ito T, Yano I, Tanaka K, Inui KI: Transport of quinolone antibacterial drugs by human P-glycoprotein expressed in a kidney epithelial cell line, LLC-PK1. J Pharmacol Exp Ther. 1997 Aug;282(2):955-60. [PubMed:9262363]
  19. Kim AE, Dintaman JM, Waddell DS, Silverman JA: Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. J Pharmacol Exp Ther. 1998 Sep;286(3):1439-45. [PubMed:9732409]
  20. Kusunoki N, Takara K, Tanigawara Y, Yamauchi A, Ueda K, Komada F, Ku Y, Kuroda Y, Saitoh Y, Okumura K: Inhibitory effects of a cyclosporin derivative, SDZ PSC 833, on transport of doxorubicin and vinblastine via human P-glycoprotein. Jpn J Cancer Res. 1998 Nov;89(11):1220-8. [PubMed:9914792]
  21. Golstein PE, Boom A, van Geffel J, Jacobs P, Masereel B, Beauwens R: P-glycoprotein inhibition by glibenclamide and related compounds. Pflugers Arch. 1999 Apr;437(5):652-60. [PubMed:10087141]
  22. Wigler PW: PSC833, cyclosporin A, and dexniguldipine effects on cellular calcein retention and inhibition of the multidrug resistance pump in human leukemic lymphoblasts. Biochem Biophys Res Commun. 1999 Apr 13;257(2):410-3. [PubMed:10198227]
  23. Hochman JH, Chiba M, Nishime J, Yamazaki M, Lin JH: Influence of P-glycoprotein on the transport and metabolism of indinavir in Caco-2 cells expressing cytochrome P-450 3A4. J Pharmacol Exp Ther. 2000 Jan;292(1):310-8. [PubMed:10604964]
  24. Asakura E, Nakayama H, Sugie M, Zhao YL, Nadai M, Kitaichi K, Shimizu A, Miyoshi M, Takagi K, Takagi K, Hasegawa T: Azithromycin reverses anticancer drug resistance and modifies hepatobiliary excretion of doxorubicin in rats. Eur J Pharmacol. 2004 Jan 26;484(2-3):333-9. [PubMed:14744620]
  25. D'Emanuele A, Jevprasesphant R, Penny J, Attwood D: The use of a dendrimer-propranolol prodrug to bypass efflux transporters and enhance oral bioavailability. J Control Release. 2004 Mar 24;95(3):447-53. [PubMed:15023456]
  26. Honda Y, Ushigome F, Koyabu N, Morimoto S, Shoyama Y, Uchiumi T, Kuwano M, Ohtani H, Sawada Y: Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux. Br J Pharmacol. 2004 Dec;143(7):856-64. Epub 2004 Oct 25. [PubMed:15504753]
  27. Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. [PubMed:14985103]
  28. Yasuda K, Lan LB, Sanglard D, Furuya K, Schuetz JD, Schuetz EG: Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. J Pharmacol Exp Ther. 2002 Oct;303(1):323-32. [PubMed:12235267]
  29. Kugawa F, Suzuki T, Miyata M, Tomono K, Tamanoi F: Construction of a model cell line for the assay of MDR1 (multi drug resistance gene-1) substrates/inhibitors using HeLa cells. Pharmazie. 2009 May;64(5):296-300. [PubMed:19530439]
  30. Dahan A, Sabit H, Amidon GL: The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: characterization of its intestinal epithelial cell efflux transport. AAPS J. 2009 Jun;11(2):205-13. doi: 10.1208/s12248-009-9092-5. Epub 2009 Mar 25. [PubMed:19319690]
  31. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674]
  32. Adachi Y, Suzuki H, Sugiyama Y: Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8. [PubMed:11785684]
  33. Seeballuck F, Ashford MB, O'Driscoll CM: The effects of pluronics block copolymers and Cremophor EL on intestinal lipoprotein processing and the potential link with P-glycoprotein in Caco-2 cells. Pharm Res. 2003 Jul;20(7):1085-92. [PubMed:12880295]
  34. Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24. [PubMed:12948019]
  35. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T: Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem. 1993 Mar 25;268(9):6077-80. [PubMed:7681059]
  36. Fricker G, Drewe J, Huwyler J, Gutmann H, Beglinger C: Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation. Br J Pharmacol. 1996 Aug;118(7):1841-7. [PubMed:8842452]
  37. Lown KS, Mayo RR, Leichtman AB, Hsiao HL, Turgeon DK, Schmiedlin-Ren P, Brown MB, Guo W, Rossi SJ, Benet LZ, Watkins PB: Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther. 1997 Sep;62(3):248-60. [PubMed:9333100]
  38. Soldner A, Christians U, Susanto M, Wacher VJ, Silverman JA, Benet LZ: Grapefruit juice activates P-glycoprotein-mediated drug transport. Pharm Res. 1999 Apr;16(4):478-85. [PubMed:10227700]
  39. Baltes S, Gastens AM, Fedrowitz M, Potschka H, Kaever V, Loscher W: Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology. 2007 Feb;52(2):333-46. Epub 2006 Oct 10. [PubMed:17045309]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Organic anion transmembrane transporter activity
Specific Function
May act as an inducible transporter in the biliary and intestinal excretion of organic anions. Acts as an alternative route for the export of bile acids and glucuronides from cholestatic hepatocyte...
Gene Name
ABCC3
Uniprot ID
O15438
Uniprot Name
Canalicular multispecific organic anion transporter 2
Molecular Weight
169341.14 Da
References
  1. Zeng H, Chen ZS, Belinsky MG, Rea PA, Kruh GD: Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32. [PubMed:11585759]
Details
3. Bile salt export pump
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Transporter activity
Specific Function
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name
ABCB11
Uniprot ID
O95342
Uniprot Name
Bile salt export pump
Molecular Weight
146405.83 Da
References
  1. Byrne JA, Strautnieks SS, Mieli-Vergani G, Higgins CF, Linton KJ, Thompson RJ: The human bile salt export pump: characterization of substrate specificity and identification of inhibitors. Gastroenterology. 2002 Nov;123(5):1649-58. [PubMed:12404239]
  2. Wang EJ, Casciano CN, Clement RP, Johnson WW: Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites. Pharm Res. 2003 Apr;20(4):537-44. [PubMed:12739759]
  3. Noe J, Hagenbuch B, Meier PJ, St-Pierre MV: Characterization of the mouse bile salt export pump overexpressed in the baculovirus system. Hepatology. 2001 May;33(5):1223-31. [PubMed:11343252]
  4. Lecureur V, Sun D, Hargrove P, Schuetz EG, Kim RB, Lan LB, Schuetz JD: Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. Mol Pharmacol. 2000 Jan;57(1):24-35. [PubMed:10617675]
  5. Stieger B, Fattinger K, Madon J, Kullak-Ublick GA, Meier PJ: Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology. 2000 Feb;118(2):422-30. [PubMed:10648470]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Transporter activity
Specific Function
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotre...
Gene Name
ABCC1
Uniprot ID
P33527
Uniprot Name
Multidrug resistance-associated protein 1
Molecular Weight
171589.5 Da
References
  1. Pec MK, Aguirre A, Fernandez JJ, Souto ML, Dorta JF, Villar J: Dehydrothyrsiferol does not modulate multidrug resistance-associated protein 1 resistance: a functional screening system for MRP1 substrates. Int J Mol Med. 2002 Nov;10(5):605-8. [PubMed:12373300]
  2. Leier I, Jedlitschky G, Buchholz U, Cole SP, Deeley RG, Keppler D: The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. J Biol Chem. 1994 Nov 11;269(45):27807-10. [PubMed:7961706]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibit...
Gene Name
SLCO1A2
Uniprot ID
P46721
Uniprot Name
Solute carrier organic anion transporter family member 1A2
Molecular Weight
74144.105 Da
References
  1. Shitara Y, Sugiyama D, Kusuhara H, Kato Y, Abe T, Meier PJ, Itoh T, Sugiyama Y: Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport. Pharm Res. 2002 Feb;19(2):147-53. [PubMed:11883641]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Bile acid:sodium symporter activity
Specific Function
Plays a critical role in the sodium-dependent reabsorption of bile acids from the lumen of the small intestine. Plays a key role in cholesterol metabolism.
Gene Name
SLC10A2
Uniprot ID
Q12908
Uniprot Name
Ileal sodium/bile acid cotransporter
Molecular Weight
37713.405 Da
References
  1. Craddock AL, Love MW, Daniel RW, Kirby LC, Walters HC, Wong MH, Dawson PA: Expression and transport properties of the human ileal and renal sodium-dependent bile acid transporter. Am J Physiol. 1998 Jan;274(1 Pt 1):G157-69. [PubMed:9458785]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Virus receptor activity
Specific Function
The hepatic sodium/bile acid uptake system exhibits broad substrate specificity and transports various non-bile acid organic compounds as well. It is strictly dependent on the extracellular presenc...
Gene Name
SLC10A1
Uniprot ID
Q14973
Uniprot Name
Sodium/bile acid cotransporter
Molecular Weight
38118.64 Da
References
  1. Schroeder A, Eckhardt U, Stieger B, Tynes R, Schteingart CD, Hofmann AF, Meier PJ, Hagenbuch B: Substrate specificity of the rat liver Na(+)-bile salt cotransporter in Xenopus laevis oocytes and in CHO cells. Am J Physiol. 1998 Feb;274(2 Pt 1):G370-5. [PubMed:9486191]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. Sweet DH, Wolff NA, Pritchard JB: Expression cloning and characterization of ROAT1. The basolateral organic anion transporter in rat kidney. J Biol Chem. 1997 Nov 28;272(48):30088-95. [PubMed:9374486]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Atpase activity, coupled to transmembrane movement of substances
Specific Function
ATP-dependent transporter probably involved in cellular detoxification through lipophilic anion extrusion.
Gene Name
ABCC10
Uniprot ID
Q5T3U5
Uniprot Name
Multidrug resistance-associated protein 7
Molecular Weight
161627.375 Da
References
  1. Chen ZS, Hopper-Borge E, Belinsky MG, Shchaveleva I, Kotova E, Kruh GD: Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). Mol Pharmacol. 2003 Feb;63(2):351-8. [PubMed:12527806]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Organic anion transmembrane transporter activity
Specific Function
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name
ABCC2
Uniprot ID
Q92887
Uniprot Name
Canalicular multispecific organic anion transporter 1
Molecular Weight
174205.64 Da
References
  1. Tang F, Horie K, Borchardt RT: Are MDCK cells transfected with the human MRP2 gene a good model of the human intestinal mucosa? Pharm Res. 2002 Jun;19(6):773-9. [PubMed:12134946]
  2. Hong J, Lambert JD, Lee SH, Sinko PJ, Yang CS: Involvement of multidrug resistance-associated proteins in regulating cellular levels of (-)-epigallocatechin-3-gallate and its methyl metabolites. Biochem Biophys Res Commun. 2003 Oct 10;310(1):222-7. [PubMed:14511674]
  3. Kamisako T, Leier I, Cui Y, Konig J, Buchholz U, Hummel-Eisenbeiss J, Keppler D: Transport of monoglucuronosyl and bisglucuronosyl bilirubin by recombinant human and rat multidrug resistance protein 2. Hepatology. 1999 Aug;30(2):485-90. [PubMed:10421658]
  4. Chen ZS, Kawabe T, Ono M, Aoki S, Sumizawa T, Furukawa T, Uchiumi T, Wada M, Kuwano M, Akiyama SI: Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter. Mol Pharmacol. 1999 Dec;56(6):1219-28. [PubMed:10570049]
  5. Horikawa M, Kato Y, Tyson CA, Sugiyama Y: The potential for an interaction between MRP2 (ABCC2) and various therapeutic agents: probenecid as a candidate inhibitor of the biliary excretion of irinotecan metabolites. Drug Metab Pharmacokinet. 2002;17(1):23-33. [PubMed:15618649]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
Gene Name
ABCG2
Uniprot ID
Q9UNQ0
Uniprot Name
ATP-binding cassette sub-family G member 2
Molecular Weight
72313.47 Da
References
  1. Ozvegy C, Litman T, Szakacs G, Nagy Z, Bates S, Varadi A, Sarkadi B: Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem Biophys Res Commun. 2001 Jul 6;285(1):111-7. [PubMed:11437380]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostagland...
Gene Name
SLCO1B1
Uniprot ID
Q9Y6L6
Uniprot Name
Solute carrier organic anion transporter family member 1B1
Molecular Weight
76447.99 Da
References
  1. Tirona RG, Leake BF, Wolkoff AW, Kim RB: Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther. 2003 Jan;304(1):223-8. [PubMed:12490595]
  2. Shitara Y, Itoh T, Sato H, Li AP, Sugiyama Y: Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ther. 2003 Feb;304(2):610-6. [PubMed:12538813]
  3. Nozawa T, Tamai I, Sai Y, Nezu J, Tsuji A: Contribution of organic anion transporting polypeptide OATP-C to hepatic elimination of the opioid pentapeptide analogue [D-Ala2, D-Leu5]-enkephalin. J Pharm Pharmacol. 2003 Jul;55(7):1013-20. [PubMed:12906759]
  4. Fehrenbach T, Cui Y, Faulstich H, Keppler D: Characterization of the transport of the bicyclic peptide phalloidin by human hepatic transport proteins. Naunyn Schmiedebergs Arch Pharmacol. 2003 Nov;368(5):415-20. Epub 2003 Oct 3. [PubMed:14530907]

Drug created on June 13, 2005 07:24 / Updated on August 14, 2018 07:16